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I. ABSTRACT 
Chronic lymphocytic leukaemia (CLL) is a lymphoid malignancy which despite 
advances in the treatment options available is still incurable.  Characterised by the 
gradual accumulation of CD5+ B cells, the paradigm that this is due to failed apoptosis 
has been challenged and a significant proliferative component has been identified.  
However, despite the crosstalk between pathways which regulate metabolism and 
proliferation the metabolic characteristics of these cells are not fully understood.  
Furthermore, there is a renewed interest in the field of cancer cell metabolism because 
of the Warburg effect, a hallmark of malignancy whereby cells preferentially switch to 
aerobic glycolysis and rapidly consume glucose.  This has led to the development of 
new drugs such as AZD3965 an inhibitor of monocarboxylate transporter 1 (MCT1), 
which along with MCT4 mediates the export of lactate, a toxic bi-product of glycolysis, 
out of the cell.  The aim of this project was to assess whether therapeutically targeting 
MCT -1 and -4 would be a viable approach for CLL.  Chapter 2 of this thesis examines 
expression of MCT -1 and -4 as well as a specific chaperone protein needed for the 
surface expression of these proteins, CD147.  This chapter confirms the presence of both 
MCT -1 and -4 and CD147 in normal B cells as well as demonstrating for the first time 
that these transporters are expressed in CLL cells using Western blotting and qRT-PCR 
to assess the MCTs and flow cytometry to measure CD147.  The levels of both MCTs 
and CD147 are demonstrated to be significantly reduced in CLL cells in comparison 
normal B cells likely due to the adoption of a quiescent phenotype to aid cell survival.  
The following chapter investigates this further by assessing whether there are any 
changes in expression under the influence of microenvironmental stimuli, specifically 
CD40 ligand (CD40L).  In this chapter it is demonstrated for the first time that MCT4 is 
upregulated in CLL cells in response to CD40L.  Analysis of gene expression using a 
Fluidigm Biomark™ array suggests this is due to the induction of glycolysis and that 
CLL cells may promote fatty acid synthesis as well as instigating changes in the 
metabolism of the tumour stroma possibly to provide substrates.  Finally, chapter 4 
evaluates the sensitivity of CLL cell lines to AZD3965 using cell death and cell viability 
assays.  Both MEC-1 and HG3 CLL cell lines are shown to be resistant to MCT1 
inhibition using AZD3965 and silencing of MCT4 using siRNA cells also has no effect 
on the viability of MEC-1 cells.  That MCT4 can compensate for MCT1 inhibition is 
shown by the transient expression of MCT4 in a Raji cell line where only MCT1 is 
expressed.  Taken together, the data presented in this study indicates that while the 
inhibition of MCT1 is likely to be ineffective dual inhibition of both MCT -1 and -4 
may be a viable strategy for the localised inhibition of CLL in the secondary tissues.  
Furthermore, MCT inhibition in this disease may have the potential to negate 
mechanisms of resistance and protection from oxidative stress mediated by CD40L.    
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1 CHAPTER 1:  GENERAL INTRODUCTION 
 
1.1 OVERVIEW 
The subject of this thesis is whether therapeutic targeting of cell metabolism through the 
inhibition of monocarboxylate transport is a viable strategy for the treatment of chronic 
lymphocytic leukaemia (CLL).  Disruption of metabolic processes in other cancer types 
has been shown to have synergy with conventional therapies, reducing the development 
of drug resistance and the process of relapse.  Specifically, monocarboxylate transporter 
(MCT) -1 and -4 are of interest due to their function in preventing intracellular 
accumulation of lactic acid.  Inhibition of these transporters has been shown to induce 
cell death in cancerous and non-cancerous cells (Murray et al., 2005, Halestrap and 
Wilson, 2012).  Investigation into therapeutic targeting of metabolic processes within 
CLL cells has not received extensive scientific attention, possibly because expansion of 
the malignant clone in this disease was attributed to failed apoptosis as opposed to 
deregulated proliferation.  The aim of this thesis is to examine MCT-1 and -4 as 
therapeutic targets in the treatment of CLL. Thus, the first chapter provides an 
introduction and justification of this aim.  Chapter 2 examines the expression 
characteristics of MCT -1 and -4 as well as a chaperone required for cell surface 
expression, CD147.  Chapter 3 builds upon this work by investigating the influence of 
microenvironment, specifically CD40 ligation, on MCT -1 and -4 expression.  Chapter 3 
also examines the effect of CD40 ligation on the expression of genes associated with 
metabolism and on metabolic flux in CLL cells.  Finally, chapter 4 assesses the 
sensitivity of CLL cell lines to the MCT1 inhibitor, AZD3965 and explores 
compensatory mechanisms by disrupting MCT4 function to determine whether 






1.2 B CELL LYMPHOCYTES 
 
1.2.1 Haematopoiesis and lymphoid cell fate 
Chronic lymphocytic leukaemia is a malignancy of B cell origin (Caporaso et al., 2007).  
B cells are produced during haematopoiesis, a process whereby haemopoietic stem cells 
(HSC) undergo a series of cell fate decisions to differentiate into cellular blood 
components such as red blood cells (RBC), white blood cells (WBC) and platelets.  
HSC’s follow one of two paths of differentiation becoming either myeloid or lymphoid 
progenitor cells, a decision that is influenced by growth factors, cytokines, interleukins, 
transcription factors and the surrounding microenvironment (He et al., 2013).   
B cells are produced during lymphopoiesis which occurs in the primary lymphoid 
tissues; the foetal liver and the bone marrow (LeBien and Tedder, 2008, Zhang et al., 
2013).  The HSC’s progress through numerous developmental steps mediated by 
transcription factors such as Ikaros, fms-like tyrosine kinase 3 (FLT3), PU.1, interleukin 
7 receptor (IL-7R), E2A, EBF1, Pax5, recombination activating gene (RAG) and 
terminal deoxynucleotidyl transferase (Tdt) (Ye and Graf, 2007, Melchers, 2005, Clark 
et al., 2014) (Figure 1.1).  The expression of these factors drives the cells to become; 
multipotent progenitor (MPP) cells, followed by lymphoid multipotent progenitor 
(LMPP) cells and then common lymphoid progenitor (CLP) cells.  The formation of 
pro-B cells is observed when expression of the gene coding for the B cell receptor 
(BCR) is induced, and differentiation to pre-B and immature B cells happens when 
intact BCR is produced and expressed on the cell surface allowing the B cell to respond 
to antigenic challenge (Figure 1.1 (A)) (Cambier et al., 2007, Nutt and Kee, 2007).   
Generation of the BCR from immunoglobulin (Ig) light and heavy chains during the 
pro-B cell and pre-B cell stages is when the cell becomes committed to becoming a B 
cell.  Heavy and light chain polypeptides collectively form the immunoglobulin 
molecule.  Both heavy and light chain polypeptides contribute to the antigen binding 
sites and allow recognition of antigen by the BCR (Pleyer et al., 2009).  To increase the 
range of antigens to which the individual can respond, diversity is created from the 
recombination of the variable (V), diversity (D) and joining (J) regions in the heavy 
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chain at the pro-B cell stage.  At the pre-B cell stage a selection step occurs where the 
immature or pre-BCR is engaged.  This is followed by recombination of the V and J 
regions of the light chain which undergoes a second selection step to avoid the 
production of self-reactive clones (Perez-Vera et al., 2011).  If the BCR receptor does 
not pass this tolerance check either the BCR Ig chains undergo receptor editing to 
generate a new BCR, the cell undergoes apoptosis, or the cell enters the periphery and is 
induced into a failsafe anergic state where it is unresponsive to stimuli (Cambier et al., 
2007).   
Following this the immature B cell progresses becoming a transitional B cell and exits 
the marrow, entering the peripheral circulation and secondary tissues such as the spleen 
and lymph nodes (Zenz et al., 2010) (Figure 1.1 (B)).  Here the cells begin to express 
surface markers such as CD23 and they continue to develop either becoming follicular B 
cells or marginal-zone B cells (Cambier et al., 2007).  Upon antigenic engagement in 
order to generate the specific antibody needed against the antigen a process called 
somatic hypermutation (SHM) occurs which induces mutations within the Ig variable 
region in order to produce a B cell with a high affinity for the antigen, a process termed 
affinity maturation.  B cells which are autoreactive or have a low affinity are removed 
following interaction with T helper cells and follicular dendritic cells (FDCs).  The 
approved B cell then transverses the germinal center migrating into the light zone where 
the cell proliferates and matures into plasma cells and memory B cells (Figure 1.1 (B)) 






Figure 1.1:  Normal B cell development.  (A) Haemopoietic stem cells (HSC’s) 
progress through developmental steps mediated by transcription factors such as Ikaros, 
fms-like tyrosine kinase 3 (FLT3), PU.1, interleukin 7 receptor (IL-7R), E2A, EBF1, 
Pax5, recombination activating gene (RAG) and terminal deoxynucleotidyl transferase 
(Tdt) to become immature B cells which express a mature BCR (Ye and Graf, 2007, 
Melchers, 2005, Clark et al., 2014).  (B) In the periphery these cells encounter antigen in 
the secondary tissues (Zenz et al., 2010) and undergo somatic hypermutation (SHM) to 
generate a B cell specific to a particular epitope.  The cell then transverses the germinal 
center and begins to proliferate and matures into plasma cells and memory B cells.  
Image adapted from Cambier et al. (2007), Nutt and Kee (2007), Nagasawa (2006).   
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1.2.2 CLL cell development 
CLL is a B cell malignancy which has been shown to arise from a population of mature 
cells (Klein et al., 2001) which have aberrant expression of CD5 (Seifert et al., 2012).  
However, the stage in B cell development from which CLL arises has yet to be shown. 
Comparison of two major subtypes of CLL indicate that CLL cells may derive from two 
cell types (Ferrarini, 2009).  These subtypes are patients with mutated IgVH genes (M-
CLL) and patients with unmutated IgVH (UM-CLL) genes which code for the BCR and 
are respectively associated with stable and progressive disease (Dighiero and Hamblin, 
2008).  Studies show both clones to be antigen experienced with a BCR gene repertoire 
differing from that of naïve B cells, and this suggests that CLL clones are selected prior 
to oncogenic transformation (Messmer et al., 2004).  This notion is important because it 
indicates that CLL may arise from a single stimulus.  Moreover, that a distinct selection 
of genes are used to produce a “stereotyped BCR” in UM-CLL suggests that cells are 
repeatedly stimulated with a single antigen or are less selective being poly-reactive to 
multiple antigens including self-antigens (Rego et al., 2012, Ferrarini, 2009).   
The degree of SHM in CLL cells is a feature which differs between M-CLL cells and 
UM-CLL cells and supports the notion that CLL has multiple cells of origin because M-
CLL cells undergo SHM in the GC while UM-CLL cells have yet to reach the GC.  
However, gene expression analyses of the two subtypes has revealed similarities which 
coupled with the fact both subtypes resemble antigen experienced memory B cells 
suggests a single cell may be the site of CLL ontogeny (Damle et al., 2002, Chiorazzi 
and Ferrarini, 2011).  At present there are two main hypotheses which describe CLL 
cells to originate from a single cell type.  The first is that CLL cells are derived from 
human B1 cells.  Evidence for this hypothesis comes from murine studies (Dorshkind 
and Montecino-Rodriguez, 2007) and is supported by studies in human B1 cells 
showing presence of CD5 and Zeta-chain-associated protein kinase (ZAP-70) as well as 
the expression of various markers (CD20+/CD27+/CD43+/CD70-) to be the same on 
both cell types (Griffin et al., 2011).  Moreover, the restricted BCR gene repertoire used 
by CLL cells is also indicative of B1 cell origin. 
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The second hypothesis is that CLL cells originate from marginal zone B cells which are 
located in the spleen (Chiorazzi and Ferrarini, 2011).  Support for this notion is provided 
by a study showing that the functional and expression characteristics between CLL cells 
and marginal zone B cells is similar (Griffin et al., 2011).  Further evidence is provided 
by studies which show that marginal zone B cells and CLL cells respond similarly to 
antigen engagement (Dono et al., 1996a, Dono et al., 1996b), and that CLL cells and 
MZ cells express the BCR using a similar range of IgVH genes (Rossi and Gaidano, 
2010).  Malignant transformation in CLL is thought to be driven, therefore, by chronic 
activation of MZ cells through constitutive engagement with self- or non-self-antigens 
(Caligaris-Cappio, 2009). Finally, SHM does not occur in human B1 cells (Griffin et al., 
2011), whereas the same can occur within MZ cells (Rossi and Gaidano, 2010).   
Despite these studies investigating the origin of CLL cells the source of this disease is 
still under debate.  Understanding the ontogeny of CLL cells is of value because it 
allows a deepened understanding of the pathology of this disease, particularly as it 




1.3 CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) 
 
1.3.1 Epidemiology 
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the 
Western world, and accounts for 25% of blood cancer diagnoses with approximately 
2,800 people each year being diagnosed in the UK alone (Cancer research UK, 2010).  
Affecting primarily older adults, the median age at diagnosis is 72 years.  CLL is rare in 
younger people, with only 20-30% of cases arising in patients less than 55 years of age 
(Howlader et al., 2012, Hayden et al., 2009).  Males are at greater risk of CLL than 
females with the incidence rate being almost double.  This disease is also more common 
in the Caucasian population as opposed to other ethnicities (Landgren et al., 2007, 
Oscier et al., 2012), and has been shown to have a familial link as relatives of CLL 
patients have a predisposition to other lymphoid malignancies (Goldin and Caporaso, 
2007, Crowther-Swanepoel and Houlston, 2009).  
 
1.3.2 Aetiology 
Although the cause of CLL has not been fully elucidated migrant studies have 
highlighted how genetic rather than environmental factors play a crucial role in the 
aetiology of CLL.  These studies have shown that migrant populations maintain the CLL 
rate of their native country (Caporaso et al., 2007, Linet et al., 2007).  As previously 
discussed, this is supported by familial studies where it is shown that first degree 
relatives of CLL patients are seven times more likely to develop the disease (Sherborne 
and Houlston, 2010, Linet et al., 2007) as well as studies that refute the involvement of 





1.3.3 Clinical overview 
 
1.3.3.1 Clinical features 
Enhanced proliferation and cell survival combine to create a characteristic 
lymphocytosis of CLL cells with CD5, CD20 and CD23 positivity in the peripheral 
blood, lymphoid tissues and bone marrow (Moran et al., 2002, Goldin and Caporaso, 
2007).  The accumulation of B cells is gradual which is reflected by chronic nature of 
this disease as symptoms develop slowly.  Because of this approximately 70-80% of 
cases are diagnosed following routine blood testing, and 25% of these patients may be 
asymptomatic (Oscier et al., 2012).  Symptoms of CLL include; frequent infections, 
lethargy, bone pain, abdominal pain, splenomegaly, hepatomegaly, feeling unwell, 
lymphadenopathy, bruising, bleeding i.e. epistaxis, weight loss, dyspnoea, anaemia, 
headaches, fever, and night sweats (Oscier et al., 2012).   
 
1.3.3.2 Diagnosis 
The symptoms listed above are considered alongside tests for the diagnosis of this 
disease.  In patients with CLL, lymphocytosis is a characteristic finding in the full blood 
count (FBC) usually exceeding 5 x 10
9
/L.  Such a finding prompts examination of blood 
film morphology (Oscier et al., 2012) where lymphocytosis and smear cells are 
characteristic features (Bennett et al., 1989, Nowakowski et al., 2007).  Following blood 
film examination, immunophenotyping is used to identify CLL cells based upon the 
expression of characteristic markers such as surface membrane immunoglobulin (smIg), 
CD5, CD23, FMC7, CD22 or CD79b and a scoring system is used to distinguish CLL 
from other B cell malignancies (Moreau et al., 1997).   
Additional investigations to aid diagnosis and monitor disease progression also include; 
lymph node biopsy, bone marrow biopsy, cytogenetics, chest x-ray and CT (Oscier et 




1.3.3.3 Staging and prognostic factors 
Clinical staging of CLL is based upon the Rai (Rai et al., 1975) and Binet (Binet et al., 
1981) systems which take into consideration clinical factors such as the degree of; 
lymphocytosis, lymphoid tissue involvement, bone marrow suppression and 
hepatosplenomegaly.  These staging systems are important because of the heterogenous 
nature of this disease, and, as such, are used to guide treatment.  However, limitations 
with both of these systems has led to the identification of a multitude of prognostic 
factors at the molecular level which are able to distinguish indolent from progressive 
disease more confidently and enable a more personalised approach to treatment 
(Dighiero and Hamblin, 2008).  For instance, ZAP-70, CD38, serum β2-microglobulin, 
thymidine kinase, CD23 and IgVH mutational status have all been shown to be valuable 
tools for predicting prognosis (Defoiche et al., 2008, Damle et al., 1999, Gonzalez et al., 
2011, Crespo et al., 2003).  Other factors such as TP53 status can affect the type of 
therapy a patient may receive.  For instance, with agents such as fludarabine the killing 
effect is dependent on p53 function, and therefore would not be an appropriate treatment 
regime if p53 function was disrupted due to mutation or deletion (Dohner et al., 1995, 
Pettitt et al., 1999). 
However, despite the information these molecular factors provide about disease 
prognosis and the pathology of CLL, their ability to reliably predict disease progression 
on a patient by patient basis is limited.  Prior to the commencement of therapy a “wait 
and watch” strategy is used which uses the rate of lymphocyte doubling, or the 
lymphocyte doubling time (LDT), over a 6 month period to assess when to start 
treatment (Molica and Alberti, 1987, Montserrat et al., 1986).  For instance, if the LDT 
is less than 6 months this suggests there is an increased likelihood of disease progression 
due to the increasing tumour burden.  In addition, if a patient begins to experience 
symptoms or complications therapy is also started as this is also an indicator that the 





As previously described, treatment may not be commenced straight away for patients 
who present with CLL which is non-aggressive and is administered based on clinical 
stage, age, and fitness (Oscier et al., 2012).  To date CLL remains incurable and 
treatment strategies are focused upon managing this disease by decreasing tumour 
burden through the destruction of CLL cells via chemotherapy and biological therapy, as 
well as managing complications such as anaemia, autoimmunity, immunosuppression 
and infection (Morrison, 2010, Oscier et al., 2012).   
The first line treatment for CLL is chemotherapy where fludarabine is the basis for the 
majority of treatment plans (Oscier et al., 2012).  However, as previously discussed, 
fludarabine induces cell death by inhibiting DNA synthesis in a p53 dependent manner, 
and this can give rise to refractory disease in patients with either p53 mutation/deletion 
(Dohner et al., 1995, Pettitt et al., 1999).  To curb the development of drug resistance 
and limit non-specific toxicity, fludarabine-combined chemotherapy is used (Hallek and 
Eichhorst, 2004).  For instance, fludarabine is given alongside; cyclophosphamide (FC), 
cyclophosphamide and rituximab (FCR), cyclophosphamide and mitoxantrone (FCM), 
and cyclophosphamide, mitoxantrone and rituximab (FCMR) (Oscier et al., 2012, 
O'Brien et al., 2001, Hillmen, 2004).   
While combination of fludarabine with cyclophosphamide is the foundation for the 
majority of regimes, new alkylating agents have entered the clinic in place of 
cyclophosphamide and another drug, chlorambucil, and are used for combination 
therapy where treatment with FC based options are no longer appropriate (Oscier et al., 
2012).  For instance, bendamustine (B), may be used with fludarabine as it is well 
tolerated by patients (El-Mabhouh et al., 2014, Woods et al., 2012).  This compound is 
also used in parallel with rituximab (BR) (Oscier et al., 2012, Zaja et al., 2013), a 
monoclonal antibody that is B cell-specific and targets CD20 to induce cell death via 
antibody-dependent cell-mediated-cytotoxicity (ADCC) (Alduaij and Illidge, 2011).  
This biological therapy may also be used in combination with fludarabine and 
cyclophosphamide, [FR and (C+R respectively)] (Oscier et al., 2012).  Other 
monoclonal antibodies such as alemtuzumab have even greater specificity for B cells 
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because it binds to CD52, a marker of B cell maturity (Tembhare et al., 2013).  This 
antibody is used in combination with fludarabine (FA) as well as cyclophosphamide, 
fludarabine, and rituximab (CFAR) (Oscier et al., 2012).  These monoclonal antibodies 
may also be used alongside glucocorticoids such as dexamethasone and high dose 
methylprednisolone (HDMPR) (Smolej et al., 2012).   
Steroids such as these are commonly used following relapse as second line treatments 
because they are associated with side effects.  CHOP, cyclophosphamide, doxorubicin, 
vincristine and prednisolone is a common second line combination therapy that is also 
used for the treatment of non-Hodgkin’s lymphoma (Hamblin, 2001).  If this round of 
second line treatment is ineffective, a stem cell transplant may be performed.  However, 
this approach is only suitable for younger, fit patients and is uncommon (Oscier et al., 
2012).   
New agents for the treatment of this disease are being developed to therapeutically 
target factors contributing to CLL pathogenesis.  For instance, compounds such as 
lenalidomide disrupt the interaction between CLL cells and the tumour 
microenvironment (Chen, 2013), while Bruton’s tyrosine kinase (Btk) inhibitors such as 
ibrutinib are directed against BCR signaling (Hendriks et al., 2014).   
 
1.3.3.5 Pathogenesis 
The treatment options described above focus on inducing cell death, however, anti-
proliferative agents are also likely to have value because of the role of proliferation in 
CLL pathogenesis (Messmer et al., 2005).  In the past the characteristic accumulation of 
lymphocytes seen in this disease was attributed to enhanced cell survival (Brody et al., 
1969).  This was because early studies showed CLL cells to be arrested in G0 of the cell 
cycle (Dameshek, 1967, Brody et al., 1969), and that these cells over express the anti-
apoptotic proteins, Mcl-1 and Bcl-2 as well as under express pro-apoptotic Bax 
(Gottardi et al., 1995, Zenz et al., 2010, Pepper et al., 1997, Kitada et al., 1998).  
However, this paradigm was challenged when CLL cells were demonstrated to have a 
significant level of proliferative activity in a study by Messmer et al. (2005) whereby 
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deuterium was used to label the DNA of newly-formed CLL cells.  Further studies using 
deuterium labelling of CLL cells showed that the level of cell division was reduced in 
comparison to normal B cells (Defoiche et al., 2008, van Gent et al., 2008), but that 
deuterium labeled CLL cells remained in circulation for longer than their healthy 
counterparts, suggesting that they have a prolonged survival.  Collectively, these studies 
showed that the characteristic lymphocytosis seen in this disease arises due to both cell 
division and enhanced cell survival. 
Proliferation of CLL cells is localised to proliferation centers in the haemic tissues such 
as the lymph node (Ramsay and Rodriguez-Justo, 2013).  Interaction within the 
microenvironment is important in the pathogenesis of this disease because it is here that 
CLL cells come into contact with supportive cells such as helper T cells, nurse like cells, 
follicular dendritic cells (FDC) and stroma cells which provide survival and proliferative 
stimuli (Pleyer et al., 2009).  For instance, stimulation of CLL cells by helper T cells 
expressing CD40 ligand (CD40L) has been shown to induce proliferation (Patten et al., 
2008, Pascutti et al., 2013).  However, despite controversy surrounding the role of T 
cells within the proliferation center the presence of CD40L has been shown to be 
localised in the germinal center following treatment with anti-CD40L (Han et al., 1995).  
Soluble factors such as IL-21 and IL-4 are also secreted by T cells to further stimulate 
cell division of CLL cells (Ahearne et al., 2013).  In addition to this, stimulation of CLL 
cells via CD40-CD40L interaction contributes to disease pathogenesis by providing anti-
apoptotic signals.  For instance, CD40 ligation has been shown to induce the expression 
of Bcl-xl and Mcl-1 as well as reducing Bcl-2 levels having the effect of promoting cell 
survival (Willimott et al., 2007).  Moreover, stimulation via CD40L can mediate 
resistance to purine analogues such as fludarabine (Citores et al., 2010). 
B cell activation via B cell receptor (BCR) signaling is another contributor to CLL 
pathogenesis, and factors affecting disease prognosis such as IgVH mutational status are 






1.4 THE IMPORTANCE OF CELL METABOLISM IN CLL 
 
As discussed above, proliferation is important to the pathogenesis of CLL.  This, 
combined with the fact that cell division is an energetically demanding process 
(Garedew et al., 2012), makes it reasonable to assume that cell metabolism may also be 
important by proxy.  A hallmark of malignancy is that cancer cells rapidly consume 
glucose and switch to a glycolytic phenotype even in the presence of ample oxygen, a 
phenomenon known as the Warburg effect (Warburg et al., 1924).  However, this effect 
has also been seen in non-cancerous cells such as lymphocytes which use this 
mechanism to provide quick energy to support rapid proliferation as part of the immune 
response (Dang, 2012).  In order to assess whether CLL cells experience the Warburg 
effect first it is important to understand the metabolic characteristics of their healthy 
counterpart, normal B cells.   
 
1.4.1 Normal B cell metabolism 
Normal B cells have been shown to change their preferred means of energy generation 
in response to antigenic engagement (Garcia-Manteiga et al., 2011).  For instance, in 
naïve and memory B cells, which are generally inactive, oxidative phosphorylation is 
the primary means of cell metabolism (Chacko, 2013).  However, once the cell is 
activated it undergoes differentiation and develops into a plasma cell, inducing aerobic 
glycolysis as well as promoting glutaminolysis to support antibody secretion (Kominsky 
et al., 2010).  Metabolic flux analyses using mouse B cells show that BCR crosslinking 
(BCR-XL) increases both the acidity of the extracellular environment indicative of 
enhanced glycolytic activity, and the degree of oxygen consumed required for oxidative 
phosphorylation (Capasso et al., 2010).  Studies by Doughty et al. (2006), and Fu et al. 
(2004) provide evidence that the main substrate metabolised by these cells is glucose, as 
activating stimuli such as BCR-XL and phytohaemagglutinin (PHA) induce the 
expression of glucose transporters such as GLUT1 to facilitate glucose uptake.   
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Taken together, these studies provide a basis with which to model the metabolism of 
CLL cells in order to assess whether the Warburg effect is a feature of CLL. 
 
1.4.2 CLL cell metabolism 
The studies in normal B cells suggest that the Warburg effect may be also a feature of 
malignant transformation in CLL because of the ‘Warburg like’ glycolytic phenotype 
that is adopted by lymphocytes during cell division (Dang, 2012).  Although glycolysis 
is less efficient than oxidative phosphorylation, there are numerous benefits associated 
with a glycolytic phenotype for malignant cells.  For example, glycolysis promotes cell 
migration (Gallagher et al., 2007, Cheung and Vousden, 2010, Su et al., 2009), aids 
nutrient uptake, promotes cell survival and protects from oxidative stress (Vander 
Heiden et al., 2009, Bensaad and Vousden, 2007, Cheung and Vousden, 2010, Sloan and 
Ayer, 2010).   
However, studies examining the metabolic characteristics of CLL cells indicate that 
rapid consumption of glucose does not occur in these cells.  In contrast to what is seen in 
other malignancies, CLL cells have been shown to have a lower glucose requirement 
when compared to normal B cells (Brody et al., 1969, Warburg et al., 1924).  This is 
supported by studies using fluorodeoxyglucose positron emission tomography (FDG-
PET), a technique which exploits rapid glucose uptake.  The use of FDG-PET is not 
sensitive enough to estimate disease progression in CLL because glucose consumption 
is at a low level (Karam et al., 2006).  These studies contradict the Warburg paradigm, 
but do not take into consideration the likely low energy requirements of circulating CLL 
cells which are arrested in G0 of the cell cycle.     
Recent work has begun to clarify the metabolic requirements of CLL cells.  Jitschin et 
al. (2014) have shown that the level of oxidative phosphorylation is increased in CLL 
cells compared to normal B cells, an observation that is in keeping with studies from this 
department where CLL cells were shown to have considerable levels of oxidative stress 
(Moran et al., 2002).  In the absence of increased glucose uptake, CLL cells may 
metabolise other substrates in order to support survival and proliferation.  For instance, 
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glutamine, glycogen (Mitus et al., 1958, Jones et al., 1962), or fatty acids as recently 
described by Spaner et al. (2013) could all act as energy reservoirs.  Glutaminolysis has 
been shown to be augmented in cervical cancer as opposed to glycolysis (Reitzer et al., 
1979, Vousden and Ryan, 2009), whereas enhanced oxidative phosphorylation is a 
feature of breast cancer (Jose et al., 2011, Bonuccelli et al., 2010a), similar to what is 
reported by Jitschin et al. (2014) in the context of CLL.  Thus, although CLL cells do 
not appear to exhibit archetypal characteristics of the Warburg effect, these cells do 
show signs of metabolic derangement.   
Evidence that the metabolism of CLL cells is altered is provided by MacIntyre et al. 
(2010) in a study whereby serum levels of metabolites are measured and compared in 
M-CLL cells and UM-CLL cells.  This shows lactate, fumarate and uridine levels to be 
increased in patients with UM-CLL suggesting changes in the pathobiology of these 
cells may alter cell metabolism.  However, because this study examined serum samples 
this may reflect the metabolic activity of not only circulating cells but proliferating cells 
in the secondary tissues also.  This would fit in with the switching between metabolic 
pathways seen in normal B cells following B cell activation (Garcia-Manteiga et al., 
2011, MacIntyre et al., 2010) and account for the differences in serum metabolites 
between M-CLL and UM-CLL cells because UM-CLL cells are chronically stimulated 
via the BCR (Chiorazzi and Ferrarini, 2003, Krysov et al., 2010).   
The differences between these two prognostic groups suggest that metabolic 
reprogramming, a known feature of the Warburg effect is occurring in these cells.  
Studies by Rodriguez et al. (2013) and Tili et al. (2012) support this notion as mutation 
of sucrose isomaltase (Rodriguez et al., 2013) and reduced miR-125b (Tili et al., 2012) 
have both been demonstrated to cause increased expression of genes specific to glucose 
metabolism.  Furthermore, the study by Tili et al. (2012) correlated miR-125b 
expression, and consequently increased glucose metabolism, with poor prognosis.   
Taken together these reports indicate that although CLL cells have not been shown to 
have enhanced glycolysis or rapid glucose consumption typical of the Warburg effect 
the aspects of their metabolism differs from normal B cells.  CLL cells likely use 
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oxidative phosphorylation when located in the circulation and switch to a more 
glycolytic phenotype during cell division, akin to normal B cells.  However, increased 
levels of oxidative phosphorylation in the absence of increased glucose uptake suggest 
that these cells may utilise alternative substrates.  Moreover, metabolic reprogramming 
is a feature in CLL. 
 
1.5 THERAPEUTIC TARGETING OF CELL METABOLISM IN CLL 
 
Although CLL cells have not been shown to promote glycolysis over oxidative 
phosphorylation, the importance of glycolysis to the pathophysiology of this disease can 
be demonstrated by inhibiting this process.  For example, inhibition of hexokinase, a key 
glycolytic enzyme, using lonidamine results in decreased cell viability in vitro as well as 
reducing lymphocyte count, lymphadenopathy and splenomegaly when it is used in vivo 
(Tura et al., 1984).  Furthermore, inhibition of the glycolytic pathway using 2-
deoxyglucose (2DG) has also been shown to cause a reduction in cell viability as well as 
attenuating ATP production (Tidmarsh et al., 2004).  Clearly inhibition of glycolysis has 
an effect in these cells.  Therapeutic targeting of cell metabolism is an approach that has 
had a degree of success for the treatment of some cancers (Zhao et al., 2013b).  One 
strategy has been to target lactate transport out of the cell because a consequence of 
enhanced glycolytic activity is the accumulation of lactic acid, a toxic bi-product 
(Polanski et al., 2014).  The export of lactate has been shown to be mediated by the 
monocarboxylate transporter (MCT) -1 and -4, inhibition of which has been shown to 
cease proliferation and induce cell death (Halestrap and Wilson, 2012).   
 
1.5.1 Monocarboxylate transporters (MCTs) 
MCTs are a family of membrane transport proteins of which 14 members have been 
identified thus far (Halestrap and Price, 1999, Halestrap and Meredith, 2004).  The 
protein consists of 12 highly conserved transmembrane domains (TMDs) which have 
the N and C termini situated in the cytoplasm (Figure 1.2) (Visser et al., 2007).   
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Sequence variations between isoforms can be observed in the C terminus and a large 
intracellular loop located between TMDs 6 and 7 which are thought to be involved in 
regulation and confer substrate specificity (Halestrap and Price, 1999, Morris and 
Felmlee, 2008).  This is demonstrated in studies by Halestrap and Price (1999) and 
Rahman et al. (1999) where substitution of Phe
360
 to Cys in the TMD 10 in Chinese-
hamster MCT1 reduced the affinity of MCT1 for lactate and pyruvate, and substitution 
of Asp
302
 to Glu in the TMD 8 in rat MCT1 eliminated lactate transport.  The N 
terminus is thought to be involved in maintenance, plasma membrane insertion and 
energy coupling, i.e. binding of a proton (Halestrap and Price, 1999). 
MCT’s have been shown to transport a wide range of substrates such as 
monocarboxylates; lactate, pyruvate, butylate; oxo-acids, and ketone bodies (Halestrap 
and Price, 1999, Morris and Felmlee, 2008).  Of the 14 identified MCT’s, only MCT’s 
1-4 have been found to be proton-linked co-transporting a single proton in association 
with the substrate across the plasma membrane (Morris and Felmlee, 2008, Halestrap 










Figure 1.2:  Structure of MCT1 and CD147.  MCT1; the diagram illustrates 12 
TMD’s, a large intracellular loop between TMD 6 and TMD 7, the N terminus and C 
termini both located in the cytoplasm.  CD147; the diagram shows two extracellular Ig-
like domains, a highly conserved a single transmembrane domain with and a short C 
terminus situated in the cytosol the latter two are thought to be responsible for 






1.5.1.1 Monocarboxylate transporter 1 (MCT1) 
MCT1 (SLC16A1, human gene locus 1p13.2) is 40-50kDa protein which has ubiquitous 
tissue expression (Halestrap and Meredith, 2004).  A proton-dependent co-
transporter/exchanger it is situated in the apical and basolateral membranes when active 
(Morris and Felmlee, 2008).  Substrates transported by MCT1 include; short chain un-
branched aliphatic monocarboxylates i.e. propionate and acetate, in addition to other 
monocarboxylates such as pyruvate, acetoacetate, lactate, α-ketoisovalerate, α-
oxoisohexanoate, α-oxoisovalerate, XP13512 and butyrate (Morris and Felmlee, 2008, 
Halestrap and Meredith, 2004). 
MCT1 also has the ability to function as a monocarboxylate exchanger transporting 
substrates such as lactate out of the cell while bringing in substrates such as pyruvate for 
use in the Tricarboxylic acid cycle (Halestrap and Meredith, 2004).  Transportation may 
be bi-directional, however MCT1 has been shown to be mainly used for substrate uptake 
(Morris and Felmlee, 2008). 
 
1.5.1.2 Monocarboxylate transporter 4 (MCT4) 
MCT4 (SLC16A3, human gene locus 17q25.3) is a 54kDa protein expressed mainly in 
cells which have a high level of glycolytic activity (Halestrap and Meredith, 2004).  For 
example WBCs, tumors, astrocytes, chondrocytes, the brain, kidneys, retinal pigment 
epithelium (RPE), placenta, heart, lungs and small intestine, all express MCT4 
(Halestrap and Meredith, 2004, Morris and Felmlee, 2008).  It is located in the 
basolateral membrane when active, similarly to MCT1, and is also a proton linked co-
transporter transporting substrates such as; lactate, pyruvate, acetoacetate, α-
ketobutyrate, α-ketoisocaproate, α-ketoisovalerate, and D-β-hydroxybutyrate (Morris 
and Felmlee, 2008).   
 




MCT2 (SLC16A7, human gene locus 12q14.1) and MCT3 (SLC16A8, human gene 
locus 22q13.1) similarly to MCT -1 and -4, are proton linked co-transporters and are 
expressed on the basolateral membrane  (Morris and Felmlee, 2008).  Unlike MCT1 
which has ubiquitous expression, expression of MCT -2 and -3 is restricted akin to 
MCT4 .  MCT2 expression has been demonstrated in the testis, liver, kidney, skeletal 
muscle, heart, brain, spleen, and pancreas (Halestrap and Meredith, 2004).  MCT3 
expression has been shown to be more restricted arising in the Retinal pigment 
epithelium (RPE), choroids plexus, aorta, placenta, and kidney (Halestrap and Meredith, 
2004).  Surface expression of these proteins is dependent on the presence of an 
accessory protein.  MCT -1, -3, and -4 share the same protein, CD147 which is 
discussed in the next section.  For the surface expression of MCT2 gp70 (EMBIGIN) is 
required (Halestrap and Price, 1999, Morris and Felmlee, 2008).  The focus of this study 
is the inhibition of lactate transport mediated by MCTs.  MCT2 transports pyruvate, 
lactate and ketone bodies while MCT3 transports lactate (Halestrap and Meredith, 
2004).  For the purposes of this study MCT3 was not considered because of its restricted 
expression however, MCT2 has been shown to be present in normal B cells by 
Merezhinskaya et al. (2004).  The inhibitors in development by AstraZeneca are targeted 
against MCT1 and 4.  AZD3965 directed against MCT1 is known to inhibit MCT2 also.  
For this reason MCT2 was not investigated in this study.   
 
1.5.1.3.1 CD147 
For the surface expression of both MCT -1 and -4 a chaperone protein, CD147, is 
required (Halestrap and Meredith, 2004, Gallagher et al., 2007).  A extracellular matrix 
metalloproteinase, CD147 has a single highly conserved transmembrane domain (Figure 
1.2) with two extracellular Ig-like domains in addition to a short C terminal situated in 
the cytosol (Halestrap and Meredith, 2004, Kirk et al., 2000).  CD147 is highly 
conserved and widely expressed with increased quantities being noted in RPE, tumors, 
activated T cells, and on the neonatal blood-brain barrier (Su et al., 2009, Kirk et al., 
2000).  The vital role of CD147 for the expression of MCT -1 and -4 is demonstrated by 
Kirk et al. (2000) and Gallagher et al. (2007) whereby silencing of CD147 in breast 
21 
 
cancer resulted in degradation of MCT4 while sole transfection of MCT -1 or -4 into 
mammalian cell lines resulted in low levels of surface expression in comparison to co-
transfection of MCT -1 or -4 with CD147.   
The process of MCT -1 or -4 surface expression is described in a general model by 
Mellman and Nelson (2008) and begins in the endoplasmic reticulum (ER).  Here the 
core-glycosylated form of CD147 (30kDa) is synthesized and accumulated alongside 
MCT -1 and -4 before forming a complex with either MCT -1 or -4 which triggers a 
conformation change in CD147 producing the fully-glycosylated form.  Dimerization 
then occurs with a second complex and the MCT-CD147 heterodimer is deposited into a 
vesicle mediated by coatomer protein complex-II (COPII).  This vesicle is then 
transported to the golgi complex by soluble NSF attachment protein receptor (SNARE) 
and vesicle tethering mechanisms where coatamer protein complex-I (COPI) mediates 
translocation of the heterodimer to the trans-golgi network (TGN).  From the TGN the 
heterodimer is transported to the plasma membrane via the cytoskeleton using similar 
mechanisms modulated by SNARE and vesicle tethering (Mellman and Nelson, 2008). 
 
1.5.1.4 Regulation of MCT -1 and -4 
Surface expression of MCT -1 and -4 has been shown to be differentially regulated.  
Factors such as CD147, substrate concentration, pH, hormones, hypoxia, and 
transcription factors such as MYC have been shown to mediate the expression of MCT -
1 and -4 (Halestrap and Meredith, 2004).  However, while some factors such as AMPK, 
testosterone, chronic stimulation/exercise and CD147 have been shown to upregulate 
expression for both these transporters other factors have been shown to have differing 
effects specific for each isoform.  For instance, MCT1 message is known to increase in 
response to increased lactate and butyrate concentrations (Halestrap and Price, 1999, 
Hashimoto et al., 2007, Kennedy and Dewhirst, 2010a) and is specific to MCT1 having 
no effect on MCT4 expression.  Other factors such as weight loss, obesity and hypoxia 
have opposing effects on MCT -1 and -4 expression.  For example, weight loss and 
hypoxia downregulate MCT1 while obesity promotes MCT1 expression, with the 
reverse being true for MCT4 (Kennedy and Dewhirst, 2010a, Ullah et al., 2006, 
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Gallagher et al., 2007).  In addition to transcriptional regulation differences between 
message and protein studies examining the expression of MCT-1 and -4 indicate that 
these transporters are regulated by post-transcriptional and post-translational 
mechanisms also (Halestrap and Wilson, 2012).   
 
1.6 AIMS AND HYPOTHESIS 
 
1.6.1 Aims 
In order to establish whether monocarboxylate transporter (MCT) -1 and -4 are possible 
therapeutic targets in CLL the first aim of this investigation was to characterise MCT-1 
and -4 expression in these cells.  The presence of the chaperone protein CD147, required 
for the function of these proteins, was measured using flow cytometry.  Localisation of 
MCT1 was performed using immunocytochemistry and confocal microscopy.  Protein 
and message levels for both transporters was examined using Western blotting and qRT-
PCR in CLL cells as well as normal B cells in addition to two CLL cell lines; MEC-1 
and HG3 cells.   
The second aim of the study was to assess the expression of these transporters following 
CD40 ligation to examine the influence of microenvironmental stimuli.  Moreover, to 
provide further insight into CLL cell metabolism and identify novel targets a Fluidigm 
Biomark™ chip was used to assess the expression of genes associated with cell 
metabolism such as glycolysis while real time measurements were obtained using the 
SeahorseXF24 metabolic flux analyser.   
The third aim of the study was to evaluate whether MCT -1 and -4 are potential 
therapeutic targets, using the MCT1 inhibitor AZD3965 and siRNA specific for MCT4.  
The sensitivity of the CLL cell lines, MEC-1 and HG3 to the compound was assessed by 
staining for cell death using 3,3'-dihexyloxacarbocyanine iodide (DiOC6) and propidium 
iodide (PI).  In addition cell viability was measured using Alamar blue®.  To assess 
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whether the compound inhibited proton mediated transport by MCT1 extracellular 




1) MCT -1 and -4 are expressed by CLL cells [H1]. 
 
MCT -1 and -4 are not expressed by CLL cells [H0]. 
 
2) The need for monocarboxylate transport is increased when CLL cells are induced to 
proliferate [H1]. 
 
The need for monocarboxylate transport is unaffected when CLL cells are induced to 
proliferate [H0]. 
 
3) CLL cells are sensitive to MCT -1 and/or -4 inhibition resulting in cell death [H1]. 
 





2 CHAPTER 2:  CHARACTERISATION OF MCT -1 AND -4 EXPRESSION 




2.1.1 MCT -1 and -4 expression in cancer cells 
As previously discussed, one consequence of enhanced glycolysis is the accumulation of 
lactic acid in the cytoplasm.  In order for a high level of glycolytic activity to be 
maintained MCT -1 and -4 fulfill a crucial role mediating lactate transport out of the 
cell.  This is particularly important for the Warburg effect, as in various cancers the 
expression of both these transporters, along with the accessory protein CD147, is 
increased in order to cope with the increased demand for lactate export (Pinheiro et al., 
2012, Halestrap and Wilson, 2012).  Expression of MCT-1 and -4 has also been 
correlated with poor prognosis in multiple types of cancer such as breast (Pinheiro et al., 
2010), gastric (Torres de Oliveira et al., 2012, Pinheiro et al., 2009), prostate (Pertega-
Gomes et al., 2011), and bone (Zhao et al., 2014).  In relation to B cell malignancies, 
CD147 expression has been associated with prognosis in acute lymphocytic leukaemia 
(ALL) as well as non-Hodgkin’s lymphoma (NHL).  This illustrates further the 
importance of these proteins in cancer biology and haemato-oncology (de Vries et al., 
2010).   
However, whilst these transporters have been investigated in the context of solid tumors, 
few studies have examined haematological malignancies such as CLL (Hartmann et al., 
2012).   
 
2.1.2 MCT -1 and -4 expression in B cells 
The aim of this chapter is to examine the expression of both MCT -1 and -4 in primary 
CLL cells and normal B cells.  Few studies have assessed the expression profile of 
MCTs in normal B cells.  The very first study of MCT expression on haemic cells 
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reported that MCT4 was present on white blood cells (WBCs) without differentiating 
between subtypes (Halestrap and Price, 1999).  Later, a specific investigation of 
lymphocytes by Merezhinskaya et al. (2004) showed expression of MCT -1, -2 and -4 
although this study did not distinguish between B and T cells.  The expression of these 
transporters is not surprising considering that normal lymphocytes are known to adopt a 
Warburg-like phenotype following activation.  This switch to a glycolytic phenotype 
supports the rapid cell division required to mount an efficient immune response (Garcia-
Manteiga et al., 2011).  In this chapter the expression of these transporters and the 
ancillary protein CD147 was investigated using flow cytometry, immunocytochemistry, 




2.2 MATERIALS AND METHODS 
 
2.2.1 Recovery of cryopreserved samples 
 
2.2.1.1 Primary chronic lymphocytic leukaemia (CLL) cells 
CLL cells were acquired from CLL patients following informed consent and the 
approval of the Liverpool Research Ethics Committee.  Peripheral blood was obtained 
via venepuncture and protected from coagulation with the addition of heparin.  WBCs 
were isolated by slowly layering the blood sample on to Lymphoprep™ (Axis-Shield, 
Stockport, UK) solution in a 2:1 ratio followed by centrifuged for 30 minutes at 800 rcf.  
The isolated mononuclear cells were then washed using Roswell Park Memorial 
Institute (RPMI) media (Biosera, Uckfield, UK) and resuspended in RPMI 
supplemented with 10% heat inactivated foetal calf serum (FCS) (Sigma, Gillingham, 
UK).  To heat inactivate the FCS, a bottle was thawed at room temperature or at 4C, 
and then heated at 58.8C for 1 hour in a water bath.  In preparation for 
cryopreservation, cooled RPMI media containing 10% FCS and 20% dimethyl sulfoxide 
(DMSO) (Sigma, Gillingham, UK) was added drop wise until a final concentration of 
10% DMSO was attained.  1mL aliquots of this cell suspension were then frozen at -
80C prior to storage at -150C within the University of Liverpool Leukaemia Biobank.   
Cryopreserved CLL cells were recovered on ice by drop wise addition of RPMI media 
modified with 100 units/mL penicillin-streptomycin (Invitrogen, Paisley, UK), 2mM L-
glutamine (Invitrogen, Paisley, UK), and 0.5% filtered bovine serum albumin (BSA) 
(Sigma, Gillingham, UK).  Once a final volume of 10mL was achieved, samples were 
centrifuged (500 rcf, 5 minutes, 4°C) and washed in modified media to remove DMSO 





2.2.1.2 Normal B cells 
Normal B cells were analysed fresh from whole blood (flow cytometry only) from 
healthy consenting volunteers or isolated from buffy coats purchased from the National 
Health Service Blood and Transplant (NHSBT, Speke, UK).  Mononuclear cells were 
separated from buffy coat samples using density-gradient centrifugation as detailed in 
section 2.2.1.1 except the buffy coat samples were diluted 1:4 with RPMI media prior to 
layering on to the Lymphoprep™.  These samples were then stored at -150ºC. 
 
2.2.1.3 Suspension cell lines 
Raji (Burkitt’s lymphoma cell line) and MEC-1 (CLL cell line) cells were purchased 
from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany).  MDA-MB-231 (breast cancer cell line) cells were 
kindly donated by Dr Guozheng Wang and Dr Helen Kalirai (University of Liverpool). 
Raji, MDA-MB-231, and MEC-1 cells were recovered at 37C in a water bath for 5 
minutes prior to the addition of 10mL of RPMI media or for the MEC-1 cells, 
Dulbecco's Modified Eagle's Medium (DMEM) (Sigma, Gillingham, UK), modified 
with 100 units/mL penicillin-streptomycin, 2mM L-glutamine, 10% heat inactivated 
FCS.   
 
2.2.2 Cell viability 
Assessment of cell viability was done using Trypan blue exclusion.  Viable cells remain 
colourless because cell membranes remain intact and exclude the dye.  Non-viable cells 
absorb Trypan blue because the membrane is compromised thereby making them appear 
blue under microscopic examination (Altman et al., 1993).  0.1% Trypan blue (Sigma, 
Gillingham, UK) was added to the cell suspension at an appropriate dilution.  Live cell 
count, dead cell count, cell viability and live cell concentration were determined using 
the Cellometer™ AutoT4 cell counter (Peqlab Ltd, Sarisbury Green, UK).  The 
Cellometer™ AutoT4 cell counter was focused according to the manufacturer’s 




2.2.3 B cell purification 
Mononuclear separation of peripheral blood was undertaken using Lymphoprep™ as 
described in 2.2.1.1.  B lymphocytes were isolated using negative selection using the 
MACS B cell purification Kit II (Miltenyi Biotec, Bisley, UK) as per the manufacturer’s 
instructions.  The cell suspension was incubated with biotin conjugated antibodies 
specific for non-B cells (anti-CD2, anti-CD14, anti-CD16, anti-CD36, anti-CD43, and 
anti-glycophorin A) followed by incubation with microbeads coated with anti-biotin 
(IgG1).  The cell suspension was then passed through a MACS column where the 
microbeads become immobilised due to the presence of a magnetic field and trap non-B 
cells, while B cells are eluted.  The quality of the purified specimen was assessed using 
flow cytometry for CD19-PE.  Autofluoresence and non-specific binding were 
accounted for using conjugated isotype specific control; IgG1,y1-PE (BD Biosciences, 
Oxford, UK).  The BD FACS Calibur™ (FACS Calibur, BD Biosciences, Oxford, UK) 
was calibrated using BD CaliBRITE™ beads (BD Biosciences, Oxford, UK) to 
compensate for spectral overlap (BD CellQuestPro User guide, 2002). 
 
2.2.4 B-CLL cell purification 
The malignant B cells from CLL patients were purified by negative selection using a 
cell purification kit designed for this purpose [MACS B Cell isolation kit (B-CLL) 
(Miltenyi Biotec, Bisley, UK)] following the manufacturer’s guidelines.  The same 
quality assurance measures were taken as described in section 2.2.3. 
 
2.2.5 Antibodies 
Rabbit polyclonal anti-MCT1 (AZ5565) (AstraZeneca, Manchester, UK), rabbit 
polyclonal anti-MCT4 (AZ5570) (AstraZeneca, Manchester, UK); rabbit polyclonal 
anti-MCT1 (ab85021) (Abcam, Cambridge, UK), rabbit polyclonal anti-MCT4 
(ab74109) (Abcam, Cambridge, UK); isoform specific rabbit polyclonal anti-MCT1, 
isoform specific rabbit polyclonal anti-MCT4 kindly provided by Dr Nancy Philp 
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(Thomas Jefferson University, PA, USA); mouse monoclonal anti-MCT1 (H-1) (sc-
365501) (Insight Biotechnology, Wembley, UK), mouse monoclonal anti-MCT4 (sc-
376101) (Insight Biotechnology, Wembley, UK), rabbit polyclonal anti-MCT4 (HS-90) 
(sc-50329) (Insight Biotechnology, Wembley, UK). 
 
2.2.6 Flow cytometry for the detection of CD147 
CLL cells and normal B cells from buffy coats that had been recovered from -150ºC 
storage were centrifuged and resuspended in modified ice cold phosphate buffered 
saline (PBS) (Fisher Bioreagents®, Fischer Scientific, Leicestershire, UK) pH 7.2 
containing 1% BSA and 0.1% sodium azide (Sigma, Gillingham, UK) to a concentration 
of 5 x 10
6
 cells/mL.  Following manufacturer’s guidelines, fluorophore-conjugated 
antibodies were added to a 96 well U bottomed plate along with 100µL of cell 
suspension.  For the purposes of this study anti-CD5-R-PE (IgG1) (ab27372; Abcam, 
Cambridge, UK) (578nm), anti-CD20-APC (IgG1) (340908; BD Biosciences, Oxford, 
UK) (660nm), anti-CD23-PerCP-Cy™5.5 (IgG1,k) (561166; BD Biosciences, Oxford, 
UK) (695nm) were used to identify the presence of CLL cells (CD5+/CD20+/CD23+) 
and normal B cells (CD5-/CD20+/CD23+).  Anti-CD147-FITC (IgG1) (ab69771; 
Abcam, Cambridge, UK) (520nm), was then used to examine CD147 expression 
specifically on these cells.  
Following addition of antibody the cell suspension was incubated in the dark 30 minutes 
on ice.  100µL of modified PBS was then added and the plate was centrifuged at 500 rcf 
for 3 minutes at 4°C.  The supernatant was then removed, and the cell pellet was 
resuspended in 100µL of modified PBS and 400µL of sheath fluid ready for analysis.   
To account for autofluoresence and non-specific binding conjugated isotype specific 
controls were used; IgG1,y1-FITC (345815; BD Biosciences, Oxford, UK), IgG1-R-PE 
(345816; BD Biosciences, Oxford, UK), IgG1-APC (554681; BD Biosciences, Oxford, 
UK), and IgG1,k-PerCp™-Cy5.5 (552834; BD Biosciences, Oxford, UK).  The analyser 
was calibrated as detailed in 2.2.3.   
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For the analysis of normal B cells from fresh whole blood specimens samples were 
treated with red cell lysis buffer [150mM NH4Cl (Sigma, Gillingham, UK), 10mM 
NaHCO3 (Sigma, Gillingham, UK), 1mM EDTANa2 (Sigma, Gillingham, UK), in 1L 
sterile ddH2O (Fresenius Kabi sterile water, Runcorn, UK)].  This was followed by a 
washing step and resuspension of the remaining cells in 200µL of sterile PBS.  Staining 




2.2.7.1 Alkaline phosphatase (APAAP) staining 
Cytospin slides were prepared using a Cytospin 2 (Shandon, Block Scientific Inc, NY, 
USA) to which 100µL of a 5 x 10
6
/mL cell suspension was added.  The slide was 
subsequently fixed in acetone (Fischer Scientific, Leicestershire, UK) for 3 minutes, air 
dried, and blocked using 10% BSA and stored at -20ºC for future use.  The slides were 
then thawed for 30 minutes and incubated with anti-MCT1 (1:100) or normal rabbit IgG 
control (1:100) (Insight Biotechnology, Wembley, UK).  For the Raji cell positive 
control a dilution of 1:200 was used.  After a 1 hour incubation period slides were 
washed with PBS and treated with biotinylated anti-rabbit IgG (H+L) (Vector 
Laboratories Inc, Peterborough, UK) for 1 hour.  Slides were then washed and incubated 
with extravidin® alkaline phosphatase (Sigma, Gillingham, UK) for 30 minutes.  Next 
slides were washed in PBS and incubated with 0.45µm filtered VECTOR® Blue 
Alkaline Phosphatase Substrate Kit III (SK-5300) (Vector Laboratories Inc, 
Peterborough, UK), washed, and counterstained with haematoxylin (Sigma, Gillingham, 
UK).  Finally slides were rinsed in tap water and cover slipped.  Images were taken 
using a Nikon DMX2100 Digital camera. 
 
2.2.7.2 Confocal microscopy 
Recovered CLL cells were resuspended at 1 x 10
7 
cells/mL in PBS.  500µL aliquots 
were fixed with the addition of an equal volume of 4% paraformaldehyde (PFH) (Sigma, 
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Gillingham, UK) for a 10 minute period and then washed by centrifugation at 1600 rpm 
for 3 minutes.  Cells were then permeablised using 0.2% Triton-X-100 (Sigma, 
Gillingham, UK) for 5 minutes and washed.  Prior to staining, cells were blocked by 
treatment with a blocking solution (0.1% gelatin (Sigma, Gillingham, UK), 0.5% BSA, 
0.1% sodium azide) for 30 minutes.  Cells were then incubated at 1:20 with anti-MCT1 
(H-1) (mouse) (sc-365501), or purified mouse monoclonal IgG1 isotype control (1:100) 
(R&D systems, Abingdon, UK) for 1 hour at followed by incubation with anti-mouse 
AlexaFluor®555 (1:100) (Invitrogen, Paisley, UK) for 1 hour and centrifuged at 1600 
rpm for 3 minutes.  Cells were subsequently resuspended in PBS and added to poly-L-
lysine (Sigma, Gillingham, UK) coated microscopy slides and air dried.  Slides were 
then mounted and cover slipped ready for examination.   
 
2.2.8 Western blot analysis for MCT -1 and -4 
 
2.2.8.1 Lysate preparation 
Samples were centrifuged at 500 rcf for 5 minutes at 4°C and resuspended in 1mL of 
modified media.  Next the samples were transferred to pre chilled 1.5mL eppendorfs and 
centrifuged at 500 rcf for 5 minutes at 4°C prior to washing using PBS to remove excess 
albumin.  The samples were then lysed using 200µL of clear SDS-PAGE lysis buffer 
(buffer recipes in appendix) per 1 x 10
7
 cells.  To release cellular fragments and shear 
DNA, specimens were sonicated for 5-10 seconds using a Sonics Vibracell™ Ultrasonic 
processor.  Samples were then heated in a heat block at 100°C for 5 minutes as a 
denaturation step.  Finally, the samples were centrifuged at 14,000 rpm for 10 minutes, 
and then transferred to a fresh eppendorf and stored at -20C. 
 
2.2.8.2 Protein determination 
0, 0.125, 0.25, 0.5, 1.0 and 2.0mg/mL BSA protein standards were produced using clear 
SDS–PAGE sample buffer.  These standards were loaded into a 96 well flat bottomed 
plate alongside appropriate dilutions of each sample.  Protein determination was 
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performed using a DC Protein assay kit (Bio-Rad-Laboratories Ltd, Hemel Hempstead, 
UK) as per the manufacturer’s instructions, and read at 630nm using the MQX200 
µQuant plate reader (BioTek®, Potton, UK).  Clear SDS–PAGE sample buffer was used 
as a blank reference.   
 
2.2.8.3 Gel preparation 
10-12% acrylamide resolving gels were used in this study.  Gels were cast using the 
following protocol; 6.45mL ddH2O, 4.25mL 4x Protogel® Resolving buffer (Geneflow 
Ltd, Lichfield, UK), 6.3mL Protogel® Acrylamide Ultra Pure (Geneflow Ltd, Lichfield, 
UK), 50µL ammonium per sulphate (APS) (Sigma, Gillingham, UK), and 15µL 
N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) (Sigma, Gillingham, UK).  5% 
acrylamide stacking gels were cast using this protocol; 4.36mL ddH2O, 1.9mL 
Protogel® Stacking buffer (Geneflow Ltd, Lichfield, UK), 1.24mL Protogel® 
Acrylamide Ultra Pure, 50µL APS and 15µL TEMED. 
The gel apparatus used was the Bio-Rad mini-Protean system, using 1.5mm thick gels 
with a calculated volume of 7.5mL for the resolving gel and 2.5mL for the stacking gel.  
 
2.2.8.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
To separate proteins SDS-PAGE gel electrophoresis was used.  10µg (15μL) of protein 
was loaded into designated wells.  A molecular weight marker (Precision Plus Protein™ 
Kaleidoscope™ Standards, Bio-Rad-Laboratories Ltd, Hemel Hempstead, UK) was 
used (10µL) as a set of standards to identify protein size.  This was diluted to 15l with 
5µL 1x Sample buffer.  1x Sample buffer was also used to adjust the final volume of 
positive control lysates (5μg in 7.5μL) to 15µL.  Once all gel lanes had been filled, the 
gel tank was filled with 1x SDS-PAGE running buffer and run at 30mA/gel for 
approximately 60 minutes.  
Electrophoretic transfer of gel-separated proteins was performed using a Bio-Rad mini-
Transblot apparatus.  Gels were washed in Transfer buffer (Geneflow Ltd, Lichfield, 
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UK) prior to assembly of the transfer sandwich.  Millipore™ Immoblion® Transfer 
membranes (Millipore, Watford, UK) (9cm x 6cm) were prepared by first wetting with 
methanol for 30 seconds (Fischer Scientific, Leicestershire, UK) and then placing them 
into Transfer buffer.  The transfer sandwich was assembled in the following order: a 
bottom sponge soaked in Transfer buffer was overlayed with Whatman paper (10cm x 
8cm) (Fischer Scientific, Leicestershire, UK).  This was followed by the gel and then the 
transfer membrane.  The sandwich was completed with another layer of Whatman paper 
and an upper sponge.  This sandwich was then put into the transfer tank along with an 
ice block and filled with Transfer buffer, noting the direction of transfer towards the 
transfer membrane.  The transfer tank was then run for 1 hour at 400mA constant 
current. 
 
2.2.8.5 Western blotting 
In order to prevent non-specific binding of probe antibodies the membranes were 
incubated in a blocking buffer for 30-60 minutes.  Probing membranes with primary 
antibodies was performed using antibody dilutions of either 1:1000 or 1:2000.  Probe 
solutions were made up using 5mL of blocking buffer plus antibody to make up the 
appropriate dilution.  The membranes were then incubated overnight at 4ºC with 
constant shaking.  Membranes were then washed with TBS-T (2x30 seconds, 2x5 
minutes and 1x15 minutes washes) and then incubated with either HRP conjugated anti-
rabbit or anti-mouse IgG secondary antibodies (1:5000) for 1 hour at room temperature.  
This was followed by another washing step with TBS-T.   
 
2.2.8.6 Detection 
For detection either Amersham ECL prime or Lumigen™ Advanced ECL detection 
reagents (GE Healthcare, Belfast, UK) were used according to the manufacturer’s 
instructions.  A Fujifilm Intelligent dark box (Fujifilm, Bedford, UK) and Fujifilm LAS-





Densitometry analysis of gel images was performed using Aida image analyzer software 
(Version 3.52) (Raytest Gmbh, Straubenhardt, Germany).  All protein amounts are 
reported relative to the expression of -actin detected using mouse monoclonal anti-β-
actin (clone AC-74) (Sigma, Gillingham, UK). 
 
2.2.9 Polymerase chain reaction (PCR) 
 
2.2.9.1 RNA extraction 
Purified samples (>71% CD19+) were centrifuged at 500 rcf for 5 minutes at 4°C and 
resuspended to 5 x 10
6
 cells/mL in media.  Samples were then transferred in 1mL 
aliquots to pre-chilled 1.5mL eppendorf tubes, and then centrifuged at 500 rcf for 5 
minutes at 4°C, washed in PBS, and re-centrifuged for a further 5 minutes.  Pellets were 
stored at -80C prior to use.   
RNA extraction was performed using a QIAshredder™ (Qiagen, Manchester, UK) and a 
RNeasy® minikit (Qiagen, Manchester, UK) as per the manufacturer’s instructions in a 
Fisherbrand UV4PCR hood.  Quantification of extracted RNA was performed using a 
NanoDrop 2000c spectrophotometer (Thermo scientific, Leicester, UK).  Only samples 
with a 260:280 ratio of <2 were used. 
 
2.2.9.2 cDNA synthesis 
Diluted RNA (0.08µg/µL, 12.5μL volume) was reverse transcribed using 1µL of oligo 
(dT)15 primer (Eurofins MWG Operon, Ebersberg, Germany) and a RT master mix 
consisting of: 4µL 5x RT Buffer (Promega, Southampton, UK), 1µL 10mM dNTP’s 
(Promega, Southampton, UK), 0.5µL RNasin plus (Promega, Southampton, UK), and 
1µL M-MLV RTase, (Promega, Southampton, UK).  Final volume was 20μL, and 
reaction tubes were centrifuged at 11,000 rcf for 30 seconds.  Samples were then 




2.2.9.3 Quantitative real-time PCR (qRT-PCR) 
Diluted cDNA (1:4) was added to each designated well in an Mx3000P® 96 well plate 
(Agilent technologies, Wokingham, UK) running each sample in triplicate.  The master 
mix (MCT1, MCT4 or β-actin) was produced using TaqMan® gene expression master 
mix (Applied Biosystems, Life technologies, Paisely, UK) and the corresponding 
primers and probe:  MCT1; TaqMan® gene expression assay Hs00161826_m1* 
(Applied Biosystems, Life technologies, Paisely, UK), MCT4; TaqMan® gene 
expression assay Hs00358829_m1 (Applied Biosystems, Life technologies, Paisely, 
UK), human ACTB (β actin) endogenous control (FAM / MGB Probe, Non-Primer 
Limited) (Applied Biosystems, Life technologies, Paisely, UK).  The master mix was 
then added to the plate as per the manufacturer’s instructions.  Once loading was 
completed the plate was sealed using Mx3000P® optical strip caps (Agilent 
technologies, Wokingham, UK) and centrifuged for 1 minute at 500 rcf.  The PCR 
reaction was then run using a Stratagene Mx3005P QPCR system (Agilent technologies, 
Wokingham, UK).  The following cycling variables were used as suggested by 
TaqMan®; 50°C, 2 minutes, 95°C, 10 minutes, 95°C 15 seconds, 60°C, 1 minute, for 40 
cycles. 
 
2.2.10 Quality assurance 
For the detection of CD147 using flow cytometry a Raji cell line was used as a positive 
control because these cells have been previously reported to express CD147 
(Vangeepuram et al., 1997, Lambert et al., 2002).   
For immunocytochemistry, confocal microscopy, Western blot analysis and qRT-PCR 
either a MEC-1 cell line or a Raji cell line was used as positive control for MCT1 as 
they have both been shown to express this transporter (Lin et al., 1998b).   
For the Western blot analysis and qRT-PCR a MDA-MB-231 cell line was used as a 
positive control for MCT4 as expression of MCT4 was confirmed by Gallagher et al. 
36 
 
(2007).  As a negative control a Raji cell line was used as MCT4 has been reported to 
absent in these cells (Lin et al., 1998b).   
 
2.2.11 Statistical analysis 
Statistical analyses were performed using Graphpad Prism (Version 6.01, Graphpad 
Software Inc., CA, USA).  The statistical tests used are identified when and where they 
are used within the results section of this chapter.  A P value of P  0.05 was considered 








2.3.1 Assessment of CD147 expression in CLL and normal B cells using flow 
cytometry 
As previously described CD147 is a chaperone protein required for the surface 
expression of MCT -1 and -4, and is specific for these members of the MCT family 
(Halestrap and Meredith, 2004, Gallagher et al., 2007, Morris and Felmlee, 2008).  
Commercially available antibodies targeting MCT -1 and -4 are directed against 
cytoplasmic C-terminal epitopes of their respective proteins, and make surface 
expression analysis difficult.  Therefore, CD147 can be used as surrogate marker of 
surface expressed MCT -1 and -4, and this was assessed on CLL and normal B cells 
using flow cytometry.  
B cells from 20 CLL patients and 14 normal controls (consisting of fresh samples from 
10 healthy volunteers and 4 cryopreserved samples prepared from buffy coats) were 
analysed for CD147.  The antibody used is specific for CD147 because it targets the N 
terminus of a fully glycosylated form of the protein that is only expressed on the cell 
surface (Gallagher et al., 2007).  A four colour profile consisting of CD5, CD20 and 
CD23 was used to identify CLL (CD5+/CD20+/CD23+) and normal B cells (CD5-
/CD20+/CD23+).  Multi-colour flow cytometry was used at this point, and the optimal 
combination of fluorophores was determined using the BD Fluorescence Spectrum 
Viewer (Figure 2.1).  Figure 2.2 shows the gating strategy used to identify CLL and 
normal B cells using CD5 and CD20.  Further characterisation of these cells was 
achieved using CD23 (Oscier et al., 2012).  To test the validity of this analytical strategy 
Raji cells were used as a positive control (Figure 2.3) (Lambert et al., 2002, 
Vangeepuram et al., 1997).  Thus, analysis of CD147 expression on CLL and normal B 
cells showed the presence of this protein on the cell surface of both cell types (Figure 
2.4), and comparison of expression levels demonstrate that CD147 levels are 




To account for any effect of cryopreservation on CD147 expression comparisons were 
made between fresh and cryopreserved normal B cells, and CLL cells and cryopreserved 
normal B cells (Figure 2.5).  This figure demonstrates no difference between CD147 
expression on fresh versus cryopreserved normal B cells (P = 0.7333, Mann Whitney U 
test).  Comparison of CD147 expression between CLL and cryopreserved normal B cells 
shows that the observations made in Figure 2.4 are preserved and B cells express 
significantly more CD147 than do CLL cells (*** P = 0.0006).  
Taken together, these data confirm surface expression of CD147 on CLL and normal B 
cells, with expression being higher on the latter cell type.  This indicates that MCT1 
and/or MCT4 are likely to be expressed on these cells, and that one or the other 









Figure 2.1:  Emission spectra of the fluorophores used for multi-colour colour flow 
cytometry.  The top histogram shows how the emission spectra for FITC, PE and 
PerCP-Cy5.5 overlap when excited with a 488nm laser.  The bottom histogram shows 
the emission spectra for APC and PerCP-Cy5.5 overlap when excited with a 635nm 
laser.  These spectra were used to design the best possible antibody profile for the 
detection of CD147 on CLL and normal B cells namely; anti-CD5-R-PE, anti-CD20-









Figure 2.2:  Identification of CLL cells and normal B cells using flow cytometry.   
(A) CLL cells were identified based on CD5-PE and CD20-APC positivity.  (B) Fresh 
normal B cells (CD5- and CD20+).  (C) Cryopreserved normal B cells from a buffy coat 
sample (CD5- and CD20+).  The left plot demonstrates the isotype controls for PE and 








Figure 2.3:  Raji cell line positive control for CD147.  (A) Raji cells were identified 
based on CD5 and CD20 positivity.  The left plot demonstrates the isotype controls for 
PE and APC while the right plot shows gated cells.  (B) Histogram showing Raji cells to 
express CD147.  The green line shows non-specific fluorescence measured using the 
isotype control FITC (FL1-H) while the section highlighted purple shows the 







Figure 2.4:  CD147 expression in CLL and normal B cells.   A) 20 CLL samples 
were analysed for surface expression of CD147 using flow cytometry.  CLL cells were 
gated as CD5+, CD20+, and CD23+.  (B) Fresh normal B cells from 10 whole blood 
samples from healthy volunteers were analysed for CD147.  Normal B cells were gated 
as CD5-, CD20+ and CD23+.  For both (A) and (B) the green line shows non-specific 
fluorescence (isotype control FITC (FL1-H)) while the purple section shows the 
fluorescence associated with the expression of CD147 (CD147-FITC (FL1-H)).  M1 
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indicates cells expressing CD147.  (C) Box and whisker plot comparing mean CD147 
expression in 20 CLL patients and 10 healthy volunteers.  A Mann Whitney U test 
revealed that there to be greater CD147 expression in fresh normal B cells in 





Figure 2.5:  The effect of cryopreservation on CD147 expression in normal B cells.  
(A) Mean CD147 expression in fresh normal B cells from the whole blood of 10 healthy 
volunteers.  (B) Mean CD147 expression in cryopreserved normal B cells from 4 buffy 
coats.  (C) Box and whisker plot comparing mean CD147 expression in 10 fresh normal 
B cell samples and 4 cryopreserved normal B cell samples.  A Mann Whitney U test 
revealed that was no significant difference between normal B cells and buffy coat 
samples (P = 0.7333).  (D) Box and whisker plot comparing CD147 expression on B 
cells from 20 CLL patients and 4 healthy control subjects (cryopreserved buffy coat 
samples).  A Mann Whitney U test revealed that there is a significant difference between 
CD147 expression in CLL cells in comparison to cryopreserved normal B cells (*** P = 
0.0006).    
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2.3.2 Alkaline phosphatase (APAAP) staining for MCT -1 and -4 in CLL cells 
To examine expression and verify the localisation of MCT -1 and -4 on CLL cells 
alkaline phosphatase staining (APAAP) was used.  The results of this staining are shown 
in Figures 2.6 and 2.7.  Figure 2.6 shows MCT1 expression in cells from 2 CLL patients 
as well as Raji cells used as a positive control.  The antibody used was a rabbit 
polyclonal anti-MCT1 (Ab85021) from Abcam against a cytoplasmic epitope of the 
protein.  In this figure specific staining appears concentrated within the cytoplasm of 
cells however it was difficult to distinguish between cytoplasmic and membrane 
localisation.  Because Raji cells express MCT1 is high amounts, a more dilute solution 
(1:200) of the antibody was prepared from the 1:100 dilution used for the CLL cells.  
Nevertheless, these results show that MCT-1 is expressed on CLL and Raji cells. 
The result generated using the Ab85021 antibody was then validated using a second 
rabbit polyclonal anti-MCT1 (AZ5565) developed in-house by AstraZeneca 
(Manchester, UK).  Again, cells from 2 CLL patients and Raji cell line were examined, 
and similar to the images in Figure 2.6, the use of AZ5565 showed cytoplasmic staining 
in both cell types (Figure 2.7).  
Validation of MCT4 expression in CLL cells was not possible because none of the 
antibodies available could be successfully used for this technique, particularly with 
respect to the positive control, MDA-MB-231 cells (data not shown) (Gallagher et al., 
2007). 
Moreover, further use of APAAP staining for the detection and quantification of MCT1 
expression was considered unsatisfactory.  Attempts were made to optimise the staining 
technique, but reproducibility remained a problem particularly with respect to intensity 
of staining.  Thus, although similar results were generated using two different 
antibodies, lending confidence to the notion that MCT1 is expressed by CLL cells, 
comparison between cells from different CLL patients and/or with normal B cells would 





Figure 2.6:  APAAP staining for MCT1 expression and localisation in CLL cells.  
MCT1 expression and distribution in 2 cases of CLL and Raji cell positive control 
treated with a 1:100 and 1:200 dilution of rabbit polyclonal anti-MCT1 (Ab85021) 
(Abcam, Cambridge, UK) respectively.  Normal rabbit IgG was used as a negative 




Figure 2.7:  APAAP staining for MCT1 expression and localisation in CLL cells.  
MCT1 expression and distribution in 2 cases of CLL and Raji cell positive control 
treated with a 1:100 and 1:200 dilution of rabbit polyclonal anti-MCT1 (AZ5565) 
(AstraZeneca, Manchester, UK) respectively.  Normal rabbit IgG was used as a negative 
control (1:100).  Blue staining indicates the expression of MCT1.  
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2.3.3 Confocal microscopy for MCT -1 and -4 localisation in CLL cells 
An attempt was made to assess immunocytochemical detection of MCT1 expression on 
CLL cells using confocal microscopy as a means of reducing the effects of preparation 
that is incumbent with the APAAP technique.  The results of this analysis are shown in 
Figure 2.8, where analysis of MCT1 expression in cells from 3 CLL patients is 
presented.  Here cells were stained with a mouse monoclonal anti-MCT1 antibody (sc-
365501) from Insight Biotechnology.  Staining with this antibody appeared restricted to 
a ring that likely corresponds to the cell cytoplasm, confirming the results generated 
with the polyclonal anti-MCT1 antibodies (Figures 2.6 and 2.7).  However, this 






Figure 2.8:  Confocal microscopy for MCT1 expression and localisation in CLL 
cells.  CLL cells from 3 different patients were stained with mouse monoclonal anti-
MCT1 (sc-365501) or with normal mouse IgG control.  CLL cell purity for the cases 
used was 88.75% (1608), 99.21% (1798) and 89.23% (2076).  Specific fluorescence 
associated with sc-365501 staining was determined by setting threshold fluorescence to 
the maximum associated with the non-specific control.    
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2.3.4 Western blot analysis for MCT -1 and -4 in CLL and normal B cells 
Immunocytochemistry indicated expression of MCT1 on CLL cells.  However, owing to 
problems with reliability these techniques were unsuitable for quantitative analysis.  
Therefore, for further exploration of MCT -1 and -4 protein levels in CLL cells Western 
blot analysis was used.   
Figure 2.9 confirms MCT1 expression in Raji cells, which were used as a positive 
control for the immunocytochemistry.  In these experiments MCT1 was detected in 
whole cell lysates as a single 48kDa band using the antibody AZ5565 and the rabbit 
polyclonal anti-MCT1 provided by Dr Philp.  The mouse monoclonal anti-MCT1 
antibody (sc-365501) used for the immunocytochemistry was not used in this section as 
this work was performed prior to the confocal analysis.  Figure 2.9 also shows MCT1 
expression in MEC-1 cells, a CLL cell line.  As with the Raji cells, MCT1 was 
identified as a 48kDa band, a band that was identified by three antibodies developed 
against MCT1 (Ab85021, AZ5565, and anti-MCT1 provided by Dr Philp).  Moreover, it 
was noted that MEC-1 cells seemed to express less MCT1 than did Raji cells despite 
equal protein loading.  Taken together, these data suggest that Western blotting can be 
used to quantitatively assess MCT1 expression in CLL cells.   
Antibody performance was further assessed using whole cell lysates prepared from the 
malignant cells from 19 CLL cases.  This experiment compared the performance of each 
antibody; Ab85021, AZ5565, and anti-MCT1 (provided by Dr Philp).  Figure 2.10 
shows that all of the antibodies can be used to detect MCT1 expression in CLL cells.  
The results obtained using AZ5565 and the anti-MCT1 provided by Dr. Philp were 
consistent with each other.  However, the results generated with Ab85021 antibody 
seemed unreliable owing to the presence of additional bands, particularly in the region 
where MCT1 was present.  Because of the availability and apparent reliability of the 
AZ5565 antibody, it was chosen for further quantitative studies. 
A comparison of MCT1 expression in CLL and normal B cells was then carried out.  
Cell lysates were prepared using purified normal B cells (>76% purity), and equal 
amounts of protein were analysed for the presence of MCT1.  Figure 2.11 shows the 
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results of this comparison with MCT1 levels being significantly raised in purified 
normal B cells compared to CLL cells (** P = 0.0081, Mann Whitney U test).  This is in 
keeping with the CD147 analysis (Figure 2.4).  Thus, taken together, these data show 










Figure 2.9:  MCT1 protein expression in Raji and MEC-1 cell lines.  3 immunoblots 
showing MCT1 expression in Raji and MEC-1 cells when treated with either (A) rabbit 
polyclonal anti-MCT1 (Ab85021) (1:2000) (Abcam, Cambridge, UK), or (B) rabbit 
polyclonal anti-MCT1 (AZ5565) (1:1000) (AstraZeneca, Manchester, UK), or (C) rabbit 
polyclonal anti-MCT1 (1:2000) provided by Dr Philp (Thomas Jefferson University, 
PA, USA).  MCT1 is visible at a molecular weight of 48kDa.  Blots were probed with 











Figure 2.10:  MCT1 protein expression in CLL cells – assessing antibody specificity 
and validation of controls.  9 immunoblots showing a total of19 CLL cases which 
heterogeneously express MCT1 when treated with either (A) a 1:1000 or a 1:2000 
dilution of rabbit polyclonal anti-MCT1 (Ab85021) (Abcam, Cambridge, UK), or (B) 
rabbit polyclonal anti-MCT1 (AZ5565) (1:1000) (AstraZeneca, Manchester, UK), or (C) 
rabbit polyclonal anti-MCT1 (1:2000) provided by Dr Philp (Thomas Jefferson 
University, PA, USA).  MCT1 is visible at a molecular weight of 48kDa.  Blots were 
probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure equal 
protein loading.  A MEC-1 cell line was used as a positive control for MCT1 






Figure 2.11:  MCT1 protein expression in purified normal B cells versus CLL cells.  
(A) Immunoblot showing 4 purified normal B cells (>76% purity) and 8 CLL cells 
expressing MCT1 when treated with rabbit polyclonal anti-MCT1 (AZ5565) (1:1000) 
(AstraZeneca, Manchester, UK).  MCT1 is visible at a molecular weight of 48kDa.  
Blots were probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to 
ensure equal protein loading.  A MEC-1 cell line was used as a positive control for 
MCT1 (AstraZeneca, Manchester, UK).  (B) Quantitative comparison of MCT1 
expression, calculated as a ratio of MCT1/actin expression, in CLL and normal B cell 
lysates using the data presented in part (A).  Statistical significance was determined 
using a Mann Whitney U test (** P = 0.0081).    
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MCT4 expression in CLL cells was next assessed.  MDA-MB-231 cells were used as a 
positive control (Gallagher et al., 2007).  Raji cells were used as a negative control 
because they are reported to lack MCT4 (Lin et al., 1998b).  Three antibodies targeting 
MCT4 expression were assessed in protein lysates prepared from MDA-MB-231, MEC-
1, and Raji cells; Ab74109, AZ5570, the rabbit polyclonal anti-MCT4 antibody 
provided by Dr Philp.  Figure 2.12 shows the results of this assessment.  MCT4 has a 
predicted molecular weight of 54kDa, but is reported to migrate with a lower molecular 
weight on SDS-PAGE gels (Halestrap and Wilson, 2012, Merezhinskaya et al., 2004).  
Thus, MCT4 appears as a single migrating band with an apparent molecular weight that 
is slightly below the 50kDa marker.  This band was strongly present in the control lane, 
and weakly observed in the lanes corresponding to MEC-1 cells using the AZ5570 
antibody, the anti-MCT4 antibody provided by Dr Philp.  Raji cell lysates showed 
absence of this band using these antibodies, confirming that MCT4 expression is absent 
from these cells.  With respect to the Ab74109 antibody, a band was visible, but was 
equally present in both the positive (MDA-MB-231 cells) and negative (Raji cells) 
control lysates, indicating that this antibody was unsuitable.   
Figure 2.13 shows that MCT4 protein levels are variable between patient samples.  
Largely similar results were obtained using the AZ5570 and the anti-MCT4 provided by 
Dr Philp.  Ideally, either of these antibodies could have been used for further analysis.  
However, neither were available in sufficient quantity.  Thus, additional antibodies 
targeted against MCT4 were purchased and validated based on the molecular weight at 
which a band was visible and the behavior with the positive and negative controls, the 
MDA-MB-231 and the Raji cell lines respectively.  Issues with availability meant that 
the antibodies sc-376101 and sc-50329 were used in subsequent experiments to detect 
MCT4.    
A comparison of MCT4 expression in CLL and normal B cells was then carried out.  
(Figure 2.14).  Here the mouse monoclonal antibody sc-376101 was used to detect 
MCT4.  The figure shows MCT4 levels in normal B cells are observed at significantly 
higher levels than in CLL cells (** P = 0.0040, Mann Whitney U test).  This result is in 
concordance with the findings relating to MCT1 and CD147 (Figures 2.11 and 2.4).   
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Taken together, the results from this section indicate that CLL cells express both MCT -




Figure 2.12:  MCT4 protein expression in MEC-1 and Raji cell lines.  3 
immunoblots showing MCT4 expression in MEC-1 and Raji cells when treated with (A) 
rabbit polyclonal anti-MCT4 (Ab74109) (1:2000) (Abcam, Cambridge, UK), (B) rabbit 
polyclonal anti-MCT4 (AZ5570) (1:1000) (AstraZeneca, Manchester, UK), or (C) 
isoform specific rabbit polyclonal anti-MCT4 (1:2000) kindly provided by Dr Philp 
(Thomas Jefferson University, PA, USA).  MCT4 is visible just below 50kDa.  Blots 
were probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure 
equal protein loading.  A MDA-MB-231cell line was used as a positive control 






Figure 2.13:  MCT4 protein expression in CLL cells – assessing antibody specificity 
and validation of controls.  4 immunoblots showing a total of 18 CLL cases which 
heterogeneously express MCT4 when treated with either (A) rabbit polyclonal anti-
MCT4 (AZ5570) (1:1000) (AstraZeneca, Manchester, UK), or (B) isoform specific 
rabbit polyclonal anti-MCT4 (1:2000) kindly provided by Dr Philp (Thomas Jefferson 
University, PA, USA).  MCT4 is visible just below 50kDa.  Blots were probed with 
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mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure equal protein 
loading.  A MDA-MB-231cell line was used as a positive control (Gallagher et al., 







Figure 2.14:  MCT4 protein expression in purified normal B cells versus CLL cells.  
(A) Immunoblot showing 4 purified normal B cells (>76% purity) and 8 CLL cells 
expressing MCT4 when treated with mouse monoclonal anti-MCT4 (sc-376101) 
(1:1000) (Insight Biotechnology, Wembley, UK).  MCT4 is visible just below 50kDa.  
Blots were probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to 
ensure equal protein loading.  A MDA-MB-231 cell line was used as a positive control 
for MCT4 (Gallagher et al., 2007).  A Raji cell line was used as a negative control for 
MCT4 (Lin et al., 1998b).  (B) Quantitative comparison of MCT4 expression, calculated 
as a ratio of MCT4/actin expression, in CLL and normal B cell lysates using the data 
presented in part (A).  A Mann Whitney U test revealed a significant difference in 
MCT4 levels between CLL cells and purified normal B cells (** P = 0.0040).  
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2.3.5 Quantitative real-time PCR (qRT-PCR) analysis for MCT -1 and -4 in CLL 
and normal B cells  
To examine the mRNA expression profiles of MCT -1 and -4 in CLL and normal B cells 
quantitative real-time PCR (qRT-PCR) was used. 
Figure 2.15 (A) shows the mean MCT1 mRNA levels in MEC-1 and Raji cell lines.  As 
expected, both cell lines expressed MCT1 message in agreement with the Western blot 
data (Figure 2.9) and Raji cells seemed to express more MCT1 than did MEC-1 cells.  
With respect to MCT4, MDA-MB-231 cells were used as a positive control and Raji 
cells were used as a negative control in agreement with the data shown in Figure 2.12 
(Figure 2.15 (B)).  MEC-1 cells expressed detectable levels of MCT4 mRNA.  Taken 
together, these data confirm Western blot data using these cell lines, and show that 
MCT-1 and -4 expression can be assessed by qRT-PCR. 
MCT-1 and -4 expression were next measured in CLL cells.  Figures 2.16 (A) and (B) 
show qRT-PCR data for mean MCT1 and mean MCT4 expression in purified CLL cells 
from 16 patient samples.  The quality of the CLL cell purification was assessed using 
flow cytometry for CD19, and all cases had >71% purity.  MCT -1 and -4 mRNA levels 
are seen to vary between patient samples, reminiscent of the heterogeneity seen upon 
examination of MCT -1 and -4 proteins by Western blot (Figures 2.10 and 2.13).  
Figures 2.16 (C) and (D) show mRNA expression levels for MCT -1 and -4 in purified 
B cells (>91% purity) isolated from  3 buffy coat samples.  A comparison of MCT1 
expression between CLL and normal B cells showed significantly higher levels of this 
mRNA species in normal B cells (*** P = 0.0002) (Figure 2.16 (E)), and is consistent 
with Western data comparing MCT1 protein in these cell types.  However, MCT4 
mRNA expression showed no significant difference between CLL and normal B cells 
(Figure 2.16 (F)) (P = 0.7053), suggesting that the lower levels of MCT4 protein in CLL 








Figure 2.15:  qRT-PCR analysis of MCT -1 and -4 mRNA levels in MEC-1, Raji 
and MDA-MB-231 cell lines.  qRT-PCR analysis of MCT -1 and -4 mRNA was carried 
out according to the method described in section 2.2.9, and quantitation was determined 
relative to expression of actin.  (A) Mean MCT1 expression in MEC-1 and Raji cell 
lines.  Data was derived from 3 technical replicates, (B) Mean MCT4 expression in 
MEC-1, Raji and MDA-MB-231 cell lines.  Data were derived from 3 technical 






Figure 2.16:  Comparison of MCT -1 and -4 mRNA levels in CLL and normal B 
cells.  For all sections MCT-1 and -4 mRNA levels are determined relative to actin 
mRNA levels in the same cell.  qRT-PCR data for; (A) mean MCT1 expression and, (B) 
mean MCT4 expression in purified CLL cases from 16 patients (>71% purity) derived 
from 3 technical replicates.  (C) mean MCT1 expression and, (D) mean MCT4 
expression, in purified B cells prepared from 3 buffy coat samples (> 91% purity) 
65 
 
derived from 3 technical replicates.  (E) A Mann Whitney U test revealed MCT1 
expression to be significantly higher (*** P = 0.0002) in normal B cells (n = 3).  (F) 
There was no significant difference in MCT4 expression (P = 0.7053).  Error bars 
represent the SEM.   
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2.3.6 Comparison of MCT -1, -4 and CD147 expression in IgVH mutated and 
IgVH unmutated CLL 
The observation that MCT -1, -4 and CD147 expression on CLL cells was variable 
between patient samples loans itself to the heterogeneous nature of this disease.  A 
characteristic marker of this heterogeneity in CLL is IgVH mutation status, whereby 
disease in UM-CLL cases is generally progressive and in M-CLL cases it is not (Oscier 
et al., 2012).  Moreover, IgVH mutational status was chosen for this comparison 
because it has been reported to be associated with increased proliferation and replicative 
capacity (Vilpo et al., 2005, Rampazzo et al., 2012).  This implies that in UM cases the 
rate of CLL proliferation may be higher and that this may be accompanied by increased 
glycolytic activity and dependency on lactate export out of the cell.  Therefore, a 
comparison of MCT -1, -4 and CD147 expression on CLL cells from M and UM-CLL 
cases was made.  
Figure 2.17 compares CD147 expression on the malignant cells from 10 M-CLL and10 
UM-CLL cases, as assessed by flow cytometry.  No difference was observed with 
respect to expression of this antigen between these cohorts of patient samples (P = 
0.2475, Mann Whitney U test).  A comparison of MCT -1 and -4 protein expression 
showed that MCT1 expression is significantly lower on M-CLL compared to UM-CLL 
cells (* P = 0.0317), whereas MCT4 expression was similar (P = 0.2222) (Figure 2.18).  
For these experiments a mouse monoclonal (sc-365501) antibody was used to detect 
MCT1 and a rabbit polyclonal (HS-90) (sc-50329) antibody was purchased and used to 
detect MCT4.  These antibodies were validated by comparing the molecular weight at 
which bands became visible to the antibodies previously used as well as their behavior 
with positive and negative controls for both MCT -1 and -4.  This was necessary due to 
the lack of availability of AZD3965, AZ5570 and the anti-MCT4 provided by Dr Philp.  
At the gene expression level both MCT -1 and -4 mRNA levels were found to be 
decreased in the malignant cells from M-CLL cases than in those from UM-CLL cases 
(respectively ****P = <0.0001 and * P = 0.0342, Mann Whitney U test) (Figure 2.19).  
Taken together, these data show that patients with M-CLL are likely to have lower 
levels of MCT1 expression in comparison to patients with UM-CLL.  Whether this is 
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related to disease progression, as is reported for the malignant cells of other cancers 
(Pinheiro et al., 2010, Torres de Oliveira et al., 2012, Pinheiro et al., 2009, Pertega-






Figure 2.17:  Comparison of CD147 expression on CLL cells from IgVH mutated 
versus IgVH unmutated cases.  CD147 expression in 10 M-CLL and10 UM-CLL 
cases was determined by flow cytometry (inset table), and then compared graphically.  






Figure 2.18:  Comparison of MCT -1 and -4 protein expression in CLL cells from 
IgVH mutated versus IgVH unmutated cases.  Protein lysates made from CLL cells 
from 5 M-CLL versus 5 UM-CLL cases.  (A) Western blot analysis of MCT1 
expression (left panel).  Blots were treated with a 1:1000 dilution of mouse monoclonal 
anti-MCT1 (sc-365501.)  Graphical comparison of the MCT1/actin ratio derived by 
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densitometry of the bands (right panel).  (B) Western blot analysis of MCT4 expression 
(left panel).  Blots were treated with a 1:1000 dilution of rabbit polyclonal anti-MCT4 
(HS-90) (sc-50329).  Graphical comparison of the MCT4/actin ratio derived by 
densitometry of the bands (right panel).  For (A) and (B) a MEC-1 cell line was used as 
a positive control (AstraZeneca, Manchester, UK) and MDA-MB-231 and Raji cell lines 
were used as positive and negative controls respectively (Gallagher et al., 2007., Lin et 
al., 1998b).  Blots were probed with mouse monoclonal anti-β-actin (clone AC-74) as a 
control to ensure equal protein loading.  (C) Table listing IgVH mutational status for the 







Figure 2.19:  Comparison of MCT -1 and -4 mRNA levels in CLL cells from IgVH 
mutated versus IgVH unmutated cases.  qRT-PCR was used to analyse MCT -1 and -
4 expression relative to actin.  (A) Table listing the IgVH mutational status for the 14 
cases of CLL used in this part of the study.  (B) Graphical comparison of MCT1 mRNA 
levels in CLL cells from M and UM-CLL cases (****P = <0.0001).  (C) Graphical 
comparison of MCT4 mRNA levels in CLL cells from M and UM-CLL cases (* P = 






The expression of the monocarboxylate transporters, MCT -1 and -4, and the accessory 
protein CD147 have not been previously investigated in CLL.  The present study is the 
first to examine the expression profile of these proteins in this disease, as well as 
confirm their expression in normal B cells (Merezhinskaya et al., 2004, Deeg et al., 
2001, Koch et al., 1999, Kasinrerk et al., 2006).   
As previously discussed, CD147 can be considered a surrogate marker of MCT -1 and -
4 expression because of the chaperone function of this protein in bringing these 
transporters to the cell membrane (Gallagher et al., 2007).  Although other transport 
proteins are chaperoned by CD147 (Zhu et al., 2013) the results of the present study 
show concordance between CD147 and MCT1/4 expression on CLL and normal B cells.  
That is, CLL cells express lower levels of CD147, MCT -1 and -4 than do normal B 
cells.  
The expression of MCT1 on CLL cells was demonstrated by immunocytochemistry, and 
detected using antibodies raised against different epitopes.  The same antibodies 
detected a band of expected molecular weight in Western blot analysis of whole cell 
lysates, indicating with confidence that CLL and normal B cells express this protein.  
Further to this, qRT-PCR showed that expression of the gene could be seen at the 
message level.  Similarly, the detection of MCT4 on CLL and normal B cells was 
carried out using different antibodies to probe for this protein by Western blotting of 
whole cell lysates, and by using qRT-PCR to assess mRNA levels.   
The expression of MCT -1 and -4 in CLL and normal B cells is not unexpected because 
a previous study has shown the presence of these transporters in normal lymphocytes, 
although this study did not distinguish between B and T cells (Merezhinskaya et al., 
2004).  In addition to this, MCT1 seems to be ubiquitously expressed by all cells 
(Halestrap and Price, 1999, Halestrap and Wilson, 2012).  However, the expression of 
MCT4 is more restricted and is seen mainly in cells which are glycolytically active, 
including WBCs (Halestrap and Price, 1999, Halestrap and Wilson, 2012).  Although 
the expression of these transporters has been in examined in other types of cancer 
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(Pinheiro et al., 2010, Torres de Oliveira et al., 2012, Pinheiro et al., 2009, Pertega-
Gomes et al., 2011, Zhao et al., 2014), in lymphoid malignancy expression of MCT -1 
and -4 has not been widely studied.  As previously discussed, the expression of MCT1 
has been shown in Raji cells, a cell line derived from Burkitt’s lymphoma as well as in a 
MOLT-4 cell line, which is derived from acute ALL (Lin et al., 1998b).  These findings 
were verified by other studies showing that MCT1 expression is raised across a panel of 
B cell malignancies compared to their normal counterparts (Arendt et al., 2012, de Vries 
et al., 2010, Liu et al., 2009, Thorns et al., 2002, Nabeshima et al., 2004, Shi et al., 
2003).  More recently, a study by Doherty et al. (2013) showed that MCT1 correlated 
with MYC expression in numerous types of cancer cell lines including Raji cells.  The 
implication of this finding is that the higher proliferative activity associated with high 
MYC expression necessitates greater need of lactate import/export by MCT1.  This is 
important because MYC has been shown to be important to CLL pathobiology (Refaeli 
et al., 2008, Put et al., 2012, Halina et al., 2010). 
The results of this chapter show that the expression of MCT -1 and -4 in CLL cells is 
less than that in normal B cells.  This finding contrasts with those of others studying 
other lymphoid malignancies (Arendt et al., 2012, de Vries et al., 2010, Liu et al., 2009, 
Thorns et al., 2002, Nabeshima et al., 2004, Shi et al., 2003), but is likely related to the 
pathophysiology of CLL cells.  Although CLL has been shown to have a significant 
proliferative component (Messmer et al., 2005) the rate of CLL cell proliferation is 
lower than that of normal B cells (Defoiche et al., 2008).  Furthermore, expansion of the 
malignant clone in CLL is localised to proliferation centres in the secondary haemic 
tissues where these cells encounter mitogenic stimuli (van Gent et al., 2008).  The 
experiments presented in this chapter use CLL cells from circulation, and these are 
known to be arrested in G0 of the cell cycle but are functionally incompetent and have 
impaired metabolism in comparison to normal B cells (Dasanu, 2008, Brody et al., 1969, 
Dameshek, 1967).  That the levels of MCT -1 and -4 as well as CD147 on CLL cells are 
down regulated is in keeping by studies which show the activity of glycolytic enzymes 
such as aldolase and glucose-6-phosphate isomerase to be lower in these cells compared 
to normal B cells (Vives Corrons et al., 1989, Ho et al., 1982, Musolino et al., 1992).  
Moreover, these findings are also in agreement with more recent work showing 
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increased oxidative phosphorylation in CLL cells but not increased aerobic glycolysis 
(Jitschin et al., 2014).  Normal B cells are also arrested in G0 and have been shown to 
rely on oxidative phosphorylation for energy homeostasis (Garcia-Manteiga et al., 
2011), but the need of these cells to respond to antigenic challenge with induction of 
glycolysis (Garcia-Manteiga et al., 2011) may require the presence of higher baseline 
expression levels of MCT1 and MCT4. 
Like normal B cells, CLL cells are also capable of becoming activated, particularly 
those which bear the UM-CLL genotype.  In this respect, similarly to the comparison 
between normal B cells and CLL cells, MCT1 expression was observed higher on CLL 
cells from UM-CLL cases in comparison to M-CLL cases.  As MCT1 is known to 
function both as an importer or exporter of substrates the increased expression of MCT1 
on UM-CLL cells may be a reflection of the higher metabolic needs of these cells over 
M-CLL cells. 
In conclusion, the data presented in this chapter shows for the first time the expression 
of MCT -1 and -4 as well as their obligate chaperone CD147 on circulating CLL cells.  
In comparison to normal B cells, the expression of these proteins is low suggesting 
different metabolic requirement of these two cell types.  This chapter did not address the 
expression of these proteins on CLL cells within areas where microenvironmental 
influences can affect their survival and proliferation.  This is the subject of the next 




3 CHAPTER 3:  INVESTIGATING THE INFLUENCE OF THE 
MICROENVIRONMENT ON THE METABOLISM OF CLL CELLS  
 
3.1 INTRODUCTION 
The data in chapter 2 show that the expression of MCT -1 and -4 is decreased in 
circulating CLL cells in comparison to normal B cells.  However, the levels of these 
transporters may change when the cells enter secondary tissues where they encounter 
microenvironmental stimuli that induce their activation and proliferation.  Studies by 
Garcia-Manteiga et al. (2011) show that normal B cells switch to a glycolytic phenotype 
in order to sustain proliferation when they come into contact with antigenic stimuli.  A 
primary mediator of B cell proliferation in germinal centers is CD40 engagement and 
IL-4 provided by cognate helper T cells (Patten et al., 2008).  CD40 engagement and IL-
4 also promote CLL cell proliferation (Hamilton et al., 2012), and, similar to normal B 
cells, such engagement on CLL cells may promote a metabolic switch to glycolysis that 
then requires increased expression of MCT -1 and/or -4.  
The aim of this chapter is to investigate the effect of microenvironmental stimuli on the 
expression profile of MCT -1 and -4 in CLL cells.  This chapter focuses on the effects of 
CD40 ligation and does not consider the additional effects of IL-4 or other cytokines.  It 
was found that CD40 engagement on CLL cells resulted in specific upregulation of 
MCT4 protein expression.  The metabolic processes requiring such regulation of MCT4, 
such as glycolysis, were investigated using a Fluidigm Biomark™ qRT-PCR chip array 
to examine gene expression and the SeahorseXF24 extracellular flux analyser to assess 




3.2 MATERIALS AND METHODS 
 
3.2.1 Culture of adherent cell lines 
Mouse parental and CD40L (human) expressing mouse fibroblasts were provided by 
Professor Gerry Cohen (MRC Toxicology, University of Leicester, UK).  Cells were 
recovered from -150C storage at 37C in a water bath for 5 minutes prior to the 
addition of 10mL of DMEM supplemented with 100 units/mL penicillin-streptomycin, 
2mM L-glutamine and 10% heat inactivated FCS.  Samples were subsequently 
centrifuged (250 rcf, 5 minutes, 4°C) and washed in modified media to remove DMSO 
cryopreservative before being seeded at a density of 3 x 10
5
 cells/mL.  Cells were 
cultured at 37C under an atmosphere containing 5% CO2, and passaged every 2-3 days 
whereby the cells were washed in PBS and trypsinised [Trypsin-EDTA (0.05%) 
(Invitrogen, Paisley, UK)] for approximately 3 minutes at 37ºC.  Loosened cells were 
washed in modified DMEM media and made ready for re-seeding.   
 
3.2.2 Poly-HEMA-coating of culture surfaces 
Culture of CLL cells took place in tissue culture plates coated with poly(2-hydroxyethyl 
methacrylate) (poly-HEMA) (Sigma, Gillingham, UK) which were prepared by 
incubating a volume (dependent on the size of the tissue culture plate) of 1.2mg/mL of 
poly-HEMA dissolved in 95% ethanol at 37C for a minimum of 48 hours. 
 
3.2.3 Activation of CLL cells using soluble CD40 ligand (sCD40L) 
Soluble CD40 ligand (sCD40L) for stimulation of CLL cells was prepared from a kit 
(Enzo Life Sciences, Exeter, UK) according to the manufacturer’s instructions.  The 
concentrations used in this study were 100, 200 and 400ng/mL of sCD40L.  Following 
addition of the prepared sCD40L solution, CLL cells were incubated at 37C and 5% 
CO2 for either 24 or 48 hours in poly-HEMA plates.  Generally 4 x 10
6
 CLL cells were 




3.2.4 Activation of CLL cells by co-culture with CD40 ligand (CD40L) expressing 
fibroblasts 
Irradiated CD40L and parental fibroblasts which had a minimum viability of 70% were 
used for these experiments.  Trypsinised cells (6 x 10
5
 cells/mL) were suspended in 
modified DMEM and irradiated using the GAMMACELL® 3000 (Best Theratronics, 
Slough, UK).  The dosage of gamma radiation delivered was 75Gy, and following 
irradiation the cells were plated at 1.8 x 10
6
 cells/well and incubated overnight at 37C 
and 5% CO2 to adhere.  Prior to co-culture experiments the monolayer washed using 
PBS. 
CLL cells were recovered from storage at -150ºC as described in 2.2.1.1 and 
resuspended to 1 x 10
7
 cells/mL in media.  3 x 10
7
 CLL cells/well were then added to 
fibroblasts, and then the co-culture was allowed to incubate at 37C and 5% CO2 for 48 
hours.  In some cases, untreated control (UT) CLL cells were prepared by culturing 3 x 
10
7
 cells/well in a 6 well plate pre-treated poly-HEMA.   
 
3.2.4.1 Confirmation of CD40 ligand (CD40L) expression 
Prior to commencement of these experiments, the fibroblasts were checked for CD40L 
expression.  This was done by preparing a suspension of the fibroblasts and then 
staining with either Mouse anti-CD40L-FITC (IgG1k) (555699, BD Biosciences, 
Oxford, UK) or IgG1,y1-FITC Isotype control (345815, BD Biosciences, Oxford, UK) 
and analysing CD40L expression by flow cytometry.  
 
3.2.5 Antibodies 
As detailed in section 2.2.5.  Additional antibodies used included; goat anti-human IgM 
(2020-01) (Southern Biotech, Cambridge, UK), donkey anti-goat IgG-HRP (Insight 




3.2.6 Western blot analysis  
A similar procedure was used and is detailed in section 2.2.8.   
 
3.2.7 Flow cytometry for the detection of CD147 
As detailed in section 2.2.6. 
 
3.2.8 Polymerase chain reaction (PCR) 
RNA extraction, cDNA synthesis and qRT-PCR analysis were performed as described 
previously in section 2.2.9, however glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as the reference gene to obtain relative quantitation (FAM/ MGB 
Probe, Non-Primer Limited) (Applied Biosystems, Life technologies, Paisely, UK). 
 
3.2.9 Fluidigm Biomark™ array 
 
3.2.9.1 Sample preparation 
Samples were prepared from CLL cells co-cultured with parental and CD40L fibroblasts 
as detailed in section 3.2.4.   
 
3.2.9.2 RNA extraction 
RNA extraction was performed using QIAshredder™ and RNeasy® minikits as per the 
manufacturer’s instructions and using a QIAcube (Qiagen, Manchester, UK).  
Quantification of extracted RNA was performed using a NanoDrop 2000c 




3.2.9.3 cDNA synthesis 
A high capacity cDNA reverse transcription kit (Applied Biosystems, Life technologies, 
Paisely, UK) was used to synthesise cDNA from RNA (50ng/20µL) as per the 
manufacturer’s guidelines.  The following cycling variables were used for the thermal 
cycler; 25°C 10 minutes, 37°C 120 minutes, 85°C 5 seconds.   
 
3.2.9.4 cDNA pre-amplification and preparation of the sample plate 
A panel reflecting genes involved in cellular metabolism was selected and is listed for 
human genes in Table 3.1 and mouse genes in Table 3.2.  The analysis is based on a 
TaqMan® gene expression assay, and all genes analysed were done using kits purchased 
from Applied Biosystems.  For the human analysis (CLL cells) a panel of housekeeping 
genes including; actin, IPO8, and PPIA were additionally used.  For the mouse analysis 
(fibroblasts) a panel of housekeeping genes including; 18S and IPO8 were additionally 
used. 
To create a pre-amplification (PreAmp) pool for the genes of interest 1μL of each gene 
expression assay (these are the PCR primers) was added to a single RNase free 
eppendorf tube.  To this PreAmp pool, Tris-EDTA (TE) buffer (pH 8.0) (Ambion, CA, 
USA) was added to produce a final volume of 100μL, and this was subsequently mixed 
and spun in a microcentrifuge.  Next, 200μL of TaqMan® PreAmp mastermix (Applied 
Biosystems, Life technologies, Paisely, UK) was added as a final step to create the 
PreAmp pool.   
The sample plate was prepared by placing 3.75μL of the PreAmp pool into each well of 
a 96 well plate.  1.25μL of cDNA prepared in section 3.2.9.3 was placed into pre-
designated wells, corresponding to the samples used, and then mixed using a multi-
channel pipette and finally centrifuged briefly to collect fluid in the bottom of each well.  
The plate was then sealed using optical adhesive cover (Applied Biosystems, Life 
technologies, Paisely, UK) and Microseal A film (Bio-Rad-Laboratories Ltd, Hemel 
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Hempstead, UK) and run on a thermal cycler.  The following cycling variables were 
used 95°C 10 minutes, 95°C 15 seconds, 60°C, 4 minutes, for 14 cycles. 
Following this thermal cycling step, 20μL of TE buffer (Ambion, Life technologies, 
Paisely, UK) was added to each well of the plate using a multi-channel pipette to obtain 
a 1:5 dilution of amplified cDNA.  The plate was again sealed with an optical adhesive 
cover, mixed, and spun.  4.5μL of this final amplified cDNA solution was then added to 
a fresh 96 well plate into pre-designated wells.  This plate, termed the “sample plate” 
was then sealed, centrifuged and stored at -20ºC if not used immediately.   
 
3.2.9.5 Fluidigm Biomark™ qRT-PCR 
 
3.2.9.5.1 Preparation of the assay plate containing the primer-probe sets (assay 
plate) 
Preparation of the assay plate was performed by placing 7.5μL of each primer-probe sets 
(FAM MGB) for the genes of interest into designated wells of a 96 well plate.  These 
plates were stored at 4ºC until used.   
 
3.2.9.5.2 Priming of the 48 x 48 Fluidigm Biomark™ chip 
To prepare the 48 x 48 Fluidigm Biomark™ chip (Fluidigm, CA, USA) control line 
fluid was added into the accumulator valves (Figure 3.1) whilst holding the plate at a 45º 
angle.  Next the plate was loaded into an IFC (integrated fluidic circuit) MX-48 machine 
(Fluidigm, CA, USA) and primed.  This ensures that the interface valves are closed to 






3.2.9.5.3 Preparation of the assay and sample plates prior to loading of the 
Fluidigm Biomark™ chip 
To the assay plate prepared in section 3.2.9.5.1, 7.5μL/well of 2x DA assay loading 
reagent (Fluidigm, CA, USA) was added to each of the wells.  The assay plate was then 
sealed with an optical adhesive cover and kept at 4ºC in the dark until assay loading of 
the Fluidigm Biomark™ chip (Fluidigm, CA, USA).   
The sample plate was prepared for loading in the following manner.  30μL of 20x DA 
sample loading reagent was added to 300μL of gene expression mastermix and mixed in 
a 1.5mL eppendorf tube.  5.5μL of this solution was added to each well of the sample 
plate prepared in section 3.2.9.4.  This sample plate is now ready for loading into the 
Fluidigm Biomark™ chip and was kept at 4ºC in dark, sealed with an optical adhesive 
cover. 
 
3.2.9.5.4 Loading of the Fluidigm Biomark™ chip 
5μL from each well of the assay plate was transferred to their designated assay inlets on 
the Fluidigm Biomark™ chip (Figure 3.1).  Following this 5μL from each well of the 
sample plate was transferred to their designated sample inlets on the Fluidigm 
Biomark™ chip (Figure 3.1).  The Fluidigm Biomark™ chip was subsequently loaded 
on to the IFC MX-48 machine which loads the chip.   
 
3.2.9.5.5 Analysis of the Fluidigm Biomark™ chip 
Following the loading step the chip was transferred to the Biomark™ machine and run 
using the following protocol; 50°C 2 minutes, 95°C 10 minutes, 95°C 15 seconds, 60°C, 
1 minute, for 40 cycles.  ROX™ was used as a passive reference to normalise well to 





3.2.9.5.6 Data analysis of the Fluidigm Biomark™ chip 
A revised panel of genes was produced by evaluating the amplification efficiency for 
each gene using a sample of reference RNA as a positive control.  Genes which had a Ct 
value of <24 were included in further analysis.  The panel of genes was further refined 
by assessing the specificity of the primers for cDNA and by including a sample of 
gDNA as a negative control.  Genes which were amplified (Ct <24) were excluded from 
further analysis.  Following this inter-individual variation across the samples was 
assessed using either a Kruskal-Wallis test or ANOVA.  This was to ensure that the 
samples were of similar quality and that the genes have performed reliably and with 
similar efficiencies to provide confidence that any variation observed in future 
comparative analyses is not due to experimental variation.  Post hoc tests were 
performed where variation was significant.  Following this a comparative analysis was 
done.  Here, linear fold change in gene expression was used to guide subsequent 
statistical analysis comparing gene expression between conditions and cell types.  A 
minimum threshold of ≥ 1.5 fold change was used as an indicator of upregulation, while 
a threshold of ≤ 0.5 was used as an indicator of downregulation.  Finally analysis of 
global changes in metabolic pathways was assessed by grouping genes into metabolic 





































3.2.10 Metabolic flux analysis using the SeahorseXF24 metabolic flux analyser 
 
3.2.10.1 Media preparation 
Unbuffered RPMI media (10x) stock (Sigma, Gillingham, UK) diluted with dH2O to 
produce 1x RPMI media was supplemented with 2mM L-glutamine, 2.5μM folic acid 
(Sigma, Gillingham, UK), and 2mM of sodium pyruvate (Sigma, Gillingham, UK).  
This was then adjusted to pH 7.4 and sterile filtered.  This media will be herein referred 
to as “Seahorse media.” 
 
3.2.10.2 Immobilisation of non-adherent cells with Matrigel™ 
To immobilise suspension cells to the XF24 cell culture microplate (Seahorse 
Bioscience, Saint Marcell, France) the cells were seeded on to a surface treated with the 
cellular adhesive Matrigel™ (BD Biosciences, Oxford, UK).  To prepare the Matrigel™ 
a frozen aliquot was thawed on ice and kept at 4ºC to prevent it from polymerising.  
This was diluted with Seahorse media in a 1:4 dilution and 38μL was added to each well 
using pre-chilled pipette tips.  The plate was subsequently left for 1 hour at room 
temperature after which excess Matrigel™ was removed and 100μL of Seahorse media 
was added to each well.  The plate was then stored at 4ºC overnight and used within 24 
hours. 
 
3.2.10.3 Calibration of the SeahorseXF24 metabolic flux analyser 
To calibrate the analyser 1mL of SeahorseXF calibrant solution (Seahorse Bioscience, 
Saint Marcell, France) was added per well to the XF24 calibration microplate and 
incubated overnight in the SeahorseXF24 Prep station (Seahorse Bioscience, Saint 
Marcell, France) at 37ºC under ambient atmospheric conditions and used within 24 




3.2.10.4 Sample preparation 
Cryopreserved CLL cells were recovered as detailed in section 2.2.1.1.  Fresh CLL cells 
were either resuspended to a concentration of 2 x 10
7
 cells/mL and left to acclimatise in 
the incubator at 37ºC and 5% CO2 overnight or the cells were added to a fibroblast 
monolayer as detailed in section 3.2.4 and co-cultured for a 48 hour period.  CLL cells 
were then removed from the fibroblast monolayer and prepared as described in the next 
section (3.2.10.5). 
 
3.2.10.5 Preparation of the XF24 cell culture microplate 
Cells were used at a density of 2 x 10
7
 cells/mL.  For the adhesion of cells on to the pre-
prepared Matrigel™ treated microplate, cells were first resuspended in media and 
supplemented with 2mM L-glutamine and 2mM sodium pyruvate, but without added 
FCS or BSA.  100μL of this suspension was added per well except for the blanks; A1, 
B4, C3 and D6.  This was then incubated in the SeahorseXF Prep station at 37ºC under 
ambient atmospheric conditions for 1 hour.  Following this adhesion step the plate was 
examined under a microscope to assess the monolayer, and then the overlying media 
was removed.  Next 450μL of pre-warmed Seahorse media was slowly added per well 
without disrupting the monolayer.  The integrity of the monolayer was then re-checked 
and the plate was left to equilibrate for 20 minutes in the SeahorseXF Prep station prior 
to analysis.  The plate was loaded following the calibration of the instrument using the 
XF24 calibration plate prepared previously. 
 
3.2.10.6 Mitochondrial stress test 
10x stock concentrations of each of the following compounds were prepared in Seahorse 
media so that upon injection a final concentration of 1.26μM oligomycin (Sigma, 
Gillingham, UK), 1.5μM trifluoromethoxy carbonyl cyanide phenylhydrazone (FCCP) 
(Sigma, Gillingham, UK) and 1μM each of antimycin-A (Sigma, Gillingham, UK) and 
rotenone (Sigma, Gillingham, UK) was added.   
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To start the assay a baseline was established.  This was done my taking a measurement, 
then mixing the plate for 2 min, allowing a delay of 2 minutes and then taking a 
measurement (mix 2 min, wait 2 min, measure 2 min).  This cycle was repeated five 
times to establish a robust baseline OCR (pMoles/min).  Following this the oligomycin 
was injected using port A.  Oligomycin inhibits ATP synthase and causes a drop in OCR 
which reflects the amount of oxygen consumed to produce ATP (Figure 3.2) (Chacko, 
2013).  The addition of this compound also causes a change in ECAR in response to the 
inhibition of ATP synthase, a component required for oxidative phosphorylation, and 
this change in ECAR reflects glycolytic capacity.  Three measurement cycles were then 
taken (mix 2 min, wait 2 min, measure 2 min) prior to the injection of port B (FCCP) 
after which three more readings of measurement cycles were obtained.  The addition of 
FCCP uncouples the mitochondria from the electron transport chain and maximises 
respiration (Figure 3.2) (Chacko, 2013).  Finally, antimycin-A and rotenone were added 
through port C.  These compounds inhibit complex I and II on mitochondria to cease 
respiration completely, after which two measurement cycles were taken (mix 2 min, 
wait 2 min, measure 2 min) (Figure 3.2) (Chacko, 2013).  From this data parameters 
such as baseline respiration, ATP production, maximal respiration, proton leak, spare 
capacity and glycolytic capacity can be calculated from the change in OCR and ECAR 
(Figure 3.2).  
 
3.2.10.7 Normalisation to total cellular DNA 
In order to compare metabolic measurements between cell samples, normalisation of the 
OCR and ECAR data was necessary.  Thus, after completion of the metabolic analyses 
on the SeahorseXF24 the media was removed from each of the wells and the plate was 
stored at -80ºC.   
The measurements obtained from the SeahorseXF24 were normalised to DNA content 
using a CyQUANT
®
 cell proliferation assay kit (Invitrogen, Paisley, UK) as per the 
manufacturer’s instructions.  Lysis buffer was prepared using 19mL of solution 
containing 180mM NaCl in 1mM of EDTA and 1mL of CyQUANT® cell lysis buffer.  
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5mL of this lysis buffer was taken and 100μL of RNase A (Qiagen, Manchester, UK) 
was added.  100μL of this final solution was added per well of the plate and left on the 
orbital shaker for 1 hour at room temperature to extract DNA.  After this lysis step, the 
lysed cells were transferred to pre-designated wells of a blacked out 96 well plate and 
diluted 1:10 with lysis buffer without RNase A.  DNA concentration in the cell lysis 
samples was determined using a standard curve for DNA content (0, 10, 50, 100, 200, 
400, 800, 1000 ng/mL), also made up with lysis buffer without RNase A.  Following 
this, dye solution was added to each well in a 1:1 dilution and this was left for 2 minutes 
prior to measurement on the POLARstar Omega plate reader (BMG LABTECH, 
Germany).  Fluorescence measurements were taken where an excitation wavelength of 





Figure 3.2:  Parameters calculated in response to mitochondrial stressors.  The 
sequential addition of oligomycin, FCCP and rotenone and antimycin-A causes 
characteristic changes in % oxygen consumption rate (OCR) (pMoles/min).  Using these 
measurements parameters such as baseline respiration, ATP production, maximal 
respiration, proton leak and spare capacity can be determined.  Change in % 





3.2.11 Quality assurance 
To ensure confidence in Western blot analysis of fibroblasts during co-culture, a quality 
assurance system was developed to detect contamination of CLL cells within fibroblast 
cell preparations.  This was done by assessing the presence of IgM.  CLL cell lysate was 
used as a positive control.  
For the Fluidigm Biomark™ array a sample of reference RNA was used as a positive 
control to test the efficiency of the assay.  This was denoted as HqPCR and MqPCR.  As 
a negative control genomic DNA was used (HgDNA and MgDNA). 
In addition to this the quality assurance steps taken in section 2.2.10 were also taken. 
 
3.2.12 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (Version 6.01, GraphPad 
Software Inc., CA, USA).  The statistical tests used are identified when and where they 
are used within the results section of this chapter.  A P value of P = <0.05 was 





3.3.1 MCT -1 and -4 expression in CLL cells following co-culture with CD40 
ligand (CD40L) expressing fibroblasts 
Various in vitro models have been developed to mirror the interactions which occur in 
vivo between CLL cells and the microenvironment (Hamilton et al., 2012).  As such, 
CLL cells can be maintained in co-culture with cell lines such as parental fibroblasts as 
well as fibroblasts which express CD40L to simulate the role of T helper cells (Patten et 
al., 2008). This system was chosen to investigate the effects of such interaction on 
expression MCT -1 and -4 in CLL cells.  
CD40L and parental fibroblasts were regularly assessed to insure cell line integrity.  
Figure 3.3 shows how flow cytometry was used to confirm the presence or absence of 
CD40L on the CD40L fibroblasts and the parental fibroblasts respectively.  Use of these 
fibroblast lines was done in lots.  Fibroblasts from a frozen aliquot were grown to 
confluence in several T75 tissue culture flasks, the cells would be removed and 
irradiated and frozen down again for subsequent use in co-culture experiments.  This 
approach kept the passage number of the fibroblast lines low, and, in this way, 
experimental consistency could be maintained.  
For co-culture experiments CLL cells were incubated with irradiated CD40L or parental 
fibroblasts, and, following co-culture for 48 hours, the CLL cells were harvested and 
MCT -1 and -4 expression was assessed using Western blot analysis.  Figure 3.4 shows 
that co-culture of CLL cells with either CD40L or parental fibroblasts induces increased 
expression of MCT1 compared to non-co-cultured CLL cells (n = 3).  However, CD40 
ligation did not seem to induce further expression of MCT1 on the CLL cells (Figure 
3.5).  There was variability between samples, but overall there was no significant change 










Figure 3.3:  Confirmation of CD40L expression in fibroblasts using flow cytometry.  
(A) CD40L fibroblasts are shown to express CD40L.  (B) Parental fibroblasts are shown 
to be negative for CD40L.  The green histogram is associated with isotype control 
antibodies, whereas the purple histogram is associated with CD40L antibodies.  M1 











Figure 3.4:  MCT1 expression in CLL cells co-cultured with CD40L and parental 
fibroblasts.  Western blot analysis of MCT1 and actin expression in whole cell lysates 
prepared from CLL cells co-cultured with CD40L and parental (Par) fibroblasts, or 
cultured in their absence (UT).  As a positive control, whole cell lysates of MEC-1 cells 
was included.  The MCT1 antibody used for these blots is AZ5565 (1:1000).   Blots 
were probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure 








Figure 3.5:  MCT1 expression is not induced in CLL cells following CD40L 
stimulation.  The malignant cells from 6 cases of CLL were co-cultured with CD40L 
and parental (Par) fibroblasts for 48 hours.  (A) Western blot analysis of whole CLL cell 
lysates for the indicated proteins.  MCT1 expression was detected using mouse 
monoclonal anti-MCT1 (H-1) (sc-365501) (1:1000) (Insight Biotechnology, Wembley, 
UK).  A MEC-1 cell lysate was used as a positive control for MCT1.  Blots were probed 
with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure equal protein 
loading.  (B) Graphical representation of the data shown in part (A).  MCT1 expression 
was determined as a densitometric ratio of MCT1:actin.  A Wilcoxon matched-pairs 
signed rank test revealed there to be no significant difference in MCT1 expression 
between the groups (P = 0.0938).    
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With respect to MCT4 expression, there seemed to be no difference between control 
CLL cells and CLL cells co-cultured with parental fibroblasts (Figure 3.6).  However, 
CLL cells co-cultured with CD40L fibroblasts show a distinct upregulation of MCT4 
(Figure 3.6), a finding that is verified in Figure 3.7 which shows there is significant 
change in MCT4 expression on CLL cells co-cultured on CD40L fibroblasts compared 
to those cultured on parental fibroblasts (* P = 0.0313, n = 6, Wilcoxon matched-pairs 








Figure 3.6:  MCT4 expression in CLL cells following co-cultured with CD40L and 
parental fibroblasts.  Western blot analysis of MCT4 and actin expression in whole 
cell lysates prepared from CLL cells co-cultured with CD40L and parental (Par) 
fibroblasts, or cultured in their absence (UT).  As a positive control, whole cell lysates 
of MDA-MB-231 cells was included.  As a negative control, whole cell lysates of Raji 
cells was included.  The MCT4 antibody used for these blots is a rabbit polyclonal anti-
MCT4 (HS-90) (sc-50329) (1:1000) (Insight Biotechnology, Wembley, UK).  Blots 
were probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure 






Figure 3.7:  MCT4 expression in CLL cells following CD40L stimulation.  The 
malignant cells from 6 cases of CLL were co-cultured with CD40L and parental (Par) 
fibroblasts for 48 hours.  (A) Western blot analysis of whole CLL cell lysates for the 
indicated proteins.  MCT4 expression was detected using sc-50329.  A MDA-MB-231 
cell lysate was used as a positive control for MCT4. Blots were probed with mouse 
monoclonal anti-β-actin (clone AC-74) as a control to ensure equal protein loading.   (B) 
Graphical representation of the data shown in part (A).  MCT4 expression was 
determined as a densitometric ratio of MCT4:actin.  A Wilcoxon matched-pairs signed 
rank test revealed there to be a significant difference in MCT4 expression between the 
groups (* P = 0.0313).    
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3.3.2 MCT -1 and -4 expression in CLL cells following incubation with soluble 
CD40 ligand (sCD40L)  
Hypoxia has been shown to regulate MCT -1 and -4 expression on cells, causing MCT1 
levels to decrease and MCT4 expression to increase (Kennedy and Dewhirst, 2010b, 
Gallagher et al., 2007).  To determine that the effects on MCT-1 and -4 observed on 
CLL cells exposed to CD40L fibroblasts was not an artefact of hypoxia, soluble CD40L 
(sCD40L) was used.  
CLL cells were incubated with increasing concentrations (100, 200, and 400ng/mL) of 
sCD40L plus enhancer for a 24 hour period.  This concentration range and incubation 
time were selected based on previous work in this laboratory examining the effect of 
sCD40L stimulation on vascular endothelial growth factor (VEGF) expression (Farahani 
et al., 2005).  Figure 3.8 shows that there is no difference in MCT1 expression on 
untreated or sCD40L-stimulated CLL cells.  With respect to MCT4, there appeared to be 
an increase in expression of this protein using the highest concentration of sCD40L 
(Figure 3.9 (A)).  Repeat experiments using different CLL cases showed a similar effect, 
(Figure 3.9 (B)), but quantitation failed to show significant change (Figure 3.9 (C), P = 
0.2500 Wilcoxon matched–pairs signed ranks test).   
3.3.3 CD147 expression following stimulation with CD40 ligand (CD40L) 
CD147 is a chaperone of MCT-1 and -4 membrane expression (Kirk et al., 2000).  
Considering that incubation of CLL cells with CD40 expressing fibroblasts upregulates 
only MCT4, it seemed logical to assume that any increase in MCT4 expression would 
be accompanied by concomitant increase in CD147.  This notion was investigated by 
flow cytometry.  Figure 3.10 shows that there was no change in CD147 expression 
between untreated CLL cells and CLL cells cultured on parental fibroblasts.  However, 
culture of CLL cells on CD40L fibroblasts resulted in a significant increase in CD147 
expression compared to either untreated CLL cells (*** P = 0.0005) or CLL cells 
cultured on parental fibroblasts (**** P = <0.0001).  These data indicate that CD147 
expression on CLL cells can be used as a surrogate marker of MCT4 upregulation in 





Figure 3.8:  MCT1 expression following treatment with sCD40L (24hrs).  A) CLL 
cells were treated with increasing concentrations of sCD40L (100, 200 and 400ng/mL) 
for 24 hours.  (B) Malignant cells from 3 cases of CLL treated with 400ng/mL of 
sCD40L.  For (A) and (B) MCT1 was detected using mouse monoclonal anti-MCT1 (sc-
365501) (1:1000) (Insight Biotechnology, Wembley, UK) in whole cell lysates using 
Western blotting.  A MEC-1 cell lysate was used as a positive control.  Blots were 
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probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure equal 
protein loading.  (C) Graphical representation of the data shown in part (B).  MCT1 
expression was determined as a densitometric ratio of MCT1:actin.  A Wilcoxon 
matched–pairs signed ranks test showed no significant difference in MCT1 expression 





Figure 3.9:  MCT4 expression following treatment with sCD40L (24hrs).  (A) CLL 
cells were treated with increasing concentrations of sCD40L (100, 200 and 400ng/mL) 
for 24 hours.  (B) Malignant cells from 3 cases of CLL treated with 400ng/mL of 
sCD40L.  MCT4 was detected using rabbit polyclonal anti-MCT4 (sc-376101) (1:1000) 
(Insight Biotechnology, Wembley, UK) in whole cell lysates using Western blotting.  
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MDA-MB-231 and Raji cell lysates were used as positive and negative controls 
respectively.  Blots were probed with mouse monoclonal anti-β-actin (clone AC-74) as a 
control to ensure equal protein loading.  (C) Graphical representation of the data shown 
in part (B).  MCT4 expression was determined as a densitometric ratio of MCT4:actin.  
A Wilcoxon matched–pairs signed ranks test showed no significant difference in MCT4 







Figure 3.10: CD147 levels following co-culture of CLL cells on CD40L and parental 
fibroblasts.  CD147 levels were measured on 18 cases of CLL following co-culture 
using flow cytometry.  CLL cells were gated as CD5+, CD20+, and CD23+.  Statistical 
analyses revealed there to be a significant increase in the mean CD147 expression 
following the incubation of CLL cells with CD40L fibroblasts in comparison to 
untreated cells (*** P = 0.0005).  The same was true when comparing cells co-cultured 
with parental fibroblasts versus co-culture with CD40L fibroblasts (**** P = < 0.0001).  
Untreated CLL cells compared to CLL cells co-cultured on the parental (Par) fibroblasts 





3.3.4 MCT -1 and -4 mRNA levels following stimulation with CD40L 
Following the assessment of protein levels for both MCT-1 and -4, qRT-PCR was used 
to evaluate whether any change observed was also seen at the mRNA level.  GAPDH 
expression was chosen as a reference gene in preference to actin because expression of 
the latter gene appeared to vary less between CLL cells cultured on parental fibroblasts 
and CLL cells cultured on CD40L fibroblasts (Figure 3.11).  However, both 
housekeeping genes appeared to have increased Ct values in untreated CLL cells 
compared to fibroblast co-cultured CLL cells.  As such, only co-cultured CLL cells were 
considered for future experiments.  
qRT-PCR analysis of MCT-1 and -4 mRNA levels show that co-culture of CLL cells 
with CD40L fibroblasts does not stimulate gene expression of these proteins (Figure 
3.12).  In fact, mRNA levels of both MCT-1 and -4 were reduced by co-culture of CLL 
cells with CD40L fibroblasts.  CD147 expression was used as a marker to insure 
activation of the CD40L-stimulated cells (data not shown).  This suggests that 
upregulation of MCT4 protein in CLL cells co-cultured with CD40L fibroblasts is likely 
to result from post-translational regulation rather than transcriptional regulation of gene 
expression. However, because there is slight variation in the level of GAPDH for both 
the CLL cells co-cultured with the CD40L and parental fibroblasts this could have 









Figure 3.11:  Assessing appropriate reference genes for PCR following immobilised 
CD40L stimulation.  CLL cells co-cultured on CD40L fibroblasts (CD40L) and 
parental (Par) fibroblasts and cultured in the absence of fibroblasts (UT); (A) relative to 
actin, and (B) relative to GAPDH.  (C) Data table showing the Ct values for each 
candidate control.  GAPDH appears to be the most reliable endogenous control with 
respect to comparing between CLL cells co-cultured on CD40L fibroblasts and those 
cultured on parental fibroblasts.  Comparison with the UT control is not appropriate here 










Figure 3.12:  MCT -1 and -4 mRNA levels in CLL cells following CD40L 
stimulation.  qRT-PCR analysis of MCT1 (A) and MCT4 (B) mRNA expression 
relative to GAPDH in CLL cells following co-culture with CD40L and parental (Par) 
fibroblasts.  The comparison is derived from three technical replicates of n = 8 CLL 
cases, and is shown as the mean±SEM.  A Wilcoxon matched-pairs signed rank test 
revealed there was a significant change in both MCT 1 (** P = 0.0078) and MCT4 
mRNA (* P = 0.0391).   
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3.3.5 MCT4 expression in fibroblast cell lines following co-culture with CLL cells  
The experiments thus far have examined the influence of fibroblasts on the expression 
of MCT -1 and -4 in CLL cells.  In this section, the effect of CLL cells on MCT -1 and -
4 in fibroblasts is assessed.   
Figure 3.13 shows that MCT-1 and -4 expression in CD40L and parental fibroblasts is 
low compared to control cells (MEC-1 and MDA-MB-231 cell lysates).  Co-culture of 
the parental fibroblasts with CLL cells did not affect this low level of expression of 
either MCT-1 or -4 (Figure 3.14).  However, co-culture of CD40L fibroblasts with CLL 
cells resulted in an increase in MCT4 expression by the fibroblasts (Figure 3.14 (A)).  
To insure that the induced increase in MCT4 expression was not an artefact of CLL cell 
contamination, IgM expression in the fibroblast cell lysates was assessed (Figure 3.14 
(B)).  IgM in CD40L fibroblasts co-cultured with CLL cells was very low in comparison 
to IgM in CLL cell lysates, suggesting little, if any, gross contamination of the fibroblast 
lysates with CLL cells.  This suggests that metabolic changes may occur in the CD40L 
fibroblasts in response to co-culture which require enhanced monocarboxylate transport 









Figure 3.13:  MCT -1 and -4 expression in CD40L and parental fibroblasts.  
Western blot analysis of MCT1 (A) and MCT4 (B) in cell lysates prepared from CD40L 
and parental (Par) fibroblast cell lines.  MCT1 was detected using AZ5565 while MCT4 
was detected using AZ5570.  As a positive control for MCT1 expression, whole cell 
lysates of MEC-1 cells were used in part (A).  Whole cell lysates of MDA-MB-231 and 
Raji cells were used as positive and negative controls for MCT4 expression.  Blots were 
probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure equal 









Figure 3.14:  MCT4 and IgM expression in fibroblast cell lines following co-culture 
with CLL cells.  Western blot analysis of MCT4 (A) and IgM (B) in cell lysates 
prepared from CD40L and parental (Par) fibroblast cell lines which had been in co-
culture with CLL cells for 48 hours (as indicated by case adjacent CLL case number).  
MCT4 was detected using sc-376101 while IgM was detected using goat anti-human 
IgM (2020-01) (Southern Biotech, Cambridge, UK).  Whole cell lysates of MDA-MB-
231 and Raji cells were used as positive and negative controls for MCT4 expression in 
part (A).  As a positive control for IgM a UT CLL cell lysate was used.  Blots were 
probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to ensure equal 





3.3.6 Fluidigm Biomark™ gene array analysis of metabolic gene expression in 
CLL cells co-cultured with CD40L fibroblasts 
Upregulation of MCT4 in CLL cells co-cultured with CD40L fibroblasts implies that 
there are metabolic changes within CLL cells that require the increased expression of 
MCT4.  To understand this change, gene expression analysis was performed using a 
Fluidigm Biomark™ chip.  The 45 genes profiled in the array are detailed in Table 3.1.   
Figure 3.15 shows a heat map of the Ct values for each gene across individual samples 
i.e. CLL cells co-cultured with CD40L and parental fibroblasts.  Amplification data 
which was not classified as linear was automatically excluded by the Fluidigm 
Biomark™ Real Time PCR Analysis Software (Version 3.1.3) (indicated by an ‘X’ on 
Figure 3.15).  Verification that the cDNA synthesis and pre-amplification steps used 
during sample preparation were successful was performed using human reference RNA 
(HqPCR, row 1 of array data).  This showed that 43 of 45 genes were amplified (Ct 
<24); the genes which were not, ACACB, and GLUD2 were excluded from further 
analysis.  Human genomic DNA (HgDNA, row 7 of the array data) was used as a 
negative control for the PCR reaction.  Here, 3 genes were amplified (Ct <24), LDHA, 
ATF4, and PPIA.  Whereas LDHA and ATF4 were excluded from further analysis, 
PPIA was not because the amplification curve for this gene was poor for the HgDNA 
sample.  Moreover, the Ct value (Ct = 19) for PPIA amplified from HgDNA was outside 
the range obtained for the analysed samples (Ct 10-18) using cDNA, indicating that 
more PPIA was present in the samples than in the genomic control. 
In order to select the most suitable gene for sample normalisation, the expression of 3 
housekeeping genes; actin, IPO8 and PPIA was investigated.  Figure 3.16 shows the Ct 
values for these housekeeping genes (n = 14).  PPIA was selected as the most 
appropriate housekeeping gene because the Ct values demonstrated the least variability 
between CD40L and parental fibroblast co-cultured CLL cells (P = 0.0781, Wilcoxon 
test).  One case of CLL, 2565, failed on the chip (Ct >999) and was excluded from 
further analysis.   
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Specificity of the primers used for the Fluidigm chip for human cDNA over mouse 
cDNA was verified by the inclusion of mouse-only control samples.  Here, irradiated 
CD40L and parental fibroblasts that had not come into contact with CLL cells were 
used.  Two of three preparations of these cells (rows 28 and 29 for CD40L fibroblasts 
and rows 34 and 35 for parental fibroblasts) showed no or very little amplification, 
indicating that the primers used are specific for human genes.  However, one preparation 
(row 30 for CD40L fibroblasts and row 36 for parental fibroblasts) showed 
amplification of the genes used for the chip.  One possible explanation is that this 
preparation was made separately from the other two, and could reflect inadvertent 
contamination.  Nevertheless, it was assumed that the array was specific for human 








Figure 3.15:  Fluidigm Biomark™ chip array for metabolic genes in CLL cells co-
cultured with CD40L and parental fibroblasts.  Heat map of the Ct values obtained 
for each gene across individual samples.  Amplification data which was not classified as 
linear was automatically excluded by the Fluidigm Biomark™ Real Time PCR Analysis 














Figure 3.16:  Selection of housekeeping genes for Fluidigm Biomark™ chip array 
in CLL cells co-cultured with CD40L and parental fibroblasts.  PPIA was selected 
as most appropriate housekeeping gene for normalisation of gene expression because it 







After establishing the most appropriate housekeeping gene, relative expression of the 
genes of interest on the chip relative to PPIA were then calculated and plotted as heat 
map (Figure 3.17).  At this point in the analysis, 11 genes (SLCA19, SLC6A14, 
SLC7A5, SLC7A10, SLC7A11, SLC22A6, SLC22A8, ACSS2, PFKFB1, ME1 and 
ME3) out of the original 45 were excluded because they failed to amplify (Ct >999).  A 
further 4 genes (SLC38A1, GLUD1, PDK4 and PHGDH) were also excluded from 
further analysis because there was less than n = 3 measurements for these genes, making 
them unsuitable for statistical analyses.   
The next step was to assess inter-individual variation between the cases used, and 
variability under each condition.  Figures 3.18 and 3.19 show relative gene expression in 
CLL cells co-cultured, respectively, with CD40L and parental fibroblasts.  Here, dCt is 
used as a measure of expression (gene of interest relative to housekeeping gene), and 
low dCt values correspond to higher gene expression.  A Kruskal-Wallis test was used 
to assess the inter-individual variation between cases.  In CLL cells co-cultured with 
CD40L fibroblasts there was no significant inter-individual variation in gene expression 
except for ATF4 (* P = 0.0271), SLC1A4 (* P = 0.0178) and SLC25A10 (* P = 
0.0362).  Further post hoc analyses using a Dunn’s test for multiple comparisons 
revealed that this apparent inter-individual variation was not significant (P = >0.05).  In 
CLL cells co-cultured with parental fibroblasts there was no significant inter-individual 
variation in gene expression except for PSAT1 (** P = 0.0095) and SLC1A5 (* P = 
0.0381).  Again, post hoc analyses using a Dunn’s test for multiple comparisons 
revealed that this apparent inter-individual variation was not significant (P = >0.05).   
Taken together, these data suggest that the RNA extraction method yields samples of 
comparable quality and provides reassurance that the genes have performed reliably and 
with similar efficiencies.  Furthermore, these findings provide confidence that any 
variation observed in future comparative analyses between CLL cells co-cultured with 
CD40L fibroblasts versus CLL cells co-cultured with parental fibroblasts will likely be 
due to differential gene modulation and not experimental variation.  Thus, the analysis 







Figure 3.17:  Heat map showing gene expression in CLL cells co-cultured with 
CD40L and parental fibroblasts.  Hierarchical clustering of gene expression was 
performed based upon negative dCt values.  Genes with higher levels of expression are 
coloured red and clustered towards the bottom of the heat map while genes with lower 










Figure 3.18:  Assessing inter-individual variation between CLLs co-cultured with 
CD40L fibroblasts.  Inter-individual variation in genes associated with cell metabolism.  
Values are relative to PPIA.  A Kruskal-Wallis test was used to assess the inter-
individual variation between cases.  In CLL cells co-cultured with CD40L fibroblasts 
there was no significant inter-individual variation in gene expression except for ATF4 (* 
P = 0.0271), SLC1A4 (* P = 0.0178) and SLC25A10 (* P = 0.0362).  Further post hoc 
analyses using a Dunn’s test for multiple comparisons revealed that this apparent inter-
individual variation was not significant (P = >0.05).  Error bars are the SEM derived 






Figure 3.19:  Assessing inter-individual variation between CLL co-cultured with 
parental fibroblasts.  Inter-individual variation in genes associated with cell 
metabolism.  Values are relative to PPIA.  A Kruskal-Wallis test was used to assess the 
inter-individual variation between cases.  In CLL cells co-cultured with parental 
fibroblasts there was no significant inter-individual variation in gene expression except 
for PSAT1 (** P = 0.0095) and SLC1A5 (* P = 0.0381).  Again, post hoc analyses 
using a Dunn’s test for multiple comparisons revealed that this apparent inter-individual 
variation was not significant (P = >0.05).  Error bars are the SEM derived from 3 
technical replicates.  
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Figure 3.20 (A) shows a heat map illustrating changes in gene expression in CLL cells 
co-cultured with CD40L fibroblasts normalised to gene expression in CLL cells co-
cultured with parental fibroblasts (parental control) (n = 4).  From this figure it was 
immediately obvious that CLL case 2646 did not behave in the same way as the three 
other CLL cases.  Moreover, the Ct associated with PPIA was higher than the other 
cases, suggesting insufficient starting material for the assay.  Thus, the values associated 
with this case were excluded from further study. 
The values associated with the three remaining CLL cases were then averaged, to 
produce average linear fold changes [shown in Figure 3.20 (B)].  None of the genes 
within this panel showed downregulation below a 0.5 fold threshold.  Increase in 
expression was observed for ELOVL6 (* P = 0.0257) and FASN (* P = 0.0385), these 
were the only genes where the P value was 0.05 (Figure 3.21).  However, if the P 
value is raised to 0.1 it is possible to include ACACA (P = 0.1), HK1 (P = 0.09), HK2 
(P = 0.1), ME2 (P = 0.09), SLC1A5 (P = 0.06), SLC25A11, (P = 0.06), and VEGFA, (P 
= 0.1) (Figure 3.21).  In keeping with the hierarchical cluster analysis shown in Figure 
3.20, all of these genes showed a minimum 1.5 fold increase in expression.  Three 
additional genes, GLS, PSAT1, SLC1A4, SLC16A1 and SLC25A10, were upregulated 
past this 1.5 fold threshold.  For GLS there were only two measurements, and with 
PSAT1, SLC1A4, SLC16A1 and SLC25A10 the P value associated with the observed 
increase was greater than 0.1.  Although the increased expression observed in these 12 
latter genes could not termed significant based on 95% confidence (P  0.05) (Figure 
3.21), they were still used in pathway analysis to provide insight into global changes in 





Figure 3.20:  Fold change in gene expression in CLL cells in response to CD40L 
stimulation (n = 4).  (A) Hierarchical clustering of gene expression based upon a log 2 
fold change.  Values were made relative to PPIA and normalised to the parental control.  
Genes with higher levels of expression are coloured red and clustered towards the top 
while genes with lower levels of expression are coloured blue and clustered towards the 
bottom of the heat map.  (B) Linear fold changes for each case of CLL (n = 3).  A fold 
change of >1.5 indicates increased gene expression.  A fold change of <0.5 indicates 




Figure 3.21:  Increased gene expression in CLL cells following co-culture with 
CD40L fibroblasts.  Values were made relative to PPIA.  A paired t test shows a 
124 
 
significant increase in expression was for ELOVL6 (* P = 0.0257) and FASN (* P = 
0.0385).  Error bars are the SEM. 
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Metabolic pathway analyses are illustrated in Figure 3.23.  Co-culture of CLL cells on 
CD40L fibroblasts appeared to stimulate fatty acid metabolism as indicated by the 
upregulation of ELOVL6 and FASN, and, to a lesser extent ACACA.  Pathways of 
energy production were also affected because HK1 and HK2, within the glycolysis 
pathway, and GLS and ME2, within the TCA pathway, were upregulated.  Levels of 
genes involved in amino acid transport (SLC1A4, SLC1A5, SLC25A10, and 
SLC25A11) and serine metabolism (PSAT1) also increased.  Finally, in keeping with a 
previous observation from this department (Farahani et al., 2005), VEGFA expression 
was also upregulated by CD40 ligation on CLL cells.  
Taken together, these data suggest that there is a global upregulation of metabolic 
activity in CLL cells exposed to CD40 stimulation.  In particular, the upregulation of 
genes involved in glycolysis support a hypothesis that this pathway is activated in 
CD40-stimulated CLL cells requiring upregulation of MCT4 protein to mediate lactate 
transport and prevent cytosolic acidification. However, correction has not been made for 





Figure 3.22:  Diagrammatic representation of the metabolic pathways investigated 
using the Fluidigm Biomark™ array.  Fatty acid metabolism (orange), glutamine 
metabolism (purple), glycolysis (green), monocarboxylate transporters (pink), pyruvate 






Figure 3.23:  Examining the changes in metabolic processes in CLL cells following 
co-culture with CD40L fibroblasts.  Linear fold changes relative to CLL cells co-
cultured with parental fibroblasts with a threshold of plus 1.5 and 0.5 to highlight the 
greatest increases and decreases in mRNA expression (n = 3).  Error bars are the SEM.  
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3.3.7 Fluidigm Biomark™ gene array analysis of metabolic gene expression in 
CD40L and parental fibroblasts following co-culture with CLL cells 
Co-culture of CLL cells with CD40L fibroblasts clearly has an effect on CLL cells.  
However, what is not clear is whether CLL cells have an effect on their stromal support, 
in this case CD40L and parental fibroblasts.  Evidence shown in Figure 3.14 (A) 
suggests that such co-culture induces MCT4 expression in CD40L fibroblasts, indicating 
the possibility of changes in metabolism.  This notion is not unfounded as a symbiotic 
relationship between cancer cells and the tumour microenvironment has been described 
in the literature (Bonuccelli et al., 2010b, Feron, 2009).  To investigate whether co-
culture with CLL cells induces change in the expression of genes associated with cell 
metabolism in supporting fibroblast cells a mouse Fluidigm Biomark™ chip was used.  
The 46 genes used in this analysis are detailed in Table 3.2.   
Figure 3.24 shows a heat map of the Ct values for each gene across CD40L and parental 
fibroblasts co-cultured with CLL cells.  Amplification data which was not classified as 
linear was automatically excluded by the Fluidigm Biomark™ Real Time PCR Analysis 
Software (Version 3.1.3) (indicated by an ‘X’ on Figure 3.24).  As with the human array 
a mouse reference RNA (MqPCR, row 1 of array data) sample was used as a positive 
control to verify that the cDNA synthesis and pre-amplification steps of the protocol 
were successful.  This data showed that all of the 46 genes within the array were 
amplified (Ct <24) except for TKTL-11 which was subsequently excluded from further 
analysis.  Once again, a genomic DNA sample was used as a negative control for the 
PCR reaction (MgDNA, row 7 of array data).  One gene was amplified, 18S, however 
the Ct value was >Ct 24 and this was deemed acceptable considering that the Ct value 
within the fibroblast samples was approximately 10. Thus, 18S was included in the 
analyses.   
A housekeeping gene was selected from a panel of two genes; 18S and IPO8.  Figure 
3.25 shows the average Ct values for these genes (n = 12).  18S was selected as the most 
appropriate housekeeping gene because the Ct values associated with this gene when 
amplified from CD40L and parental fibroblasts were similar.  The same could not be 
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said of IPO8 where the Ct value associated with this gene amplified from parental 
fibroblasts looked to be lower than that from CD40L fibroblasts.  Moreover, the Ct 
value of IPO8 was much higher than that of 18S.  One experiment, enumerated 2565, 
highlighted a problem where the Ct value of 18S was high.  Further examination of the 
genes of interest showed this sample had failed on the chip, and this was also evident 
from the analysis of the CLL cells associated with this experiment.  Case 2565 was 







Figure 3.24:  Fluidigm Biomark™ chip array for metabolic genes in CD40L and 
parental fibroblasts co-cultured with CLL cells.  Heat map of the Ct values obtained 
for each gene across individual samples.  Amplification data which was not classified as 
linear was automatically excluded by the Fluidigm Biomark™ Real Time PCR Analysis 














Figure 3.25:  Selection of housekeeping genes for Fluidigm Biomark™ chip array 
in CD40L and parental fibroblasts co-cultured with CLL cells.  18S was selected as 
the best housekeeping gene to which the genes of interest were normalised because it 






The heat map shown in Figure 3.26 illustrates expression of the genes of interest relative 
to expression of 18S.  From this figure it is obvious that the sample designated CD40L 
3335 did not behave in the same way as did the three other CD40L cases and was 
excluded from further study.   
As done previously for the human array, an ANOVA was used to assess the inter-
individual variation between preparations of CD40L fibroblasts which had been co-
cultured with CLL cells (Figure 3.27 and 3.28).  At this point in the analysis PPARG 
was excluded from further analyses due to undetectable levels of expression (Ct >999), 
and PPARα was excluded because there were less than n = 3 measurements for this 
gene.  For each of the remaining genes of interest there was no significant inter-
individual variation (P = >0.05).   
Examination of the parental fibroblast preparations is shown in Figure 3.29 and 3.30.  
Once again PPARG was excluded from the analysis due to undetectable levels of 
expression (Ct >999).  For each of the genes there was no significant inter-individual 
variation except for ACACA (* P = 0.0250), ME2 (* P = 0.0483), PDK4 (** P = 
0.0040), PHGDH (* P = 0.0400), SLC16A1 (* P = 0.0225) and SREBF2 (* P = 
0.0263).  Post hoc analyses using a Tukey’s multiple comparison test revealed that there 
was no significant variation in ME2 (P = >0.05).  However, significant variation was 
seen for the other genes listed above highlighting Par 2646 to be the source of the 
variation.  As such this sample was excluded from further analyses.   
Taken together, these data suggest that the extraction method yields samples of 
comparable quality and provides reassurance that the genes have performed reliably and 









Figure 3.26:  Heat map showing changes in gene expression for genes in CD40L 
and parental fibroblasts co-cultured with CLL cells.  Hierarchical clustering of gene 
expression was performed based upon negative dCt values.  Genes with higher levels of 
expression are coloured red and clustered towards the bottom of the heat map while 
genes with lower levels of gene expression are coloured blue and clustered towards the 







Figure 3.27:  Assessing variation in metabolic gene expression in CD40L 
fibroblasts co-cultured with CLL cells.  An ANOVA was used to assess the inter-
individual variation between preparations of CD40L fibroblasts which had been co-
cultured with CLL cells.  Values were normalised to 18S.  There was no significant 





Figure 3.28:  Assessing variation in metabolic gene expression in CD40L 
fibroblasts co-cultured with CLL cells.  An ANOVA was used to assess the inter-
individual variation between preparations of CD40L fibroblasts which had been co-
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cultured with CLL cells.  Values were normalised to 18S.  PPARG was excluded due to 
undetectable levels of expression (Ct >999), and PPARα was excluded as there were 
less than n = 3.  For the remaining genes of interest there was no significant inter-





Figure 3.29:  Assessing variation in metabolic gene expression in parental 
fibroblasts co-cultured with CLL cells.  An ANOVA was used to assess the inter-
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individual variation between preparations of parental fibroblasts which had been co-
cultured with CLL cells.  Values were normalised to 18S.  There was no significant 
inter-individual variation except for ACACA (* P = 0.0250) and ME2 (* P = 0.0483).  
Post hoc analyses using a Tukey’s multiple comparison test revealed that there was no 
significant variation in ME2 (P = >0.05).  However, significant variation was seen for 
the other genes highlighting Par 2646 to be the source of the variation.  As such this 
sample was excluded from further analyses.  Error bars are the SEM derived from 3 






Figure 3.30:  Assessing variation in metabolic gene expression in parental 
fibroblasts co-cultured with CLL cells.  An ANOVA was used to assess the inter-
individual variation between preparations of parental fibroblasts which had been co-
cultured with CLL cells.  Values were normalised to 18S.  PPARG was excluded from 
the analysis due to undetectable levels of expression (Ct >999).  For each of the genes 
there was no significant inter-individual variation except for PDK4 (** P = 0.0040), 
PHGDH (* P = 0.0400), SLC16A1 (* P = 0.0225) and SREBF2 (* P = 0.0263).  Post 
hoc analyses using a Tukey’s multiple comparison test revealed that there was 
significant variation highlighting Par 2646 to be the source of the variation.  As such this 
sample was excluded from further analyses.  Error bars are the SEM derived from 3 
technical replicates.  
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The influence of CLL cells on supportive fibroblasts was assessed by comparing gene 
expression in CD40L and parental fibroblasts co-cultured with CLL cells relative to 
those which were not.  The CD40L and parental fibroblast control samples (those 
cultured in the absence of CLL cells) were prepared at a different time to the co-cultured 
samples; however, the conditions of this preparation were the same.  Inter-variation 
between preparations of the control fibroblast (CD40L and parental) samples was 
assessed (Table 3.3), and at this point SOD2 was excluded from the analysis for both 
CD40L and parental fibroblasts because there were less than 3 measurements.  No 
significant variation was seen between the different preparations except for PPARGC1 
in the CD40L fibroblast samples (* P = 0.0351, unpaired t test).  Because of this 
variance, this gene was excluded from further analysis.  Taken together, these data 
provide confidence that any variation seen in future comparative analyses between 
fibroblast cells co-cultured with CLL cells versus those cultured in the absence of CLL 
cells will likely be due to CLL cell-induced changes in gene expression and not 
experimental variation.  Therefore, the study can progress to make comparisons between 
these culture conditions. 
Figure 3.31 shows a heat map illustrating changes in gene expression in CD40L and 
parental fibroblasts that have been co-cultured with CLL cells and normalised to control 
fibroblast preparations (n = 3).  The effect of CLL cell co-culture on CD40L fibroblasts 
was assessed first.  The average fold change in gene expression in co-cultured CD40L 
fibroblasts is illustrated in Figures 3.32 and 3.33; 4 genes (HK2, LDHA, PDK1 and 
SLC16A3) showed significant upregulation above a 1.16 fold threshold, and 18 genes 
showed significant downregulation below a 0.61 fold threshold (ACACA, ACLY, 
ELOVL5, ELOVL6, FASN, G6PD, GLS, NDUFB5, NDUFB9, PAPRG, PHGDH, 






Table 3.3:  Comparing inter-individual variation between untreated irradiated 
fibroblast (CD40L and parental) controls.  Variation between irradiated control 
samples cultured in the absence of CLL cells (untreated, UT).  (A) Comparison of UT 
irradiated control preparations of CD40L fibroblasts showed significant variation with 
one gene, PPARGC1, using an unpaired t test.  (B) Comparison of UT irradiated control 








Figure 3.31:  Change in gene expression in CD40L fibroblasts and parental 
fibroblasts following co-culture with CLL cells.  Linear fold changes were calculated 
by normalisation of CD40L and parental fibroblasts co-cultured with CLL cells to 
irradiated CD40L and parental fibroblasts which had not been in contact with CLL cells 














Figure 3.32:  Fold change in gene expression in CD40L fibroblasts following co-
culture with CLL cells (n = 3).  Linear fold increases for CD40L fibroblasts co-
cultured with CLL cells made relative to an irradiated CD40L fibroblast control.  A 
minimum threshold fold change of ≥1.16 indicates there are 5 genes which are 
upregulated; HK1, HK2, LDHA, PDK1 and SLC16A3 (n = 3) while a minimum 
threshold of ≤ 0.61 suggests there are 19 genes which are downregulated; ACACA, 
ACLY, ELOVL5, ELOVL6, FASN, G6PD, GLS, NDUFB5, NDUFB9, PAPRG, 










Figure 3.33:  Increased and decreased gene expression in CD40L fibroblasts 
following co-culture with CLL cells.  (A) An unpaired t test showed significant 
upregulation of HK2, LDHA, PDK1 and SLC16A3 (n = 3).  (B) An unpaired t test 
showed significant downregulation of ACACA, ACLY, ELOVL5, ELOVL6, FASN, 
G6PD, GLS, NDUFB5, NDUFB9, PAPRG, PHGDH, SLC1A5, SLC7A5, SLC16A1, 
SLC25A1, SREBF1, SREBF2 and TRFC.  
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The effect of CLL cell co-culture on parental fibroblasts was next assessed.  Figures 
3.34 and 3.35 show the data for the comparative analysis between parental fibroblasts 
co-cultured with CLL cells and control parental fibroblasts.  Thresholds for gene 
upregulation and downregulation were set at 1.5 and 0.66 fold, respectively.  In terms of 
upregulated genes, only two (INSIG2 and PDK4) of the 9 potentially upregulated genes 
showed significance (P < 0.05).  16 genes (ACACA, CPT1A, ELOVL5, ELOVL6, 
FASN, GLS, G6PD, GLUD1, NDUFB5, PHGDH, SLC1A5, SLC7A5, SOD1, SREBF1, 
SREBF2 and TRFC) showed significant downregulation in parental fibroblasts co-
cultured with CLL cells compared to control. Taken together with the data generated 
using CD40L fibroblasts, these data show that co-culture with CLL cells affects gene 
expression in fibroblasts.  However, correction has not been made for the use of multiple 













Figure 3.34:  Fold change in gene expression in parental fibroblasts following co-
culture with CLL cells (n = 3).  Linear fold change increases for parental fibroblasts 
co-cultured with CLL cells made relative to an irradiated parental fibroblast control.  A 
minimum threshold fold change of ≥1.5 indicates there are 9 genes which are 
upregulated, HIF1A, HK2, INSIG2, LDHA, PAPRG, PDK1, PDK4, PFKB3, PFKB4, 
while a minimum threshold of ≤ 0.66 suggests there are 17 genes which are 
downregulated; ACACA, CAMKK2, CPT1A, ELOVL5, ELOVL6, FASN, GLS, G6PD, 






Figure 3.35:  Changes in gene expression in parental fibroblasts following co-
culture with CLL cells.  (A) An unpaired t test revealed 2 genes to be significantly 
upregulated, INSIG2 and PDK4 (n = 3).  (B) 16 genes were shown to be significantly 
down regulated using an unpaired t test (n = 3).    
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Following on from the comparative analyses, changes in gene expression were 
examined in relation to metabolic pathways as was done when CLL cells were analysed 
(Figure 3.36).  Incubation of CD40L fibroblasts with CLL cells seemed to promote 
energy generating processes such as glycolysis (HK1, HK2, LDHA) as well as pyruvate 
metabolism (PDK1).  SLC16A3 (the gene which codes for MCT4) is upregulated, likely 
as a consequence of enhanced glycolytic activity, and is in agreement with protein data 
(Figure 3.14).  Incubation of CD40L fibroblasts with CLL cells also seemed to suppress 
amino acid transport (SLC1A5, SLC7A5, SLC25A1), fatty acid metabolism (ACACA, 
ACLY, ELOVL5, ELOVL6, PAPRG, SREBF1, SREBF2 and TRFC), glutamine 
metabolism (GLS), and serine metabolism (PHGDH).  Interestingly, a similar gene 
profile was suppressed in parental fibroblasts co-cultured with CLL cells.  Thus, genes 
involved in amino acid transport (SLC1A5, SLC7A5), fatty acid metabolism (ACACA, 
ACLY, CPT1A, ELOVL5, ELOVL6, FASN, SREBF1, SREBF2 and TRFC), glutamine 
metabolism (GLS, GLUD1) the pentose phosphate pathway (G6PD), serine metabolism 
(PHGDH) and were all downregulated.  This suggests that there are common effects of 
CLL cells on their stromal support.  However, the strong upregulation of SLC16A3 in 
the CD40L fibroblasts indicates a specific effect of engaged CD40L, caused either 
within the CD40L fibroblast itself (a signalling effect) or by the increased metabolic 









Figure 3.36:  Examining the changes in metabolic processes in CD40L and parental 
fibroblasts following co-culture with CLL cells.  Linear fold changes relative to 
irradiated controls with a threshold of plus 1.5 and 0.5 to highlight the greatest increases 
and decreases in mRNA expression (n = 3).  Error bars are the SEM.  
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3.3.8 Assessing mitochondrial function in CLL cells using the SeahorseXF24 
metabolic flux analyser 
Co-culture of CLL cells with CD40L fibroblasts results in upregulation of MCT4 
protein and is accompanied by a switch in gene expression favouring fatty acid 
metabolism and glycolysis.  This switch in energy metabolism was next analysed using 
the SeahorseXF24 metabolic flux analyser.  This method was chosen to compliment the 
Fluidigm array data and provide real time information about the metabolic phenotype of 
these cells.  To assess oxidative phosphorylation OCR (oxygen consumption rate) was 
measured while ECAR (extracellular acidification rate) was used as an indicator of 
glycolytic activity.  By examining changes in both OCR and ECAR it is possible to 
assess metabolic competency through the addition of agents such as; oligomycin, FCCP, 
rotenone and antimycin-A to produce parameters such as; basal respiration, ATP 
turnover, proton leak, maximal respiration, spare respiratory capacity and glycolytic 
capacity. 
First of all it was necessary to optimise this measuring technique for the analysis of CLL 
cells.  Attempts were made to use cryopreserved CLL cells, however, addition of 
oligomycin, FCCP, rotenone and antimycin-A produced little change in the 
measurements despite using different cell numbers [Figure 3.37 (A)].  Addition of 
pyruvate to the analysis media, as is suggested by a paper by Chacko (2013) using 
primary B cells, showed that CLL cells became responsive to mitochondrial stressors 
[Figure 3.37 (B)].  However, in this case repeat experiments using the same case did not 
generate reproducible results.  Finally, fresh CLL cells were used, and these showed 
good responses to mitochondrial stressors in comparison to cryopreserved CLL cells 
[Figure 3.37 (C)].  This is supported in the literature where it is described how 
cryopreservation may irreparably damage mitochondria (Trusal et al., 1984, Larsen et 
al., 2012, Tsutsaeva and Gordienko, 1982).  Moreover, in lymphocytes specifically, 
cryopreservation has been demonstrated to alter the phenotype of cells as well as change 
the expression of adhesion molecules which may also have a role in regulating 
metabolic function (Faint et al., 2011, Costantini et al., 2003, Deneys et al., 1999).  
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Thus, CLL cell responsiveness to the mitochondrial stressors was always robust when 
fresh cells were used.  
The next step in measuring metabolic flux in CLL cells involved further optimisation 
titrating the concentration of FCCP.  This is because the effects of this compound can 
vary between different cell types, and because too much or too little can affect final 
measurement.  Figure 3.38 shows OCR data following the addition of FCCP at 0.5, 
0.75, 1.0, 1.5 and 3µM concentrations.  1.5µM FCCP was selected because this 
concentration was consistent with data generated using cell lines that is presented later 






Figure 3.37:  Optimisation of the SeahorseXF24 analysis technique.  (A) To assess 
seeding density CLL cells were plated out at 2 x 10
5 
cells/well, 6 x 10
5
 cells/well, and 2 
x 10
6
 cells/well and subjected to a mitochondrial stress test (oligomycin 1.26μM, FCCP 
1.5μM and rotenone and antimycin-A 1μM).  (B) CLL cells (2 x 10
6
 cells/well) were 
shown to be responsive to mitochondrial stressors following the addition of 2mM 
sodium pyruvate to analysis media.  (C) Fresh CLL cells (case 3359) and thawed CLL 
cells (cases 2683 and 2751) (2 x 10
6
 cells/well) were subjected to a mitochondrial stress 
test.  Fresh cells were seen to respond to stressors while the thawed cells were 






Figure 3.38:  FCCP titration.  Fresh CLL cells (2 x 10
6
 cells/well) were subjected to a 
mitochondrial stress test (oligomycin 1.26µM, FCCP 0.5, 0.75, 1.0, 1.5 and 3µM and 
rotenone and antimycin-A 1µM).  OCR (pMoles/min) was measured.  Data was made 
relative to the baseline (%) and normalised to DNA content (μgDNA).  1.5µM was 




Mitochondrial respiration of cultured (untreated) and co-cultured CLL cells (with 
CD40L and parental fibroblasts) were next examined to determine whether CD40 
ligation induces changes in metabolic flux.  This was done by removing the CLL cells 
from the fibroblast monolayer and plating them out to create a monolayer from which  
OCR (pMoles/min/μgDNA) could be measured in response to mitochondrial stressors 
(oligomycin 1.26μM, FCCP 1.5μM, and rotenone and antimycin-A 1μM).   
This experiment was performed using freshly isolated CLL cells from 5 patients.  In all 
cases co-culture of the CLL cells with CD40L fibroblasts induced MCT4 expression 
(Figure 3.39).  This shows that the CLL cells from the cases used responded as 
expected.  Figure 3.40 shows the recorded OCR traces of variously cultured CLL cells 
as they respond to the different mitochondrial stressors.  Figure 3.41 captures this data 
as baseline respiration, ATP production, maximal respiration, proton leak, and spare 
capacity.  Culture of CLL cells on fibroblasts, either CD40L or parental, seems to 
support CLL cell metabolism because baseline respiration, ATP production, maximal 
respiration and spare capacity all increased in the co-cultured CLL cells.  Variability 
was observed on a case to case basis and tests for statistical significance proved 
inconclusive.  However, this variability seemed confined to the untreated and parental 
fibroblast co-cultured CLL cells [respectively the red and dark blue traces in Figures 
3.40(A-E)].  Where consistency was observed is in the CD40L fibroblast co-cultured 
CLL cells [light blue trace in Figures 3.40(A-E)].  Here, addition of oligomycin lowered 
OCR consistent with inhibition of ATP synthase in all cases tested.  Addition of FCCP 
to induce maximal respiration raised OCR in all cases tested.  Taken together, these data 
imply that co-culture of CLL cells with CD40L fibroblasts induces intracellular 
conditions consistent with fully functional mitochondria.  
The glycolytic capacity of CLL cells under these culture conditions was next assessed.  
This was done by measuring changes in ECAR (mpH/min/μgDNA) in response to 
oligomycin (1.26μM).  Figure 3.42 shows the response of each case individually.  
ECAR was largely unaffected by the addition of oligomycin in untreated CLL cells 
consistent with the low level of oxygen-dedicated ATP production measured in Figure 
3.41 (B).  In CLL cells cultured on parental fibroblasts, ECAR was also unaffected by 
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oligomycin addition in 3 of the 5 cases tested (Figure 3.42). However, addition of 
oligomycin to CLL cells co-cultured on CD40L fibroblasts consistently increased 
glycolytic capacity in these cells, and this is in line with the consistent ability of 
oligomycin to decrease oxygen consumption in these cells (Figure 3.40). Taken 
together, these data suggest that CD40 ligation on CLL cells induces increased 







Figure 3.39:  Western blot analysis to check for MCT4 upregulation following 
CD40 ligation in samples used for metabolic flux analyses.  As a positive control for 
CD40L stimulation MCT4 expression was assessed using Western blotting for each of 
the cases used analysed using the SeahorseXF24 (A-E).  Blots were treated with rabbit 
polyclonal anti-MCT4 (sc-376101) (1:1000) (Santa Cruz Biotechnology, CA, USA).  
Blots were probed with mouse monoclonal anti-β-actin (clone AC-74) as a control to 
ensure equal protein loading.  A MDA-MB-231cell line and a Raji cell line were used as 








Figure 3.40:  Change in OCR in response to mitochondrial stressors.  Fresh CLL 
cells (2 x 10
6
 cells/well) were co-cultured with CD40L or parental fibroblasts or 
cultured alone (UT) for 48 hours.  Cells were subjected to a mitochondrial stress test 
(oligomycin 1.26μM, FCCP 1.5μM, and rotenone and antimycin-A 1μM).  OCR 










Figure 3.41:  Examining the effect of CD40L stimulation on oxidative 
phosphorylation.  Graphical presentation of data shown in Figure 3.40.  Changes in 
OCR (pMoles/min/μgDNA) were measured in response to the mitochondrial stressors to 
calculate; basal respiration, ATP production, proton leak, maximal respiration, and spare 
respiratory capacity (n = 5).  A Wilcoxon test revealed there to be no significant change 
in any of these parameters in CLL cells following co-culture with CD40L and parental 








Figure 3.42:  Examining the effect of CD40L stimulation on glycolysis.  Fresh CLL 
cells (2 x 10
6
 cells/well) were co-cultured with either; no supportive cells (UT), CD40L 
fibroblasts or parental fibroblasts for 48 hours.  To assess glycolytic capacity 
oligomycin 1.26μM was added and ECAR (mpH/min/μgDNA) was measured (n = 5).  
(A) Shows the glycolytic capacity for each case under each culture condition.  (B) 
Comparison of all of the cases tested showed there to be no significant change in the 
glycolytic capacity of CLL cells following co-culture with CD40L and parental 






This chapter further examines MCT -1 and -4 expression on CLL cells by assessing the 
expression of these transporters in response to microenvironmental stimuli, specifically 
CD40 ligation.  Chapter 2 showed that MCT -1 and -4 expression is reduced in non-
dividing CLL cells located in the circulation in comparison to their healthy counterparts.  
As previously discussed, proliferation of CLL cells is localised in the secondary tissues 
(van Gent et al., 2008) and stimulation of CLL cells using CD40L has been shown to 
induce cell division (Pascutti et al., 2013, Scielzo et al., 2011).  This process is likely 
associated with an increase in metabolic activity because entry of normal B cells into S 
phase has been shown to prompt a metabolic switch to glycolysis (Garcia-Manteiga et 
al., 2011) thus it is likely that CLL cell contact with CD40L causes proliferation 
associated metabolic changes and may have increased reliance on monocarboxylate 
transport.  The aim of this chapter was to examine the effect of CD40-CD40L 
engagement on expression of MCT -1 and -4, and whether this is associated with 
enhanced metabolic activity.   
The principle finding of this chapter is that ligation of CD40 on primary CLL cells 
upregulates MCT4 expression.  This upregulation is best observed when CLL cells are 
co-cultured with CD40L fibroblasts.  However, co-culture of CLL cells with fibroblasts, 
either CD40L or parental, induces expression of MCT1.  This suggests that the 
microenvironment affects CLL cells such that they require increased monocarboxylate 
transport.  This effect seems to work reciprocally, especially under the condition where 
CLL cells are co-cultured with CD40L fibroblasts.  Here, MCT4 expression is 
stimulated in the host fibroblasts.  
To investigate why MCT4 expression increases in CD40-stimulated CLL cells an 
analysis of metabolic gene expression was carried out using a Fluidigm Biomark™ 
array.  For this experiment only cells more than 70% viability were used to ensure that 
fibroblasts with the maximum potential for stimulating CLL cells and CLL cells with 
the maximum potential for being stimulated were used.  Here is was found that in 
response to CD40L there is an upregulation in expression of genes involved in 
glycolysis and fatty acid metabolism.  This is in keeping with a study by Gricks et al. 
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(2004) whereby gene expression was assessed in normal B cells and CLL following 
CD40 activation.  In this study it was reported that such stimulation results in increased 
metabolic gene expression.  Changes in metabolic gene expression in CLL cells 
responding to CD40 engagement are also reported by Willimott and Wagner (2012) and 
Jiang et al. (2012) where the expression of microRNA’s (miR’s) was examined.  Here, 
miR’s, such as miR-155, are increased in CLL cells in response to CD40 ligation, and 
the effect of these miR’s is to influence the expression of genes involved in glucose 
metabolism such as HK2 (Jiang et al., 2012).  The results of the current study show 
increase in expression of HK1 and HK2. 
To further study glucose metabolism in CD40-stimulated CLL cells direct analysis of 
cell metabolism was performed by metabolic flux analysis.  Thus, CLL cells co-cultured 
with CD40L fibroblasts consistently increase glycolytic capacity in agreement with the 
data generated by the gene array.  This finding is in keeping with what is observed in 
normal B cells which have been stimulated to proliferate (Garcia-Manteiga et al., 2011).  
However, CD40 ligation on CLL cells does not induce proliferation, a second stimulus, 
either IL-4 or IL-21, is required (Pascutti et al., 2013, Ghia et al., 2005).  CD40 
stimulation alone may therefore prepare CLL cells metabolically for entry into S phase 
of the cell cycle.  Variability in the extent of glycolytic capacity induction between 
patient samples limits the strength of this interpretation; further replicates are required to 
provide verification. 
Mitochondrial function in CLL cells seemed maintained by co-culture with CD40L 
fibroblasts.  3 of the 5 CLL cases tested showed consistent increases in mitochondrial 
indices such as baseline respiration, ATP production, maximal respiration and spare 
capacity.  This is important because a recent study has shown that circulating CLL cells 
use mitochondrial metabolism and have resulting in the increased production of ROS 
(Jitschin et al., 2014). Increased levels of ROS are cytotoxic to cells unless they have a 
mechanism in place to counteract the oxidative stress created by ROS.  Induction of 
glycolysis is one of these mechanisms.  Therefore, the results of this chapter provide 
insight into cytoprotective effects of CD40 ligation on CLL cells.  Moreover, increased 
ROS levels within malignant cells can be harnessed to mediate change in the 
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surrounding tumour stroma (Martinez-Outschoorn et al., 2011).  It is possible that CD40 
ligation on CLL cells facilitates the ability of these cells to produce ROS and thereby 
provide a potential mechanism through which CLL cells influence the metabolism of 
supportive cells.   
That CLL cells can affect supportive cells is demonstrated by Fluidigm array analysis of 
gene expression in CD40L and parental fibroblasts.  Co-culture of CD40L fibroblasts 
with CLL cells seemed to induce expression of genes involved in glycolysis.  In 
particular, MCT4 expression was induced, and this was confirmed by Western blot 
analysis.  A study by Martinez-Outschoorn et al. (2013) describes a similar result and 
shows that upregulated MCT4 expression accompanied by an increase in glycolysis is 
induced in fibroblasts following co-culture with HaCaT cells, a keratinocyte cell line 
which has a high proliferative capacity.  The ability of cancer cells to exert an influence 
over the metabolism of supportive cells within the microenvironment has been described 
in other malignancies (Bonuccelli et al., 2010b, Martinez-Outschoorn et al., 2013).  
Taken together, these data suggest that future experiments are required to examine the 
mechanisms through which CLL cells can manipulate the metabolism of the adjacent 
stromal cells.   
In addition to the increased expression of genes associated with glycolysis, CD40 
activation of CLL cells also had an effect on fatty acid metabolism.  ELOVL6 and 
FASN, and to a lesser degree ACACA, were all upregulated suggesting that fatty acid 
synthesis (FAS) is stimulated.  This is important because it suggests that CLL cells may 
utilise fatty acids to fuel energy generating processes to support cell division (Cheng et 
al., 2014).  In particular, increased expression of FASN is reported in other 
malignancies, and has been shown to be correlated with disease progression (Hamada et 
al., 2014, Long et al., 2014, Menendez and Lupu, 2007).  The importance of fatty acid 
metabolism in CLL has not been fully explored although oxidation of fatty acids in 
circulating CLL cells has been shown in studies by Tung et al. (2013) and Spaner et al. 
(2013) showing these cells to be vulnerable to disrupted lipolysis.   
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The upregulation of other metabolic genes in response to CD40L such as GLS and ME2 
may facilitate FAS.  For instance, GLS and ME2 are involved in glutaminolysis and the 
TCA cycle, and have the ability to provide substrates for FAS while increased 
expression of SLC1A5 and SLC25A11 aids substrate uptake (Hassanein et al., 2013, 
Catalina-Rodriguez et al., 2012).  Alternatively, the upregulation of GLS may be 
indicative of a “glutamine addiction” whereby the cells rely on glutaminolysis as their 
primary energy generating process as is the case in cervical cancer (Jose et al., 2011, 
Vousden, 2010).  However, this is unlikely to be the case in CLL because inhibition of 
glycolysis using lonidamide and 2DG has been shown to induce cell death (Tura et al., 
1984, Tidmarsh et al., 2004). 
In conclusion, the findings presented in this chapter shows for the first time that the 
microenvironment modulates the expression of MCT -1 and -4 in CLL cells.  
Specifically contact of CLL cells with fibroblasts may induce MCT1 expression 
whereas MCT4 is upregulated in CLL cells following CD40 ligation.  The data collected 
from the Fluidigm Biomark™ array and SeahorseXF24 implies this is likely due to the 
induction of glycolysis, and that CLL cells may instigate changes in the metabolism of 
the supportive cells of the microenvironment.  This is important because it suggests that 
CLL cells may become vulnerable to disrupted monocarboxylate transport, specifically 
MCT4 inhibition.  Moreover, because the upregulation of MCT4 is mediated by CD40L 
this has the potential to overcome CD40L dependent mechanisms of drug resistance.  
However, further work is needed to truly assess whether the degree of CD40L-mediated 
glycolysis induction in CLL cells is large enough to sensitise these cells to disrupted 





4 CHAPTER 4:  ASSESSING THE SENSITIVITY OF CLL CELLS TO MCT -
1 AND -4 INHIBITION 
 
4.1 INTRODUCTION 
Recognition of the importance of cell metabolism with respect to cancer biology has 
lead to an increase in compounds directed against metabolic processes.  One of the aims 
of this study is to examine the effect of disrupting monocarboxylate transport by 
inhibiting MCT1 function in CLL cells using the specific inhibitor, AZD3965.  This 
compound is a small molecule inhibitor which exerts its effect on MCT1 by binding to 
the transporter and disrupting glycolytic activity by preventing lactate export (Polanski 
et al., 2014).  It is derived from a similar compound known as AR-C155858, that was 
originally developed because of its activity as an immunosuppressive agent (Ekberg et 
al., 2007), and this fits with known upregulation of glycolysis in antigen stimulated B 
and T cells (Garcia-Manteiga et al., 2011, Michalek and Rathmell, 2010).   
MCT1 as a therapeutic target has been investigated in several types of cancer.  For 
instance, MCT1 inhibition has been shown to have anti-tumor effects in lung, breast, 
colorectal, and prostate cancers, as well as in brain tumors (Guo et al., 2013, Miranda-
Goncalves et al., 2013, Doherty et al., 2013, Kim et al., 2012, Shim et al., 2007, Zhang 
et al., 2002).  Moreover, a study by Sonveaux et al. (2008) showed that inhibiting MCT1 
function in tumor-adjacent endothelial cells disrupted tumor angiogenesis.  In B cell 
malignancies MCT1 inhibition has been examined in lymphoma, and has been taken 
forward into phase I/II clinical trials (Doherty et al., 2013, Kumar et al., 2013, Dhup et 
al., 2012, Cheong et al., 2012).   
Following on from the examination of MCT -1 and -4 expression in CLL cells in the 
previous chapters of this thesis, the aim of this chapter is to examine the potential of 
MCT1 as a therapeutic target in CLL.  This was done by investigating the sensitivity of 
CLL cell lines to AZD3965, and examining any potential additional role of MCT4.   
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4.2 MATERIALS AND METHODS 
 
4.2.1 Suspension cell lines 
The HG3 cell line, which are Epstein Barr Virus-transformed CD40-stimulated CLL 
cells, were obtained from Professor Anders Rosén (Linköping University, Sweden) 
(Rosen et al., 2012).  Details of the other cell lines used in this section are detailed in 
section 2.2.1.3.  Prior to use each of the cell lines were tested for the presence of 
mycoplasma (Appendix 6.3).  These analyses were performed using an EZ PCR 
Mycoplasma test kit (Biological Industries, Salisbury, Cellseco, UK) in accordance with 
the manufacturer’s guidelines. 
 
4.2.2 Cell culture 
HG3 cells were maintained in RPMI supplemented with 100 units/mL penicillin-
streptomycin, 2mM L-glutamine, and 10% heat inactivated FCS.  The other cell lines 
were maintained as previously described.  
 
4.2.3 Treatment with MCT1 inhibitor AZD3965 
The MCT1 inhibitor AZD3965 was provided by AstraZeneca (AstraZeneca, 
Manchester, UK).  A 10mM stock was prepared in DMSO and aliquots were stored at -
20C to avoid repeat freeze thawing.  DMSO was used as a diluent to obtain working 
concentrations of this drug.  Assays were normally carried out in a flat bottomed 96 well 
plate using 100l of Raji cells (2 x 10
5 
cells/mL), MEC-1 cells (2 x 10
5 
cells/mL) or 
HG3 cells (1 x 10
5 
cells/mL).  Each experiment was run in triplicate.  Plates were 
incubated for 48-72 hours at 37C and 5% CO2. 
 
4.2.4 Alamar blue® cell viability assay 
Cell viability was assessed using AlamarBlue® Cell viability reagent according to the 
manufacturer’s instructions (Invitrogen, Paisley, UK).  For this assay a blacked out 96 
171 
 
well plate with a clear flat bottom was used (BD Biosciences, Oxford, UK).  The plate 
was prepared as in section 4.2.3.  The plate was read using the MQX200 µQuant plate 
reader at 540nm (samples) and 620nm (blank) as per the manufacturer’s guidelines.  
 
4.2.5 3,3'-Dihexyloxacarbocyanine Iodide (DiOC6) and Propidium iodide (PI) 
staining for cell death 
Following incubation with AZD3965 50µL of each well was transferred to a FACS 
tube.  To this 50µL of 80nM 3,3'-dihexyloxacarbocyanine Iodide (DiOC6) (Merck 
KGaA, Middlesex, UK) was added and the samples were incubated for 20 minutes in 
the dark at 37°C.  100µL of propidium iodide (PI) (Sigma, Gillingham, UK) was then 
added (1:1 final concentration 0.1μg/mL) and the samples were analysed using the 
BD™ FACS Calibur™. 
 
4.2.6 Metabolic flux analysis of Raji and MEC-1 cells using the SeahorseXF24 
metabolic flux analyser 
As detailed in section 3.2.10.  Seeding densities of 2 x 10
6
 cells/mL was used for the 
Raji cells while 5 x 10
6
 cells/mL was used for the MEC-1 cells.  Experiments on MEC-1 
cells were carried out using unbuffered DMEM (Sigma, Gillingham, UK) modified with 
10mM glucose (Sigma, Gillingham, UK), 2mM L-glutamine and 2mM sodium 
pyruvate.  For injection of the MCT1 inhibitor AZD3965, this was first prepared as in 
section 4.2.3 using appropriate unbuffered media.  The designated concentrations 
including an untreated (UT) media only and DMSO vehicle control (DMSO) were then 
added (50μL) into injection port A of the XF24 calibration microplate (Seahorse 
Bioscience, Saint Marcell, France).  Measurements were taken every 6 minutes for 5 
hours and values were later normalised to the baseline and DNA content.   
 
4.2.7 Nucleofection 
siRNA and plasmid transfections were carried out using nucleofection.  A cell 
suspension of 2 x 10
6
 cells/mL of MEC-1 or Raji cells was allowed to recover in the 
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incubator at 37C and 5% CO2 for 1 hour.  1mL aliquots of MEC-1 or Raji cells were 
then added into a sterile eppendorf tube and centrifuged at 500 rcf for 5 minutes and 
washed in warm PBS (37ºC).  After removing the supernatant the samples were 
nucleofected using the Amaxa solution V transfection kit according to the 
manufacturer’s instructions (Lonza Biologics, Slough, UK).  The nucleofector program 
used for MEC-1 cells was X-01.  The nucleofector program used for Raji cells was M-
13.   
 
4.2.8 MCT4 knockdown using siRNA 
Cells were treated with either specific MCT4 siRNA (Insight Biotechnology, Wembley, 
UK) or a scrambled control (Insight Biotechnology, Wembley, UK) at a final 
concentration of 0.1μM.  To assess transfection efficiency a sample was also 
nucleofected with a GFP plasmid (Lonza Biologics, Slough, UK) and assessed for GFP 
expression after 24 hours using flow cytometry.   
 
4.2.9 Transient transfection with MCT4 expression vector 
 
4.2.9.1 Plasmid 
A pMCT4-EGFP expression vector was kindly provided by Dr Nancy Philp (Thomas 
Jefferson University, PA, USA).  Details relating to the production of this plasmid can 
obtained from a publication by Castorino et al. (2011).   
 
4.2.9.2 Plasmid preparation 
 
4.2.9.2.1 Transformation of E coli 
0.5μL of plasmid DNA was added to a sterile eppendorf at 4ºC.  Next 25μL of DH5α 
competent cells (Invitrogen, Paisley, UK) were thawed on ice and added to the plasmid 
DNA and incubated for a further 20 minutes at 4ºC.  The cells were then heat shocked at 
42ºC for 50 seconds and then put back on ice for 2 minutes after which an aliquot of 
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950μL of sterile super optimal broth with catabolite repression (SOC) medium (Sigma, 
Gillingham, UK) was added at room temperature.  This reaction mixture was 
subsequently incubated at 37ºC for 1.5 hours with constant shaking at 150 rpm.  
Following the incubation period either 10μL or 100μL of the reaction mixture was 
added to LB-kanamycin agar plates (Sigma, Gillingham, UK) and incubated overnight 
at 37ºC for less than 16 hours to ensure the kanamycin (Sigma, Gillingham, UK) 
maintained its efficacy.  The plates were then wrapped in parafilm and stored at 4ºC.  
Colonies were extracted using a sterile pipette tip which was placed into 5mL of LB-
kanamycin broth in a universal and cultured overnight at 37ºC at 150 rpm.  The plates 
were then stored at 4ºC.  After 16 hours the cultures were also stored at 4ºC. 
 
4.2.9.2.2 Selection of transformed E coli 
To select for transformed colonies a LB-kanamycin (0.01mg/mL) selection plate was 
used.  The pEGFP-N1 vector confers kanamycin resistance thus cells successfully 
transformed with the plasmid are resistant to the drug. 
 
4.2.9.2.3 Isolation of plasmid DNA 
Plasmid DNA was isolated using a Zyppy™ plasmid miniprep kit (Zymo research, 
Cambridge Bioscience, Cambridge, UK) as per the manufacturer’s instructions.  
Quantification of the DNA was performed using a NanoDrop 2000c spectrophotometer.  
Sample quality was assessed using the measurement of the 260:280 ratio. 
 
4.2.9.3 DNA Sequencing 
The pMCT4-EGFP plasmid was sequenced to ensure the plasmid contained MCT4 
using four forward primers (Figure 4.1) designed using GenScript Sequencing Primer 
Design (WWW, genscript.com/cgi-bin/tools/sequencing_primer_design) in addition to 
in house CMV forward and EGFP-N1 reverse primers from Source Bioscience 
(Nottingham, UK).  Sequencing was performed by Source Bioscience (Nottingham, 
UK) and then subjected to a Basic Local Alignment Search Tool (BLAST) search for 
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human MCT4.  Figure 4.2 shows the results of the sequencing and the analysis 
demonstrating the 100% alignment of MCT4.   
 
4.2.10 Western blot analysis 
As detailed section in 2.2.8. 
 
4.2.11 Antibodies 
As detailed in section 2.2.5.  In addition to this mouse monoclonal anti-GFP (sc-9996) 















Figure 4.1:  Primers used for DNA sequencing of the pMCT4-EGFP plasmid.  
Primer 1 is located in the multiple cloning site (MCS) while primers 2-4 are located 









Figure 4.2:  BLAST analysis for MCT4 in pMCT4-EGFP plasmid.    
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4.2.12 Quality assurance 
To control for the solvent used to dissolve AZD3965 a vehicle control of 5µL 6% 
DMSO was added to a 95µL cell suspension (final concentration 0.3%).  This was used 
to control for the toxicity of the DMSO which has been shown to cause cell death at 
room temperature.   
To ensure that the DiOC6 and PI cell death and Alamar blue® cell viability assays were 
working a death inducing positive control was used.  10nM of staurosporine was used 
for this purpose as described (Twomey et al., 1990).  This was added 4 hours prior to the 
addition of the AlamarBlue® Cell viability reagent 4 hours prior to analysis by DiOC6 
and PI staining.  A P value of P = <0.05 was considered to be statistically significant.   
 
4.2.13 Statistical analysis 
Statistical analyses were performed using GraphPad Prism (Version 6.01, GraphPad 
Software Inc., CA, USA).  The statistical tests used are identified when and where they 
are used within the results section of this chapter.  A P value of P = <0.05 was 






4.3.1 Pre-clinical evaluation of the MCT1 inhibitor AZD3965 in CLL 
 
4.3.1.1 Inhibition of MCT1 using AZD3965 in a Raji cell line 
Raji cells only express MCT1, and are susceptible to AZD3965.  Preliminary data 
obtained from AstraZeneca shows that these cells undergo apoptosis when exposed to 
nanomolar concentrations [IC50 of 10nM (0.01µM)] of this compound.  Therefore, they 
serve as a positive control for subsequent experiments. 
Proliferation of Raji cells was first determined so that an optimal seeding density could 
be obtained.  Figure 4.3 shows a cell counting experiment in which the cells were plated 
out in a 24 well plate at the following densities; 1 x 10
5
, 2 x 10
5
 and 4 x 10
5
 cells/mL.  
The experiment was run over a period of four days to account for the amount of time the 
cells would be incubated with the compound.  Cell counts were performed in duplicate 
using the trypan blue exclusion assay as previously described in section 2.2.2.  A density 
of 2 x 10
5 
cells/mL was chosen as cells continued to double for the four day time period 
whereas at 4 x 10
5 
cells/mL the count no longer increased after day three.  This is in 
agreement with the seeding density optimised by AstraZeneca who also used 2 x 10
5
 
cells/mL.   
Flow cytometry was used to measure DiOC6 and PI staining and assess cell death in 
experiments measuring the cytotoxicity of AZD3965.  Figure 4.4 illustrates the gating 
procedure used to distinguish live from dead cells.  A typical dotplot of side scatter 
versus forward scatter shows two distinct populations of the total number of cells to be 
analysed, and this was designated R3.  Live cells are gated within region 2 (R2) and 




 cells (upper left hand quadrant, marked in green) in the 
quadrant plot of DiOC6 versus PI.  Dead or late apoptotic cells are gated with region 1 




 cells (lower right hand quadrant, marked in red) 
in the quadrant plot of DiOC6 versus PI.  Treatment of Raji cells with 0.01µM of 
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AZD3965 resulted in an increase in the number of cells included within R1 [compare 








Figure 4.3:  Evaluation of seeding density for the Raji cell line.  Cells were plated 
out in a 24 well plate at the following densities; 1 x 10
5
, 2 x 10
5
 and 4 x 10
5
 cells/mL.  
Cell counts were performed in duplicate using the trypan blue exclusion assay.  A 
density of 2 x 10
5 
cells/mL was chosen as cells continued to double for the four day time 
period whereas at 4 x 10
5 
cells/mL the count no longer increased after day three.  Error 








Figure 4.4:  3,3'-Dihexyloxacarbocyanine Iodide (DiOC
6
) and Propidium iodide 
(PI) staining for cell death.  A representative example of the gating strategy used for 
analysis by flow cytometry.  The two distinct populations of the total number of cells to 
be analysed shown in the dotplot are designated R3.  Live (R2) and dead/late apoptotic 
(R1) cell populations correspond to the live cells (green) which are DiOC
6
 positive/PI 
negative and dead cells (red) which are DiOC6 negative/PI positive respectively. (A) 
Raji cell untreated (UT) control.  (B) Raji cells treated with 0.01µM of AZD3965.    
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Figures 4.5 and Figure 4.6 show the killing effect of AZD3965 on Raji cells after 48 
hours treatment.  The Raji cells were seeded at a density of 2 x 10
5
 cells/mL and 
incubated with 0, 0.001, 0.01, 0.1 and 1µM of AZD3965.  There was no significant 
difference in DiOC6 and PI staining between UT and DMSO vehicle control treated Raji 
cells (DiOC6; P = 0.1100, PI; P = 0.2143), providing confirmation for the inert nature of 
the DMSO solvent used to dissolve AZD3965.  Increasing cell death was observed with 
increasing concentration of AZD3965 over the concentration range tested, and 0.1µM 
was shown to be the most effective at inducing apoptosis of Raji cells (DiOC6; *** P = 
0.0008, PI; ** P = 0.0019) (n = 3).   
Figure 4.6 verifies the results obtained using DiOC6 and PI staining.  Here, a 
AlamarBlue® Cell viability assay showed that 0.1µM of AZD3965 was the most 
effective concentration at reducing cell viability (** P = 0.0052).   
In both Figures 4.5 and 4.6 staurosporine was used to induce apoptosis in cells.  In each 
figure the presence of this compound reduced cell viability. 
Taken together, these results show that 0.1μM of AZD3965 could be used for future 





Figure 4.5:  Inhibition of MCT1 using increasing concentrations of AZD3965 in a 
Raji cell line (DiOC
6
 and PI staining).  Raji cells (2 x 10
4
) were incubated with 
AZD3965 (0-1µM) for 48 hours.  A paired t test showed there was no significant 
difference between the UT and DMSO vehicle control (DiOC6; P = 0.1100, PI; P = 
0.2143).  A significant difference was seen between the vehicle control versus each 
concentration of the drug with 0.1µM of AZD3965 being the most effective (DiOC6; 
*** P = 0.0008, PI; ** P = 0.0019).  10nM staurosporine was used as a positive control 









Figure 4.6:  Inhibition of MCT1 using increasing concentrations of AZD3965 in a 
Raji cell line (Alamar blue® cell viability assay).  Raji cells (2 x 10
4
) were incubated 
with AZD3965 for 48 hours.  A paired t test showed there was no significant difference 
between the UT and DMSO vehicle control (P = 0.1747).  A significant difference was 
seen between the vehicle control and each concentration of the drug 0.001-1µM (P = 
<0.05) excluding 0.01µM (P = >0.05).  0.1µM of AZD3965 was shown to be the most 
effective (** P = 0.0052).  10nM staurosporine was used as a positive control (QC).  






4.3.1.2 Investigating the effect of proliferation on the sensitivity of the Raji cell 
line to AZD3965  
The effect of AZD3965 on Raji cells cultured under different proliferation conditions 
was next examined because metabolic activity within cells can be linked to their ability 
to divide (Garedew et al., 2012).  To assess the effect of proliferation on the sensitivity 
of the Raji cells to AZD3965 the cells were cultured in serum rich (10% FCS) and serum 
free media (SFM) and incubated with 0.1µM of the drug.  Figure 4.7 shows a cell 
counting experiment which was used to ensure the Raji cells ceased to divide in serum 
free conditions whilst they continued to proliferate in the presence of FCS (n = 3).  
Figure 4.8 shows that Raji cells cultured in serum rich conditions are sensitive to MCT1 
inhibition with AZD3965, while Raji cells cultured in serum free conditions remained 
resistant to the drug.  Importantly, the presence of staurosporine induced apoptosis of 
Raji cells regardless of culture conditions. These data suggest that AZD3965 is effective 







Figure 4.7:  Cell counting experiment to show the effect of serum free media on 
proliferation of Raji cells.  Raji cells were seeded at 2 x 10
5
 cells/mL and grown over a 
3 days period in (A) RPMI media supplemented with 100 units/mL penicillin-
streptomycin, 2mM L-glutamine and 10% heat inactivated FCS or (B) SFM 
supplemented with 100 units/mL penicillin-streptomycin and 2mM L-glutamine.  In 
serum rich conditions the cell count increased doubling after 2 days while in SFM the 






Figure 4.8:  Sensitivity to AZD3965 in Raji cells cultured in serum rich and serum 
free media (DiOC6 and PI staining) (48hrs).  Raji cells (2 x 10
4
) were incubated for 
48 hours with AZD3965 in (A) RPMI media modified with 100 units/mL penicillin-
streptomycin, 2mM L-glutamine and 10% heat inactivated FCS or (B) Raji cells in 
SFM.  In serum rich media a paired t test showed no significant difference between the 
UT and DMSO vehicle control (DiOC6; P = 0.3445, PI; P = 0.2353).  A significant 
decrease in the live cell population was observed between the vehicle control and 0.1µM 
AZD3965 (DiOC6; * P = 0.0490, PI; P = 0.0808).  In serum free conditions a paired t 
test showed no significant difference between the UT and DMSO vehicle control 
(DiOC6; P = 0.6351, PI; P = 0.1404).  10nM staurosporine was used as a positive 




4.3.1.3 Inhibition of MCT1 using AZD3965 in a MEC-1 cell line 
Following the validation of the Raji cell line as a positive control for AZD3965 the 
effect of MCT1 inhibition was assessed using the CLL cell line, MEC-1.  Both MCT -1 
and -4 expression was detected using Western blot analysis (Figures 2.9 and 2.12) and 
qRT-PCR (Figure 2.15), and this is akin to the expression profile seen in primary CLL 
cells (Figures 2.10, 2.11, 2.13, 2.14 and 2.16). 
Figure 4.9 shows a cell counting experiment to assess the appropriate seeding density 
for these cells as done previously with the Raji cell line.  Cells were plated out in a 24 
well plate at the following densities; 1 x 10
5
, 2 x 10
5
 and 4 x 10
5
 cells/mL.  Over four 
days cell counts were performed in duplicate using the trypan blue exclusion assay as 
previously described in section 2.2.2.  A density of 2 x 10
5 
cells/mL was chosen as the 
cells continued to double at a higher rate than when seeded at the lower density for the 
four day time period despite the count dropping slightly on the final day.  Further to this, 
use of this seeding density replicated the work with the Raji cell line meaning that the 
same amount of the compound would be added to the same number of cells. 
Figure 4.10 (A) illustrates the effect of MCT1 inhibition in the MEC-1cell line with 
AZD3965 after 48 hours.  Cells were seeded at 2 x 10
5
 cells/mL and incubated with 0, 
0.001, 0.01, 0.1, 1µM of AZD3965 for 48 hours.  No effect of AZD3965 was observed 
on MEC-1 cells.  In contrast, the presence of staurosporine induced significant cell death 
as detected using DiOC6/PI staining or Alamar blue ® (Figure 4.11).  Similar results 
were observed even if the cells were cultured for 72 hours (Figures 4.10 and 4.11). This 
result indicates that AZD3965 has no clear concentration effect on MEC-1 cell viability 
within the same range that it affects Raji cells.  However, when used at 30M, 
AZD3965 did reduce MEC-1 cell viability.  Considering that at this concentration 
AZD3965 also inhibits MCT4, it is possible that the reduction in cell viability is due to 






Figure 4.9:  Evaluation of seeding density for the MEC-1 cell line.  Cells were plated 
out in a 24 well plate at the following densities; 1 x 10
5
, 2 x 10
5
 and 4 x 10
5
 cells/mL.  
Cell counts were performed in duplicate using the trypan blue exclusion assay.  A 
density of 2 x 10
5
 cells/mL was chosen as the cells continued to double at a higher rate 
than when seeded at the lower density for the four day time period despite the count 
dropping slightly on the final day.  Further to this, use of this seeding density replicated 
the work with the Raji cell line meaning that the same amount of the compound would 






Figure 4.10:  Inhibition of MCT1 using increasing concentrations of AZD3965 in a 
MEC-1 cell line (DiOC6 and PI staining).  MEC-1 cells (2 x 10
4
) were incubated with 
increasing concentrations of AZD3965 (0-30µM) for 48 (A) or 72 hours (B).  (A) A 
paired t test showed there was no significant difference between the DMSO vehicle 
control and 0.001-30µM of AZD3965 (DiOC6; P = > 0.05, PI; P = > 0.05) except for 
0.1µM (DiOC6; P = 0.2050, PI; * P = 0.0180).  (B) A paired t test showed there was no 
significant difference between the vehicle control and 0.001-10µM of AZD3965 except 
for 0.001µM (DiOC6; * P = 0.0417, PI; P = 0.1076) and 30µM (DiOC6; P = 0.6111, PI; 







Figure 4.11:  Inhibition of MCT1 using increasing concentrations of AZD3965 in a 
MEC-1 cell line (Alamar blue® cell viability assay).  MEC-1 cells (2 x 10
4
) were 
incubated with increasing concentrations of AZD3965 (0-30µM) for either 48 (A) or 72 
hours (B).  (A) A paired t test showed there was no significant difference between the 
DMSO vehicle control and 0-30µM of AZD3965 (P = >0.05).  (B) A paired t test 
showed there was no significant difference between the vehicle control and 0-30µM of 
AZD3965 even at 30µM (P = >0.05).  10nM staurosporine was used as a positive 




4.3.1.4 Inhibition of MCT1 using AZD3965 in a HG3 cell line 
In addition to investigating the sensitivity of MEC-1 cells to MCT1 inhibition a second 
CLL cell line was examined.  Described by Rosen et al. (2012) the HG3 cell line was 
established from IgM positive UM-CLL cells cultured on CD40L fibroblasts by in vitro 
infection of Epstein-Barr virus (EBV).  These cells express both MCT -1 and -4 as 
detected by Western blot analysis (Figures 4.12). 
Figure 4.13 shows a cell counting experiment to assess optimal seeding density.  Cells 
were plated out in a 24 well plate at the following densities; 1 x 10
5
, 2 x 10
5





 cells/mL and counted in duplicate over four days using trypan blue (section 
2.2.2).  A density of 1 x 10
5 
cells/mL was chosen as cells continued to double in 
comparison to the other seeding densities which began to plateau after two to three days.   
The results showing the effect of MCT1 inhibition in HG3cells with AZD3965 are 
shown in Figure 4.14.  Cells were seeded at 1 x 10
5
 cells/mL and incubated with 0, 
0.001, 0.01, 0.1, 1µM of AZD3965.  As observed with MEC-1 cells, there was no effect 
of AZD3965 on HG3 cell viability, except when the concentration reached 30M 








Figure 4.12:  MCT -1 and -4 expression in a HG3 cell line.  Western blot analysis 
showing MCT -1 and -4 expression in HG3 cells when treated with (A) mouse 
monoclonal anti-MCT1 (H-1) (sc-365501) (Insight Biotechnology, Wembley, UK) and 
(B) mouse monoclonal anti-MCT4 (sc-376101).  Blots were probed with mouse 
monoclonal anti-β-actin (clone AC-74) as a control to ensure equal protein loading.  A 
MEC-1 cell line was used as a positive control for MCT1 (AstraZeneca, Manchester, 
UK).  A MDA-MB-231cell line and a Raji cell line were used as positive and negative 








Figure 4.13:  Evaluation of seeding density for the HG3 cell line.  Cells were plated 
out in a 24 well plate at the following densities; 1 x 10
5
, 2 x 10
5
, 4 x 10
5
 and 2 x 
10
6
cells/mL.  Cell counts were performed in duplicate using the trypan blue exclusion 
assay.  A density of 1 x 10
5
 cells/mL was chosen as cells continued to double in 
comparison to the other seeding densities which began to plateau after two to three days.  









Figure 4.14:  Inhibition of MCT1 using increasing concentrations of AZD3965 in a 
HG3 cell line (DiOC6and PI staining).  HG3 cells (1 x 10
4
) were incubated with 
increasing concentrations of AZD3965 (0-30µM) for 48 (A) or 72 hours (B).  (A) A 
paired t test showed there was no significant difference between the DMSO vehicle 
control and 0.001-30µM of AZD3965 (DiOC6; P = > 0.05, PI; P = > 0.05).  (B) A paired 
t test showed there was no significant difference between the vehicle control and 0.001-
10µM of AZD3965 (DiOC6; P = > 0.05, PI; P = > 0.05).  30µM was shown to have a 
significant effect on cell viability (DiOC6; * P = 0.0243, PI; * P = 0.0120).  10nM 







Figure 4.15:  Inhibition of MCT1 using increasing concentrations of AZD3965 in a 
HG31 cell line (Alamar blue® cell viability assay).  HG3 cells (1 x 10
4
) were 
incubated with increasing concentrations of AZD3965 (0-30µM) for 48 (A) or 72 hours 
(B).  (A) A paired t test showed there was no significant difference between the DMSO 
vehicle control and 0-30µM of AZD3965 (P = >0.05).  (B) A paired t test showed there 
was no significant difference between the vehicle control and 0-30µM of AZD3965 (P = 





4.3.2 Assessment of the effect of MCT4 disruption in CLL 
 
4.3.2.1 siRNA knockdown of MCT4 expression in a MEC-1 cell line 
One of the initial aims of this study was to examine the therapeutic potential of 
inhibiting MCT -1 and -4 in CLL cells using compounds developed by AstraZeneca.  
However, throughout the course of the project the MCT4 inhibitor remained in 
development and was unavailable.  Therefore, in the absence of a specific inhibitor of 
MCT4, siRNA was used as an alternative means of investigating the importance of this 
transporter. 
MEC-1 cells were chosen for these experiments because they seemed to have 
comparatively less MCT4 expression than did HG3 cells (Figure 4.12), and it was 
thought that MCT4 knockdown would be easier.  Figures 4.16 (A) and (B) show 
Western blot analysis of MCT -1 and -4 expression in MEC1 cells following treatment 
with MCT4 specific and control siRNA.  The presence of the specific siRNA distinctly 
lowered the expression of MCT4 in treated cells, while MCT1 expression remained 
constant.  However, knockdown was not complete and there remained a residual level of 
MCT4 expression [Figure 4.16 (C)].  Such reduction in MCT4 expression had no effect 
on cell viability (Figure 4.17).  Subsequent experiments testing the effect of the MCT1 
inhibitor on MEC-1 cells where MCT4 expression was reduced showed no effect on cell 






Figure 4.16:  siRNA knockdown of MCT4 in a MEC-1 cell line.  Immunoblot 
showing MCT -1 and -4 expression following silencing of MCT4 using siRNA in a 
MEC-1 cell line when treated with either mouse monoclonal anti-MCT1 (sc-365501) 
(1:1000) (Insight Biotechnology, Wembley, UK) or rabbit polyclonal anti-MCT4 (sc-
50329) (1:1000) (Insight Biotechnology, Wembley, UK).  (A) MCT1 expression 
remains unchanged.  (B) MCT4 expression is reduced.  (C) A paired t test showed 
MCT1 to be unchanged (P = 0.3902) while MCT4 was significantly down regulated (** 
P = 0.0081) producing a mean knockdown of 48.08%.  (D) Transfection efficiency (% 
GFP) confirmed by flow cytometry after 24 hours and %MCT4 knockdown for all three 
cases.  A MEC-1 lysate used in the previous Western analyses was used as a positive 
control for MCT1.  A MDA-MB-231 was used as a positive control for MCT4 
(Gallagher et al., 2007).  A Raji cell line was used as a negative control for MCT4 (Lin 
et al., 1998b).  Blots were probed with mouse monoclonal anti-β-actin (clone AC-74) as 








Figure 4.17:  Effect of silencing MCT4 on cell death in MEC-1 cells (DiOC6 and PI 
staining).  Knockdown of MCT4 in MEC-1 cells after 48 hours appears to have no 
effect on cell death as shown by DiOC6 and PI staining.  A paired t test showed there 
was no significant difference between the UT versus the mock transfected sample 
(DiOC6; P = > 0.05, PI; P = > 0.05).  There was also no significant difference between 
the mock transfected sample versus the control or the control versus MCT4 siRNA 
respectively (DiOC6; P = > 0.05, PI; P = > 0.05), (DiOC6; P = > 0.05, PI; P = > 0.05).  





4.3.3 Investigating compensatory effects of MCT4 following MCT1 inhibition 
To further investigate whether MCT4 compensates for MCT1 inhibition, Raji cells were 
transiently transfected with an expression plasmid coding for MCT4 which was C-
terminally tagged with EGFP.  This construct coded for a functional protein as was 
shown in a recent paper by Castorino et al. (2011), from whom the plasmid was 
obtained.  The plasmids were validated using sequencing as previously discussed in the 
methods section.  As a control Raji cells were transiently transfected with the empty 
pAc-EGFP1-N1 plasmid.  
Figure 4.18 shows the results of the transient transfections.  Both MCT4-EGFP and 
EGFP were detectable in Raji cells 24 hours post nucleofection [Figure 4.18 (A)].  
Transfection efficiency was estimated at approximately 22%, and Western blot analysis 
for MCT4 and GFP expression further validated the plasmid by showing similar MW 
bands for MCT4-EGFP in transfected cells (Figure 4.18 B and C).  These results 
demonstrate that a recovery period of 24 hours post transfection was sufficient for the 
Raji cells to take up the pMCT4-EGFP plasmid.   
The transfected Raji cells were then treated with AZD3965.  Figure 4.19 illustrates the 
rescue effect of induced MCT4 expression in Raji cells.  Thus, the presence of 
AZD3965 noticeably reduced the number of live cells in mock- and EGFP-transfected 
Raji cells, whereas in MCT4-EGFP-transfected Raji cells a small population of live cells 
was preserved.  Analysis of this small population of AZD3965-resistant cells showed 
that they expressed GFP [Figure 4.20 (A)], suggesting that Raji cells able to express 
MCT4 had gained resistance to the compound.  Comparison of the effect of AZD3965 
on EGFP- and MCT4-EGFP-transfected Raji cells showed that AZD3965 reduced cell 
viability of EGFP-transfected Raji cells, but had no effect on MCT4-EGFP-transfected 
Raji cells which increased in number [Figure 4.20 (B)].  Those cells which did not take 
up the pMCT4-EGFP plasmid remained sensitive to the killing effects of AZD3965, and 
this was apparent when the total cell population was analysed [Figure 4.20 (C)].  These 





Figure 4.18:  MCT4 and GFP expression following transient transfection of a Raji 
cell line with pMCT4-EGFP plasmid (24 hours).  (A) GFP transfection efficiency 
(17.86-23.04%) measured using flow cytometry.  The green line shows non-specific 
fluorescence (isotype control FITC (FL1-H)) while the purple section shows the 
fluorescence associated with the expression of GFP (FL1-H).  M1 shows cells selected 
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as being positive for CD40L expression. (B) Immunoblot showing MCT4 expression 
following incubation with rabbit polyclonal anti-MCT4 (sc-50329) (1:1000) (Insight 
Biotechnology, Wembley, UK).  Blots were probed with mouse monoclonal anti-β-actin 
(clone AC-74) as a control to ensure equal protein loading.  MCT4 is expressed in the 
Raji cells transiently transfected with the pMCT4-EGFP colonies (~74kDa).  20ug of 
protein was loaded.  MDA-MB-231 and Raji preparation were used as positive and 
negative controls for MCT4 expression (Lin et al., 1998b) (Gallagher et al., 2007).  (C) 
Immunoblot showing GFP expression after incubation with mouse monoclonal anti-GFP 
(sc-9996) (1:2000) (Insight Biotechnology, Wembley, UK).  GFP is expressed in the 





Figure 4.19:  Cell death following MCT1 inhibition using AZD3965 in Raji cells 
transiently transfected with pMCT4-EGFP visualized by side scatter (SSC) and 
forward scatter (FSC).  Representation of the rescue effect of transient MCT4 
expression in Raji cells following treatment with AZD3965.  Incubation of the mock 
transfected control (mock) and the Raji cells transfected with the control plasmid pAc-
EGFP1-N1 (control) can be seen to result in a reduction in the live cell population (R2 
in green) with an increase in the dead cell population (R1 in red) which is absent when 
incubated with the DMSO vehicle control.  Incubation of the Raji cells transfected with 
pMCT4-EGFP with AZD3965 has little effect on the live (R2) or dead cell populations 




Figure 4.20:  Inhibition of MCT1 using AZD3965 in Raji cells transiently 
transfected with pMCT4-EGFP (PI staining).  Raji cells were transiently transfected 
with either a pAc-EGFP1-N1 (control) or pMCT4-EGFP for 24 hours and then 
incubated with 0.1µM of AZD3965 for 48 hours.  (A) Quadrant analysis of the live 
(green) population of cells in R2 (Figure 4.19) showing them to express GFP whereas 
the majority of the cell population for the control corresponds to dead cells (red).  (B) 
0.1μM of AZD3965 caused a significant cell death (red) in the % of GFP positive cells 
(LR quadrant) in the control plasmid pAc-GFP1-N1 (* P = 0.0414) while no significant 
loss (live cells = green) in the % of GFP positive cells (LR) was seen in the Raji cells 
transfected with the pMCT4-EGFP (P = >0.05).  (C) PI showed the untreated (UT), the 
mock transfected (mock), and the control to be sensitive to AZD3965 (**** P = 
<0.0001), (** P = 0.0045), (** P = 0.0088) respectively using a paired t test.  No 
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significant cell death was seen with the DMSO vehicle control (P = >0.05) for either the 
UT, mock or control.  For the pMCT4-EGFP plasmid cell death was seen (* P = 0.0403) 
in comparison to the vehicle control.  Error bars are the SEM.  
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4.3.4 Examining of the effect of the AZD3965 on cell metabolism in CLL cell lines 
The previous data investigating the sensitivity of CLL cell lines to the MCT1 inhibitor 
AZD3965 primarily focused on measuring parameters such as cell death and cell 
viability to ascertain the functional effects of the compound.  Although this is of clinical 
interest, it is also important to examine metabolic changes which may occur in the cell 
prior to these events to understand the mechanism through which AZD3965 works.  
Metabolic flux analyses were performed using the SeahorseXF24 metabolic flux 
analyser as described in chapter 3.  This method was chosen because transport of 
substrates across the plasma membrane is proton linked and allows a broader question 
about monocarboxylate transport to be addressed.   
Firstly, the protocol was optimised for Raji cells.  These cells were plated out at 2 x 
10
5
/mL, 6 x 10
5
/mL, and 2 x 10
6
/mL, and subjected to a mitochondrial stress test (Figure 
4.21).  A seeding density of 2 x 10
6
 cells/mL had the highest baseline oxygen 
consumption rate [OCR (pMoles/min)], and it was determined that the mitochondrial 
stress test for this density was successful because of the notable changes in OCR that 
were evident following addition of each of the mitochondrial stressor drugs. Next, the 
concentration of FCCP was titrated over a concentration range of 0.5-3μM (Figure 
4.22).  It was determined that maximum respiration measured by OCR (pMoles/min) 
was obtained using a concentration of 1.5μM FCCP.   
The effect of AZD3965 on Raji cell metabolism was tested by measuring the normalised 
extracellular acidification rate [%ECAR (mpH/min/μgDNA)] and normalised OCR 
[%OCR (pMoles/min/μgDNA)] against an increasing concentration range of 0.1-30μM 
of this compound (Figure 4.23).  Injection of AZD3965 causes a concentration-
dependent drop in %ECAR indicating a slowing of the acidification rate of the 
extracellular media.  This is accompanied by an increase in %OCR indicating a potential 
greater reliance on aerobic metabolism.  Thus, the presence of AZD3965 leads to 
changes in the energy-generating pathways of Raji cells consistent with a decrease in 
glycolytic activity and increase in oxidative phosphorylation.  For subsequent 
experiments the lower concentration of 0.1μM AZD3965 was selected because it was 











Figure 4.21:  Evaluation of seeding density for the Raji cell line for metabolic flux 
analyses.  Raji cells were plated out at 2 x 10
5
/mL, 6 x 10
5
/mL, and 2 x 10
6
/mL and 
subjected to a mitochondrial stress test (oligomycin 1.26μM, FCCP 1.5μM and rotenone 
and antimycin-A 1μM).  OCR (pMoles/min) was measured.  A density of 2 x 10
6
/mL 
was selected for future use because of the higher baseline OCR and responsiveness to 









Figure 4.22:  FCCP titration in a Raji cell line.  Raji cells were plated out at 2 x 
10
6
/mL and subjected to a mitochondrial stress test (oligomycin 1.26μM, FCCP and 
rotenone and antimycin-A 1μM) with increasing concentrations of FCCP (0, 0.5, 0.75, 
1, 1.5, 3μM).  %OCR (pMoles/min/μgDNA) was measured.  1.5μM was selected as the 






Figure 4.23:  Effect of MCT1 inhibition using AZD3965 on ECAR and OCR in the 
Raji cell line.  Raji cells were seeded at a density of 2 x 10
6
/mL and treated with 
increasing concentrations of AZD3965 0.1, 1, 10, 30μM.  (A) %ECAR 
(mpH/min/μgDNA) and (B) %OCR (pMoles/min/μgDNA) were measured in real time 
for 5 hours post drug injection.   
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To confirm that AZD3965 affected glycolytic activity in Raji cells, oligomycin 
(1.26μM) was used to shut down ATP synthase and force the cells to use glycolysis as 
an energy-generating pathway (glycolytic capacity).  The presence of 0.1μM AZD3965 
leads to a significant decrease in the %ECAR of the cultured Raji cells [Figure 4.24 (A) 
and (B)].  When oligomycin is added, untreated Raji increase the %ECAR consistent 
with a switch to glycolysis as the preferred metabolic pathway.  With AZD3965-treated 
Raji cells, the addition of oligomycin also induces an increase in %ECAR [Figure 4.24 
(A)], but the extent is significantly less than that of the untreated Raji cells [Figure 4.24 
(B)].  Thus, this experiment shows that AZD3965-treated Raji cells have significantly 
reduced glycolytic capacity. 
Examination of oxidative phosphorylation in Raji cells was assessed next.  Figure 4.25 
(A) shows %OCR in untreated and AZD3965-treated Raji cells.  The %OCR of 
AZD3965-treated Raji cells is significantly greater than that of untreated cells [Figure 
4.25 (B)].  When oligomycin is added, there is a similar drop in %OCR for both 
untreated and AZD3965-treated Raji cells, and this indicates that oxidative 
phosphorylation produces similar levels of ATP under both conditions [Figure 4.25 (C)].  
This result suggests that the increased OCR associated with AZD3965-treated Raji cells 
is not due to increased respiration.  The integrity of mitochondrial respiration is shown 
to be intact when FCCP is added to uncouple the mitochondria.  Thus, there is no 
significant difference in the %OCR between untreated and AZD3965-treated Raji cells 
when FCCP is added [Figure 4.25 (D)].  Moreover, the final addition of rotenone and 
antimycin-A to measure proton leak and spare respiratory capacity show that both 
untreated and AZD3965-treated Raji cells respond in a similar fashion [Figures 4.25 (E) 
and (F)].  Taken together, these data suggest that increased oxygen consumption by the 
AZD3965-treated Raji cells is not due to increased respiration because excess ATP is 
not produced, and that the reason why excess ATP is not produced is not a result of 






Figure 4.24:  Effect of treatment with 0.1μM of AZD3965 in the Raji cell line on 
glycolytic capacity.  Raji cells (2 x 10
6
/mL) were treated with 0.1μM of AZD3965 left 
for 5 hours.  Oligomycin 1.26μM was then added.  (A) %ECAR (mpH/min/μgDNA) 
and (B) glycolytic capacity calculated by subtracting measurement 28 (after oligomycin) 
from measurement 25 (before oligomycin).  A paired t test revealed a significant 
decrease in glycolytic capacity following treatment with AZD3965 (* P = 0.0504).  




Figure 4.25:  Effect of treatment with 0.1μM of AZD3965 in the Raji cell line on 
responsiveness to mitochondrial stressors.  Raji cells (2 x 10
6
/mL) were treated with 
0.1μM of AZD3965 left for 5 hours.  Cells were then subjected to a mitochondrial stress 
test (oligomycin 1.26μM, FCCP 1.5μM and rotenone and antimycin-A 1μM).  (A) OCR 
(pMoles/min/μgDNA).  (B) Paired t tests revealed there to be a significant change in 
213 
 
baseline OCR in response to AZD3965 (* P = 0.0451).  No significant difference in 
response to the mitochondrial stressors was observed (P = > 0.05).  Error bars are SEM.  
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To understand why MEC-1 cells are resistant to the cytotoxic effects of AZD3965, they 
were also subjected to metabolic flux analysis.  Seeding density of this cell line was 
optimised as shown in Figure 4.26.  Only seeding densities of 2 x 10
6
/mL and 2 x 
10
7
/mL were responsive to the mitochondrial stressors. However, for the seeding density 
of 2 x 10
6
/mL there was not enough difference in OCR in response to mitochondrial 
stressors to afford reliable measurement, and a seeding density of 2 x 10
7
/mL yielded 
values at the top of the measurable range. Therefore, a density of 5 x 10
6
/mL was 
selected for future use. 
MEC-1 cells were then treated with increasing concentrations of AZD3965 (0.1, 1, 10, 
30μM) to assess whether the compound affected %ECAR and %OCR (Figure 4.27).  An 
initial increase in %ECAR was observed following injection from port A, and this was 
apparent for all injections regardless of treatment.  The presence of 30M AZD3965 
increased %ECAR above untreated and DMSO-treated MEC-1 cells, an observation that 
is inconsistent with those obtained using Raji cells (Figure 4.24).  This result suggests 
that AZD3965 does not shut down monocarboxylate transport in MEC-1 cells, even 
when used at concentrations which kill MEC-1 cells and also potentially shut down 
MCT-1 and -4 function.  With respect to %OCR, the presence of AZD3965 had the 
effect of decreasing oxygen consumption by MEC-1 cells.  This is in contract to Raji 
cells where the presence of AZD3965 lead to increased %OCR (Figure 4.25).  Taken 
together, these results indicate that MEC-1 cells are resistant to the effects of AZD3965 






Figure 4.26:  Evaluation of seeding density for the MEC-1 cell line for metabolic 
flux analyses.  MEC-1 cells were plated out at (A) 2 x 10
5
/mL, 6 x 10
5
/mL, and 2 x 
10
6
/mL and (B) 2 x 10
5
/mL, 2 x 10
6
/mL, and 2 x 10
7
/mL and subjected to a 
mitochondrial stress test (oligomycin 1.26μM, FCCP 1.5μM and rotenone and 
antimycin-A 1μM).  OCR (pMoles/min/μgDNA) was measured.  (A) Shows only 2 x 
10
6
/mL responds to stressors.  (B) Suggests 2 x 10
7
/mL to be out of range and confirms 
the data shown in (A).  Because the baseline value was low for 2 x 10
6
/mL and out of 
range for 2 x 10
7
/mL a density of 5 x 10
6







Figure 4.27:  Effect of MCT1 inhibition using AZD3965 on ECAR and OCR in the 
MEC-1 cell line.  MEC-1 cells were seeded at a density of 5 x 10
6
/mL and treated with 
increasing concentrations of AZD3965 0.1, 1, 10, 30μM.  (A) %ECAR 
(mpH/min/μgDNA) and (B) %OCR (pMoles/min/μgDNA) were measured in real time 




Inhibitors of MCT-1 and -4 were originally designed to modulate immunosuppression 
based on an understanding that antigen receptor signalling induces glycolysis (Garcia-
Manteiga et al., 2011, Michalek and Rathmell, 2010).  The potential of these compounds 
in the treatment of CLL has not been previously explored, but seemed important because 
of the role of antigen in progression of this disease.  In chapter 2 CLL cells were 
demonstrated to express both MCT -1 and -4, and chapter 3 demonstrated that CD40-
stimulated CLL cells upregulated expression of MCT4.  The aim of this chapter was to 
investigate whether MCT1 could be therapeutically targeted in cells where both MCT -1 
and -4 were present.   
The experiments in this chapter are primarily based on Raji and MEC-1 cells, the former 
cell line expressing only MCT1, while the latter expresses both MCT1 and 4.  
Preliminary data suggested that Raji cells are sensitive to nM concentrations of 
AZD3965 (Critchlow et al., 2012), and the results presented in this chapter confirm this 
using DiOC6 and PI staining to assess cell death, and Alamar blue® to assess cell 
viability.  Thus, AZD3965 has a concentration-dependent cytotoxic effect on Raji cells, 
where 100nM was observed as the optimal concentration.  This concentration of 
AZD3965 was then demonstrated to have effect on the metabolism of Raji cells.  
Metabolic analyses using the SeahorseXF24 metabolic flux analyser revealed that Raji 
cells treated with this drug changed their ECAR suggesting that proton-linked transport 
(i.e. monocarboxylate transport) was inhibited.  This finding is in agreement with work 
recently published by Doherty et al. (2013) where Raji cells were treated with similar 
MCT1 inhibitors AR-C122982 and AR-C155858.  Importantly, AZD3965 is derived 
from AR-C155858 and is reported to show 10 fold greater affect (Ekberg et al., 2007).  
The work of this chapter provides greater insight into the mechanism of action of MCT1 
inhibition because the change in ECAR following the addition of oligomycin shows that 
AZD3965-treated Raji cells have lost glycolytic capacity.  This, in turn, suggests that 
glycolysis is being shut down in treated Raji cells most likely because of lowering of 
optimal pH for the enzymes involved in this pathway (Mansour, 1963).  Metabolic 
measurements also show that the presence of AZD3965 induced increased oxygen 
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consumption by Raji cells.  This is likely not due to increased respiration because the 
indices of mitochondrial function, ATP production, maximal respiration, proton leak 
and spare capacity all remained unaffected by the presence of this drug.  However, this 
does not mean that AZD3965 does not lead to mitochondrial damage because the time 
scale of the experiment may be too short.  Maximal respiration was measured 3 hours 
following the addition of AZD3965, and this may be too short an incubation to observed 
significantly different rates of maximal respiration between untreated and treated cells.  
AZD3965-treated Raji cells did seem to have reduced maximal respiration, and further 
experimentation is necessary to determine the full mechanism through which this drug 
induces its cytotoxic effect.  
In contrast to Raji cells, the presence of AZD3965 had no effect on the metabolism of 
MEC-1 cells.  MEC-1 cells were also largely resistant to the cytotoxic effects of this 
drug.  With respect to monocarboxylate transporter expression, it may be that MCT4 
compensates for the function of MCT1 when AZD3965 is present in MEC-1 cell 
cultures.  This notion is tested by ectopic expression of MCT4 in Raji cells, these cells 
also become resistant to the cytotoxic effects of AZD3965.  Attempts were made to 
knock down expression of MCT1 in MEC-1 cells, however, only a partial knockdown 
was achieved and this was insufficient for further experiments measuring the effects of 
AZD3965 to take place.  Nevertheless, this approach may be successful in future 
experiments because studies of this compensation mechanism in small cell lung cancer 
(SCLC) cell lines show that siRNA knockdown of MCT4 increases sensitivity to MCT1 
inhibition (Polanski et al., 2014).  
In conclusion the data presented in this chapter suggests that the therapeutic targeting of 
MCT1 is likely to be ineffective without the inhibition of MCT4 in cells that express 
both transporters.  These data, in combination with the previous data from chapter 3, 
suggests that inhibition of MCT1 will unlikely be effective in killing CLL cells within 
the microenvironment because of the upregulation of MCT4 that is induced when these 




5 CHAPTER 5:  GENERAL DISCUSSION AND FUTURE WORK 
 
The overall aim of this thesis was to examine the potential of targeting the metabolism 
of chronic lymphocytic leukaemia (CLL) cells through the inhibition of MCT -1 and -4.  
This was accomplished by investigating the expression profile of these transporters on 
primary CLL cells from the peripheral circulation, and examining how their expression 
is affected during contact with the microenvironment where CLL cells encounter 
proliferative and survival stimuli.  Finally, potential sensitivity of CLL cells to MCT-1 
inhibition was assessed using AZD3965.   
The work presented in this thesis is important because it explores the possibility of 
therapeutically targeting a fundamental area of cancer cell biology, an area which for 
CLL is relatively uncharted.  Other studies looking at new therapeutic approaches for 
this disease focus on targeting recurrent/refractory disease.  These new therapies take 
the approach of disrupting; BCR signaling (ibrutinib), the PI3K pathway (idelalisib), 
modulating the immune system (lenalidomide), or inducing cell death by targeting Bcl-2 
(AZD4320) (Tausch et al., 2014).   
As previously discussed, early work suggested that the gradual accumulation of 
malignant B cells in CLL was due to failed apoptosis (Brody et al., 1969, Dameshek, 
1967, Gottardi et al., 1995, Zenz et al., 2010, Pepper et al., 1997, Kitada et al., 1998).  
Thus, within this paradigm CLL cells would likely have low levels of metabolic activity, 
a notion which was supported by studies examining glucose uptake as well as the 
expression levels of glycolytic enzymes (Vives Corrons et al., 1989, Ho et al., 1982, 
Musolino et al., 1992).   
However, in the last decade cancer cell metabolism has come into the forefront of 
cancer research because a hallmark of malignancy is the rapid consumption of glucose 
coupled with enhanced aerobic glycolysis; the Warburg effect (Warburg et al., 1924).  
Renewed interest in this field has led to the development of new drugs which target cell 
metabolism, which, when combined with standard therapies have been shown to have a 
synergistic effect (Xie et al., 2011, Rosilio et al., 2014, Zhao et al., 2013).  The potential 
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of this approach in the context of CLL has not been realised, although a significant 
proliferative component of the malignant clone has been identified. 
Chapter 2 begins to address the aims of this study by first examining the expression of 
MCT -1 and -4 as well as their chaperone protein CD147 in CLL and normal B cells.  
The results shown in this chapter are the first to demonstrate the presence of MCT -1, -4 
and CD147 on CLL cells, as well as confirm the expression of these transporters in their 
healthy counterparts (Merezhinskaya et al., 2004).  Typically, the levels of MCT -1, -4 
and CD147 are higher on malignant cells compared to normal cells, however, on CLL 
cells they show reduced expression in comparison to normal B cells (Arendt et al., 2012, 
de Vries et al., 2010, Liu et al., 2009, Thorns et al., 2002, Nabeshima et al., 2004, Shi et 
al., 2003).  This may be because other lymphoid cancers are known to experience a 
much higher rate of cell turnover in comparison to CLL, which require 
microenvironmental stimuli for cell proliferation to occur.  In other lymphoid cancers a 
consequence of proliferative activity is greater energy demand and an increased need for 
monocarboxylate transport, hence the need for increased MCT -1 and -4 expression.  
That expression of these transporters is low on CLL cells suggests that these cells have a 
decreased level of metabolic activity which reflects their non-dividing state, or that their 
primary energy source is not glycolysis. 
The former notion that metabolism is slowed in circulating CLL cells is a feature seen in 
other malignancies whereby a quiescent phenotype is adopted to enhance cell survival 
and protect against metabolic stress (Leontieva et al., 2012, Valcourt et al., 2012).  This 
is of interest with respect to disease pathology because the longer a CLL cell can survive 
in circulation, the better chance it will have of re-entering secondary tissues and 
encountering proliferative and survival signals (van Gent et al., 2008).  Ricciardi et al. 
(2001) have shown quiescence to be correlated to progressive disease.  This study 
compared cells from patients with stable and progressive disease using RNA content and 
p27
kip1
 to measure the ability of the cell to cycle.  In the cells obtained from patient’s 
with progressive disease RNA content was reduced and p27
kip1
 expression was 
increased, both features associated with a quiescent state.  Moreover, ‘progressive’ cells 
were shown to be less susceptible to apoptotic stimuli suggesting that by becoming 
221 
 
quiescent cell survival is enhanced.  Whether the adoption of a quiescent state by 
circulating CLL cells is therapeutically targetable has value not only in the context of 
CLL, but may have relevance in other malignancies where circulating tumour cells are 
present within peripheral blood. 
That glycolysis is likely not the primary means of energy generation by CLL cells is 
supported by a recent paper by Jitschin et al. (2014), who show that peripheral blood 
CLL cells rely on oxidative phosphorylation.  This study shows that CLL cells have 
increased levels of mitochondrial respiration in comparison to normal B cells, and this is 
in keeping with a previous report describing high levels of oxidative stress in CLL cells 
(Moran et al., 2002).  These findings are important for understanding CLL cell 
bioenergetics because they suggest that circulating CLL cells utilise the same metabolic 
pathway as naïve and memory B cells, and prefer oxidative phosphorylation (Garcia-
Manteiga et al., 2011).  Thus, it is likely that following contact with microenvironmental 
stimuli CLL cells adopt a more glycolytic phenotype to support proliferation as is seen 
with normal B cells.  Induction of glycolysis implies that expression of MCT -1 and/or -
4 is likely to increase in order to mediate lactate efflux.   
Chapter 3 of this thesis examines whether the levels of MCT -1 and -4 change when 
CLL cells come into contact with the microenvironment; modelled using CD40L-
expressing fibroblasts.  The initial aims of this project were based on the assumption 
that circulating CLL cells would be vulnerable to MCT1 inhibition, either alone or in 
combination with MCT4 inhibition.  Because of the protective role microenvironment 
has in mediating resistance to traditional therapies such as fludarabine (Hallaert et al., 
2008, Hayden et al., 2010), it was hypothesised that such contact may also effect CLL 
cell response to MCT inhibition.  The data presented in this chapter demonstrate that 
contact with fibroblasts appears to stimulate expression of MCT1 expression on CLL 
cells, and contact with CD40L-expressing fibroblasts strongly stimulates the expression 
of MCT4.  This indicates that CLL cells are unlikely to become vulnerable to the MCT1 
inhibitor, AZD3965, either in circulation or when the cells are within the 
microenvironment.  However, what is evident is that MCT4 may be a viable target, 
particularly when CLL cells are within so-called proliferation centres where they receive 
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stimulation to proliferate through engagement of CD40.  This is important not only 
because it provides an avenue by which cells which are resistant to fludarabine may be 
killed, but also because activation through CD40 is a potential mechanism by which 
resistance may arise to the newly available compounds which target BCR signalling.  
Furthermore, the cell-specific distribution of MCT4 in glycolytic cells in comparison to 
the more ubiquitous expression of MCT1 may be a more desirable target owing to the 
limited degree of non-specific toxicity to normal cells (Halestrap and Wilson, 2012).   
The mechanism by which AZD3965 is thought to induce cell death is by preventing the 
MCT1-mediated export of lactic acid out of cells resulting in intracellular acidification.  
It can be assumed that inhibition of MCT4 would likely cause cell death via the same 
mechanism; cell death would result from an increase in intracellular acidification from 
lactate accumulation that results from glycolytic activity.  The data collected from the 
Fluidigm Biomark™ chip array indicates that CD40 ligation on CLL cells induces 
expression of genes involved in glycolysis by showing the expression of genes involved 
in glycolysis to be upregulated, namely; HK1 and HK2.   
To complement this work measurement of real time metabolic flux were attempted 
using the SeahorseXF24.  CLL cells either cultured alone or co-cultured with parental 
and CD40L expressing fibroblasts were analysed.  However, no differences in the ability 
of the cells to utilise either oxidative phosphorylation or glycolysis were seen.  
Reproducibility was an issue due to the lack of freshly obtained cells and it was felt that 
injection of a soluble CD40L was a better approach however preliminary experiments 
using the soluble ligand from previous experiments yielded no results, possibly because 
of the strength of the stimulation was too weak.  Further experiments would be desirable 
with a stronger immobilised CD40L, but this was not commercially available and 
remained unobtainable throughout the course of the project.   
The array data also revealed changes in the microenvironmental cells following CD40-
CD40L interaction.  For these experiments CD40L was brought into contact with CLL 
cells using a co-culture system whereby human CD40L was engineered to be expressed 
on a mouse fibroblast cell line.  Upregulation of MCT4 in these cells was accompanied 
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by an increase in glycolytic activity and slowing of other metabolic processes which 
may utilise the same substrates such as the pentose phosphate pathway, fatty acid 
synthesis, and the TCA cycle.  This is important because it suggests that a symbiotic 
relationship may be occurring between the CLL cells and the tumour microenvironment.  
Evidence of this reciprocal metabolic activity has been described as being important in 
cancer biology (Bonuccelli et al., 2010, Feron, 2009).  Thus, the therapeutic targeting of 
MCT4 may also promote cell death by disrupting the metabolism of neighboring 
supportive cells.  However, further work is required to understand the interactions which 
occur between CLL cells and the microenvironment and how these interactions 
influence the metabolism of both cell types.   
The work presented in the first two results chapters suggests that MCT4 inhibition is a 
more promising therapeutic target than MCT1 for the treatment of CLL.  Chapter 2 
shows how both transporters are downregulated in circulating CLL cells in comparison 
to healthy counterparts, while chapter 3 shows a meager increase in MCT1 following 
contact with fibroblasts cells and a stark increase in MCT4 expression following CD40L 
stimulation.  Chapter 4 demonstrates that targeting of MCT1 is likely to be ineffective in 
CLL as well as providing evidence that inhibition of MCT4 alone is also likely to have 
limited efficacy.   
Assessment of the sensitivity of the CLL cell lines, MEC-1 and HG3, to AZD3965 a 
specific inhibitor of MCT1 revealed that treatment with this compound had no death 
inducing effects in either cell type up to a concentration of 10µM.  Increasing the 
concentration of the drug to 30µM did induce an apoptotic effect, however at this 
concentration AZD3965 is reported to lose specificity for MCT1 and can additionally 
target MCT4, suggesting that MCT4 may compensate for MCT1 function (Critchlow et 
al., 2012).  However, metabolic flux analyses within the present study indicated that the 
cytotoxicity of 30µM AZD3965 in MEC-1 cells is likely due to non-specific effects 
rather than to a change in cell metabolism.  The presence of 30µM AZD3965 did not 
affect ECAR by MEC-1 cells, which would suggest that proton-linked transport was not 
inhibited by this compound.  In contrast, Raji cells, which only express MCT1, showed 
a dose dependent change in ECAR that was accompanied by an increase in OCR when 
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exposed to AZD3965 even at nM concentrations.  Cell death analyses showed these 
cells to be sensitive to AZD3965, the apoptotic effects likely being caused by 
intracellular acidification and reduced glycolysis because the glycolytic capacity of 
AZD3965-treated Raji cells was shown to be significantly reduced.   
To explore the notion that the presence of MCT4 in the MEC-1 cells may account for 
AZD3965 resistance, the effect of transiently expressing MCT4 in the Raji cell line was 
examined.  This experiment showed that Raji cells induced to express MCT4 became 
resistant to the inhibition of MCT1 using AZD3965 suggesting that MCT4 can 
compensate for disrupted MCT1 function, a finding that is in keeping with recent studies 
in small cell lung cancer (SCLC) (Polanski et al., 2014).  In an attempt to investigate 
whether it would be possible to target MCT1 in cells which express both MCT -1 and -4 
siRNA was used to examine the effect of silencing MCT4 expression in MEC-1 cells 
because no specific inhibitor was available.  While no significant cell death was seen in 
MEC-1 cells treated with MCT4 specific siRNA only a partial knockdown of MCT4 
expression was achieved making this technique unsuitable for further experiments in the 
primary cells.  Preliminary attempts to silence MCT4 in CLL cells co-cultured with 
CD40L fibroblasts were unsuccessful.  As previously mentioned the use of an 
alternative immobilised CD40L would have simplified the experiment giving it a greater 
chance of success.  Taken together, these data provide evidence that further work is 
needed to investigate the potential of targeting MCT -1 and -4 in cell types such as CLL 
which express both transporters.   
In the absence of specific inhibitors for MCT4 alternative techniques may be used in 
future work to attenuate MCT4 expression such as lentiviral transfection and CRISPR® 
genome editing as well as the generation of a stable cells.  However, this approach may 
not be sufficient to demonstrate sensitivity to MCT1 inhibition if the cells are not fully 
stimulated to divide.  As CD40L stimulation is the basis for other models simulating the 
influence of the microenvironment, the addition of other factors such as IL-4 and IL-21 
would also be an avenue by which this work may be progressed.  Further to this other 
end points in addition to the measurement of cell death could be more closely examined.  
For instance, the levels of substrates transported by MCT -1 and -4 could be directly 
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measured using NMR or mass spectrometry to better understand the metabolic 
characteristics of these cells and understand the mechanism by which MCT inhibition 
causes cytoxicity.  In addition to this strategy further work could also be completed 
using the SeahorseXF24 metabolic flux analyser which was optimised for this study.  
Preliminary experiments within this investigation were unable to sufficiently 
demonstrate whether CD40L stimulation of CLL cells induces a change in metabolic 
flux.  The use of a soluble ligand did not induce a significant change in MCT4 
expression by which to adequately control a metabolic flux experiment and the co-
culture with CD40L expressing fibroblasts failed to show any real time changes in 
ECAR or OCR.  As previously mentioned the use of an alternative immobilised CD40L 
would allow real time measurements.  Moreover, the addition of further stimuli such as 
IL-4 and IL-21 as previously described would allow the assessment of how each stimuli 
contributes to the induction of metabolic activity as well as allowing a drug injection 
port for the addition of a inhibitor such as AZD3965 (Ahearne et al., 2013).  
Combination of a CD40L, IL-4 and IL-21 into one port would also allow for the 
addition of multiple compounds plus AZD3965 such as metformin, an approach that is 
becoming popular with users of the SeahorseXF24 because its use in the treatment of 
diabetes and the effect it has on glucose metabolism (Doherty et al., 2013). 
In conclusion, this thesis aimed to assess the potential of therapeutically targeting the 
metabolism of CLL cells by inhibiting monocarboxylate transporters.  The data 
presented addressed this aim by testing three hypotheses.  The findings in chapter 2 
proved that MCT -1 and -4 are expressed by CLL cells.  However, this data indicates 
that the inhibition of MCT1 is unlikely to be effective because levels of this transporter 
are reduced in CLL cells in comparison to normal B cells.  Chapter 3 showed that the 
need for monocarboxylate transport is increased when CLL cells are induced to 
proliferate.  Although similarly to MCT1, MCT4 levels are seen to be reduced in 
circulating CLL cells, when stimulated with CD40L MCT4 is increased likely due to an 
increased demand for monocarboxylate transport as a consequence of enhanced 
glycolytic activity.  Thus, MCT4 may be a viable target.  Chapter 4 examines the third 
hypothesis.  This chapter is unable to prove that CLL cells are sensitive to MCT -1 
and/or -4 inhibition however; work in cell lines in this chapter does show that MCT4 is 
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able to compensate for disrupted MCT1 function mediating resistance to AZD3965.  
Whether or not MCT1 can compensate for MCT4 remains unanswered therefore 
inhibition of MCT -1 and -4 may be required to induce cell death.  This work provides a 
foundation for future research concentrating on targeting CLL cell metabolism 
therapeutically as well as supporting recent publications examining MCTs in other cell 








SDS-PAGE clear lysis buffer: 
 
1% Sodium dodecyl sulfate (SDS) (1mL of 10% stock) (Fischer Scientific, 
Leicestershire, UK). 
50mM Tris pH 6.8 (1mL 0.5M Tris) (Fischer Scientific Chemicals, Leicestershire, UK). 
5mM EDTA (1mL of 50mM EDTA) (Sigma, Gillingham, UK). 
10% glycerol (1mL) (Sigma, Gillingham, UK). 
6mL dH2O. 
 
5 x Sample buffer: 
 
1M Tris pH 6.8. 
50% glycerol. 
15% SDS. 
25% β-metacaptoethanol (Sigma, Gillingham, UK). 
Bromophenol blue (Fischer Scientific, Leicestershire, UK). 
 
1 x Sample buffer: 
 
5 x Sample buffer diluted 1:5 in dH2O. 
 













0.25M Tris (pH 6.8). 
1.92M glycine. 
 





10mM Tris (pH 7.4) 













6.2 Sample purity 
 
 
Table 6.1:  Sample purity following co-culture.  CD19 was measured using flow 
cytometry to assess sample purity following the removal of CLL cells from the 









Figure 6.1:  Mycoplasma analysis.  Example of the mycoplasma analysis in HG3 and 
MEC-1 (CLL) cell lines and the Raji (B cell lymphoma) cell line.  Cell lines were 
shown to be negative for Mycoplasma, the presence of which can slow proliferation.    
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6.4 Fluidigm Biomark™ chip array 
 
6.4.1 Sample loading 
 
 
Figure 6.2:  ROX™ expression.  ROX™ expression was measured at cycle 1 as a 
passive reference control to normalise non-PCR-related fluctuations in fluorescence.  
The Fluidigm Biomark™ Real Time PCR Analysis Software (Version 3.1.3) draws a 






Figure 6.3:  ROX™ expression.  ROX™ expression was measured at cycle 40 as a 
passive reference control to normalise non-PCR-related fluctuations in fluorescence.  
The Fluidigm Biomark™ Real Time PCR Analysis Software (Version 3.1.3) draws a 






AHEARNE, M. J., WILLIMOTT, S., PINON, L., KENNEDY, D. B., MIALL, F., 
DYER, M. J. S. & WAGNER, S. D. 2013. Enhancement of CD154/IL4 
proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased 
numbers of circulating cells resembling Tfh cells in chronic lymphocytic 
leukaemia. British Journal of Haematology, 162, 360-370. 
ALDUAIJ, W. & ILLIDGE, T. M. 2011. The future of anti-CD20 monoclonal 
antibodies: are we making progress? Blood, 117, 2993-3001. 
ALTMAN, S. A., RANDERS, L. & RAO, G. 1993. Comparison of trypan blue dye 
exclusion and fluorometric assays for mammalian cell viability determinations. 
Biotechnology Progress, 9, 671-674. 
ARENDT, B. K., WALTERS, D. K., WU, X., TSCHUMPER, R. C., HUDDLESTON, 
P. M., HENDERSON, K. J., DISPENZIERI, A. & JELINEK, D. F. 2012. 
Increased expression of extracellular matrix metalloproteinase inducer (CD147) 
in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia, 
26, 2286-2296. 
ARSHAM, A. M., HOWELL, J. J. & SIMON, M. C. 2003. A novel hypoxia-inducible 
factor-independent hypoxic response regulating mammalian target of rapamycin 
and its targets. Journal of Biological Chemistry, 278, 29655-29660. 
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. 
A., GRALNICK, H. R. & SULTAN, C. 1989. Proposals for the classification of 
chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) 
Cooperative Group. J Clin Pathol, 42, 567-84. 
BENSAAD, K. & VOUSDEN, K. H. 2007. p53: new roles in metabolism. Trends in 
Cell Biology, 17, 286-291. 
BINET, J. L., AUQUIER, A., DIGHIERO, G., CHASTANG, C., PIGUET, H., 
GOASGUEN, J., VAUGIER, G., POTRON, G., COLONA, P., OBERLING, F., 
THOMAS, M., TCHERNIA, G., JACQUILLAT, C., BOIVIN, P., LESTY, C., 
DUAULT, M. T., MONCONDUIT, M., BELABBES, S. & GREMY, F. 1981. A 
new prognostic classification of chronic lymphocytic leukemia derived from a 
multivariate survival analysis. Cancer, 48, 198-206. 
BONUCCELLI, G., TSIRIGOS, A., WHITAKER-MENEZES, D., PAVLIDES, S., 
PESTELL, R. G., CHIAVARINA, B., FRANK, P. G., FLOMENBERG, N., 
HOWELL, A., MARTINEZ-OUTSCHOORN, U. E., SOTGIA, F. & LISANTI, 
M. P. 2010a. Ketones and lactate "fuel" tumor growth and metastasis evidence 
that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle, 
9, 3506-3514. 
BONUCCELLI, G., WHITAKER-MENEZES, D., CASTELLO-CROS, R., 
PAVLIDES, S., PESTELL, R. G., FATATIS, A., WITKIEWICZ, A. K., 
VANDER HEIDEN, M. G., MIGNECO, G., CHIAVARINA, B., FRANK, P. 
G., CAPOZZA, F., FLOMENBERG, N., MARTINEZ-OUTSCHOORN, U. E., 
SOTGIA, F. & LISANTI, M. P. 2010b. The reverse Warburg effect glycolysis 
inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer 
associated fibroblasts. Cell Cycle, 9, 1960-1971. 
234 
 
BRODY, J. I., OSKI, F. A. & SINGER, D. E. 1969. Impaired pentose phosphate shunt 
and decreased glycolytic activity in lymphocytes of chronic lymphocytic 
leukemia metabolic pathway. Blood-the Journal of Hematology, 34, 421-&. 
BURGER, J. A. & CHIORAZZI, N. 2013. B cell receptor signaling in chronic 
lymphocytic leukemia. Trends in Immunology, 34, 592-601. 
CALIGARIS-CAPPIO, F. 2009. Chronic lymphocytic leukemia: "Cinderella" is 
becoming a star. Mol Med, 15, 67-9. 
CAMBIER, J. C., GAULD, S. B., MERRELL, K. T. & VILEN, B. J. 2007. B-cell 
anergy: from transgenic models to naturally occurring anergic B cells? Nature 
Reviews Immunology, 7, 633-643. 
CAPASSO, M., BHAMRAH, M. K., HENLEY, T., BOYD, R. S., LANGLAIS, C., 
CAIN, K., DINSDALE, D., PULFORD, K., KHAN, M., MUSSET, B., 
CHERNY, V. V., MORGAN, D., GASCOYNE, R. D., VIGORITO, E., 
DECOURSEY, T. E., MACLENNAN, I. C. M. & DYER, M. J. S. 2010. 
HVCN1 modulates BCR signal strength via regulation of BCR-dependent 
generation of reactive oxygen species. Nature Immunology, 11, 265-U12. 
CAPORASO, N., GOLDIN, L., PLASS, C., CALIN, G., MARTI, G., BAUER, S., 
RAVECHE, E., MCMASTER, M. L., NG, D., LANDGREN, O. & SLAGER, S. 
2007. Chronic lymphocytic leukaemia genetics overview. British Journal of 
Haematology, 139, 630-634. 
CASTORINO, J. J., DEBORDE, S., DEORA, A., SCHREINER, R., GALLAGHER-
COLOMBO, S. M., RODRIGUEZ-BOULAN, E. & PHILP, N. J. 2011. 
Basolateral Sorting Signals Regulating Tissue-Specific Polarity of Heteromeric 
Monocarboxylate Transporters in Epithelia. Traffic, 12, 483-498. 
CATALINA-RODRIGUEZ, O., KOLUKULA, V. K., TOMITA, Y., PREET, A., 
PALMIERI, F., WELLSTEIN, A., BYERS, S., GIACCIA, A. J., GLASGOW, 
E., ALBANESE, C. & AVANTAGGIATI, M. L. 2012. The mitochondrial 
citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget, 
3, 1220-35. 
CHACKO, B. K., KRAMER, PHILIP A., RAVI, SARANYA., JOHNSON, 
MICHELLE S., HARDY, ROBERT W., BALLINGER, SCOTT W., AND 
DARLEY-USMAR, VICTOR M. 2013. Methods for defining distinct 
bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and 
the oxidative burst from human blood. Laboratory Investigation, 00, 1-11. 
CHEN, C. I. 2013. Lenalidomide Alone and in Combination for Chronic Lymphocytic 
Leukemia. Current hematologic malignancy reports, 8, 7-13. 
CHENG, C., CHEN, Z. Q. & SHI, X. T. 2014. MicroRNA-320 inhibits osteosarcoma 
cells proliferation by directly targeting fatty acid synthase. Tumour Biol, 35, 
4177-83. 
CHEONG, H., LU, C., LINDSTEN, T. & THOMPSON, C. B. 2012. Therapeutic targets 
in cancer cell metabolism and autophagy. Nature Biotechnology, 30, 671-678. 
CHEUNG, E. C. & VOUSDEN, K. H. 2010. The role of p53 in glucose metabolism. 
Current Opinion in Cell Biology, 22, 186-191. 
CHIORAZZI, N. & FERRARINI, M. 2003. B cell chronic lymphocytic leukemia: 
lessons learned from studies of the B cell antigen receptor. Annual Review of 
Immunology, 21, 841-894. 
235 
 
CHIORAZZI, N. & FERRARINI, M. 2011. Cellular origin(s) of chronic lymphocytic 
leukemia: cautionary notes and additional considerations and possibilities. 
Blood, 117, 1781-91. 
CITORES, M. J., CASTEJON, R., VILLARREAL, M., ROSADO, S., GARCIA-
MARCO, J. A. & VARGAS, J. A. 2010. CD154 expression triggered by purine 
analogues in vitro: Correlation with treatment response and autoimmune events 
in chronic lymphocytic leukemia. Experimental Hematology, 38, 165-173. 
CLARK, M. R., MANDAL, M., OCHIAI, K. & SINGH, H. 2014. Orchestrating B cell 
lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor 
signalling. Nat Rev Immunol, 14, 69-80. 
COSTANTINI, A., MANCINI, S., GIULIODORO, S., BUTINI, L., REGNERY, C. M., 
SILVESTRI, G. & MONTRONI, M. 2003. Effects of cryopreservation on 
lymphocyte immunophenotype and function. Journal of Immunological 
Methods, 278, 145-55. 
CRESPO, M., BOSCH, F., VILLAMOR, N., BELLOSILLO, B., COLOMER, D., 
ROZMAN, M., MARCE, S., LOPEZ-GUILLERMO, A., CAMPO, E. & 
MONTSERRAT, E. 2003. ZAP-70 expression as a surrogate for 
immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 
New England Journal of Medicine, 348, 1764-1775. 
CRITCHLOW, S., HOPCROFT, L., MOONEY, L., CURTIS, N., WHALLEY, N., 
ZHONG, H., LOGIE, A., REVILL, M., XIE, L., ZHANG, J., YU, D., 
MURRAY, C. & SMITH, P. D. Pre-clinical targeting of the metabolic 
phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate 
transporter 1 (MCT1).  American Association for Cancer Research, April 15, 
2012 2012 Chicago, IL. 
CROWTHER-SWANEPOEL, D. & HOULSTON, R. S. 2009. The molecular basis of 
familial chronic lymphocytic leukemia. Haematologica-the Hematology Journal, 
94, 606-609. 
DAMESHEK, W. 1967. Chronic lymphocytic leukemia-an accumulative disease of 
immunolgically incompetent lymphocytes. Blood, 29, Suppl:566-84. 
DAMLE, R. N., GHIOTTO, F., VALETTO, A., ALBASIANO, E., FAIS, F., YAN, X. 
J., SISON, C. P., ALLEN, S. L., KOLITZ, J., SCHULMAN, P., 
VINCIGUERRA, V. P., BUDDE, P., FREY, J., RAI, K. R., FERRARINI, M. & 
CHIORAZZI, N. 2002. B-cell chronic lymphocytic leukemia cells express a 
surface membrane phenotype of activated, antigen-experienced B lymphocytes. 
Blood, 99, 4087-4093. 
DAMLE, R. N., WASIL, T., FAIS, F., GHIOTTO, F., VALETTO, A., ALLEN, S. L., 
BUCHBINDER, A., BUDMAN, D., DITTMAR, K., KOLITZ, J., LICHTMAN, 
S. M., SCHULMAN, P., VINCIGUERRA, V. P., RAI, K. R., FERRARINI, M. 
& CHIORAZZI, N. 1999. Ig V gene mutation status and CD38 expression as 
novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 1840-
1847. 
DANG, C. V. 2012. Links between metabolism and cancer. Genes & Development, 26, 
877-890. 
DANILOV, A. V., DANILOVA, O. V., BROWN, J. R., RABINOWITZ, A., KLEIN, A. 
K. & HUBER, B. T. 2010. Dipeptidyl peptidase 2 apoptosis assay determines the 
236 
 
B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. 
Experimental Hematology, 38, 1167-1177. 
DASANU, C. A. 2008. Intrinsic and treatment-related immune alterations in chronic 
lymphocytic leukaemia and their impact for clinical practice. Expert Opin 
Pharmacother, 9, 1481-94. 
DE VRIES, J. F., MARVELDE, J. G. T., WIND, H. K., VAN DONGEN, J. J. M. & 
VAN DER VELDEN, V. H. J. 2010. The potential use of basigin (CD147) as a 
prognostic marker in B-cell precursor acute lymphoblastic leukaemia. British 
Journal of Haematology, 150, 624-626. 
DEEG, H. J., BLAZAR, B. R., BOLWELL, B. J., LONG, G. D., SCHUENING, F., 
CUNNINGHAM, J., RIFKIN, R. M., ABHYANKAR, S., BRIGGS, A. D., 
BURT, R., LIPANI, J., ROSKOS, L. K., WHITE, J. M., HAVRILLA, N., 
SCHWAB, G. & HESLOP, H. E. 2001. Treatment of steroid-refractory acute 
graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. 
Blood, 98, 2052-2058. 
DEFOICHE, J., DEBACQ, C., ASQUITH, B., ZHANG, Y., BURNY, A., BRON, D., 
LAGNEAUX, L., MACALLAN, D. & WILLEMS, L. 2008. Reduction of B cell 
turnover in chronic lymphocytic leukaemia. British Journal of Haematology, 
143, 240-247. 
DENEYS, V., THIRY, V., HOUGARDY, N., MAZZON, A. M., LEVEUGLE, P. & DE 
BRUYERE, M. 1999. Impact of cryopreservation on B cell chronic lymphocytic 
leukaemia phenotype. Journal of Immunological Methods, 228, 13-21. 
DHUP, S., DADHICH, R. K., PORPORATO, P. E. & SONVEAUX, P. 2012. Multiple 
biological activities of lactic acid in cancer: influences on tumor growth, 
angiogenesis and metastasis. Current Pharmaceutical Design, 18, 1319-1330. 
DIGHIERO, G. & HAMBLIN, T. J. 2008. Chronic lymphocytic leukaemia. Lancet, 
371, 1017-1029. 
DOHERTY, J. R., YANG, C., SCOTT, K. E., CAMERON, M. D., FALLAHI, M., LI, 
W., HALL, M. A., AMELIO, A. L., MISHRA, J. K., LI, F., TORTOSA, M., 
GENAU, H. M., ROUNBEHLER, R. J., LU, Y., DANG, C. V., KUMAR, K. G., 
BUTLER, A. A., BANNISTER, T. D., HOOPER, A. T., UNSAL-KACMAZ, 
K., ROUSH, W. R. & CLEVELAND, J. L. 2013. Blocking Lactate Export by 
Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis. 
Cancer Res. 
DOHNER, H., FISCHER, K., BENTZ, M., HANSEN, K., BENNER, A., CABOT, G., 
DIEHL, D., SCHLENK, R., COY, J., STILGENBAUER, S., VOLKMANN, M., 
GALLE, P. R., POUSTKA, A., HUNSTEIN, W. & LICHTER, P. 1995. P53 
gene deletion predicts for poor survival and non-response to therapy with purine 
analogs in chronic B cell leukemias. Blood, 85, 1580-1589. 
DONO, M., BURGIO, V. L., TACCHETTI, C., FAVRE, A., AUGLIERA, A., ZUPO, 
S., TABORELLI, G., CHIORAZZI, N., GROSSI, C. E. & FERRARINI, M. 
1996a. Subepithelial B cells in the human palatine tonsil. I. Morphologic, 
cytochemical and phenotypic characterization. Eur J Immunol, 26, 2035-42. 
DONO, M., ZUPO, S., AUGLIERA, A., BURGIO, V. L., MASSARA, R., 
MELAGRANA, A., COSTA, M., GROSSI, C. E., CHIORAZZI, N. & 
237 
 
FERRARINI, M. 1996b. Subepithelial B cells in the human palatine tonsil. II. 
Functional characterization. Eur J Immunol, 26, 2043-9. 
DORSHKIND, K. & MONTECINO-RODRIGUEZ, E. 2007. Fetal B-cell 
lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol, 7, 
213-9. 
DOUGHTY, C. A., BLEIMAN, B. F., WAGNER, D. J., DUFORT, F. J., MATARAZA, 
J. M., ROBERTS, M. F. & CHILES, T. C. 2006. Antigen receptor-mediated 
changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-
kinase signaling in the glycolytic control of growth. Blood, 107, 4458-4465. 
EKBERG, H., QI, Z., PAHLMAN, C., VERESS, B., BUNDICK, R. V., CRAGGS, R. 
I., HOLNESS, E., EDWARDS, S., MURRAY, C. M., FERGUSON, D., 
KERRY, P. J., WILSON, E. & DONALD, D. K. 2007. The specific 
monocarboxylate transporter-1 (MCT-1) inhibitor, AR-C117977, induces donor-
specific suppression, reducing acute and chronic allograft rejection in the rat. 
Transplantation, 84, 1191-9. 
EL-MABHOUH, A. A., AYRES, M. L., SHPALL, E. J., BALADANDAYUTHAPANI, 
V., KEATING, M. J., WIERDA, W. G. & GANDHI, V. 2014. Evaluation of 
bendamustine in combination with fludarabine in primary chronic lymphocytic 
leukemia cells. Blood. 
FAINT, J. M., TUNCER, C., GARG, A., ADAMS, D. H. & LALOR, P. F. 2011. 
Functional consequences of human lymphocyte cryopreservation: implications 
for subsequent interactions of cells with endothelium. J Immunother, 34, 588-96. 
FARAHANI, M., TREWEEKE, A. T., TOH, C. H., TILL, K. J., HARRIS, R. J., 
CAWLEY, J. C., ZUZEL, M. & CHEN, H. 2005. Autocrine VEGF mediates the 
antiapoptotic effect of CD154 on CLL cells. Leukemia, 19, 524-530. 
FERON, O. 2009. Pyruvate into lactate and back: from the Warburg effect to symbiotic 
energy fuel exchange in cancer cells. Radiotherapy and Oncology, 92, 329-333. 
FERRARINI, M. 2009. The continuing search for the cell of origin of chronic 
lymphocytic leukemia. 7th Meeting New Insights in Hematology, 3, 81-85. 
FU, Y. C., MAIANU, L., MELBERT, B. R. & GARVEY, W. T. 2004. Facilitative 
glucose transporter gene expression in human lymphocytes, monocytes, and 
macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and 
foam cell formation. Blood Cells Molecules and Diseases, 32, 182-190. 
GALLAGHER, S. M., CASTORINO, J. J., WANG, D. & PHILP, N. J. 2007. 
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to 
the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. 
Cancer Research, 67, 4182-4189. 
GARCIA-MANTEIGA, J. M., MARI, S., GODEJOHANN, M., SPRAUL, M., 
NAPOLI, C., CENCI, S., MUSCO, G. & SITIA, R. 2011. Metabolomics of B to 
plasma cell differentiation. Journal of Proteome Research, 10, 4165-4176. 
GAREDEW, A., ANDREASSI, C. & MONCADA, S. 2012. Mitochondrial dynamics, 
biogenesis, and function are coordinated with the cell cycle by APC/C-CDH1. 
Cell Metabolism, 15, 466-479. 
GHIA, P., CIRCOSTA, P., SCIELZO, C., VALLARIO, A., CAMPOREALE, A., 
GRANZIERO, L. & CALIGARIS-CAPPIO, F. 2005. Differential effects on 
238 
 
CLL cell survival exerted by different microenvironmental elements. Chronic 
Lymphocytic Leukemia, 294, 135-145. 
GOLDIN, L. R. & CAPORASO, N. E. 2007. Family studies in chronic lymphocytic 
leukaemia and other lymphoproliferative tumours. British Journal of 
Haematology, 139, 774-779. 
GONZALEZ, D., MARTINEZ, P., WADE, R., HOCKLEY, S., OSCIER, D., 
MATUTES, E., DEARDEN, C. E., RICHARDS, S. M., CATOVSKY, D. & 
MORGAN, G. J. 2011. Mutational status of the TP53 gene as a predictor of 
response and survival in patients with chronic lymphocytic leukemia: results 
from the LRF CLL4 trial. Journal of Clinical Oncology, 29, 2223-2229. 
GOTTARDI, D., ALFARANO, A., DE LEO, A. M., STACCHINI, A., BERGUI, L. & 
CALIGARIS-CAPPIO, F. 1995. Defective apoptosis due to bcl-2 overexpression 
may explain why B-CLL cells accumulate in G0. Current topics in microbiology 
and immunology, 194, 307-12. 
GRICKS, C. S., ZAHRIEH, D., ZAULS, A. J., GORGUN, G., DRANDI, D., 
MAUERER, K., NEUBERG, D. & GRIBBEN, J. G. 2004. Differential 
regulation of gene expression following CD40 activation of leukemic compared 
to healthy B cells. Blood, 104, 4002-9. 
GRIFFIN, D. O., HOLODICK, N. E. & ROTHSTEIN, T. L. 2011. Human B1 cells in 
umbilical cord and adult peripheral blood express the novel phenotype CD20+ 
CD27+ CD43+ CD70. J Exp Med, 208, 67-80. 
GUO, F.-C., WANG, L.-Q., ZHANG, J. & WANG, Y.-S. 2013. Study on the anti-Lewis 
lung carcinoma effect of metformin combined with MCT1 inhibitor CHC. 
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical 
science edition, 44, 375-8. 
HALESTRAP, A. P. & MEREDITH, D. 2004. The SLC16 gene family - from 
monocarboxylate transporters (MCTs) to aromatic amino acid transporters and 
beyond. Pflugers Archiv-European Journal of Physiology, 447, 619-628. 
HALESTRAP, A. P. & PRICE, N. T. 1999. The proton-linked monocarboxylate 
transporter (MCT) family: structure, function and regulation. Biochemical 
Journal, 343, 281-299. 
HALESTRAP, A. P. & WILSON, M. C. 2012. The monocarboxylate transporter family 
role and regulation. Iubmb Life, 64, 109-119. 
HALINA, A., ARTUR, P., BARBARA, M. K., JOANNA, S. & ANNA, D. 2010. 
Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 
expression associated with progression in B-CLL. Folia Histochem Cytobiol, 48, 
534-41. 
HALLAERT, D. Y., JASPERS, A., VAN NOESEL, C. J., VAN OERS, M. H., KATER, 
A. P. & ELDERING, E. 2008. c-Abl kinase inhibitors overcome CD40-mediated 
drug resistance in CLL: implications for therapeutic targeting of chemoresistant 
niches. Blood, 112, 5141-9. 
HALLEK, M. & EICHHORST, B. F. 2004. Chemotherapy combination treatment 
regimens with fludarabine in chronic lymphocytic leukemia. Hematology 
Journal, 5, S20-S30. 
HAMADA, S., HORIGUCHI, A., ASANO, T., KURODA, K., ASAKUMA, J., ITO, K., 
MIYAI, K. & IWAYA, K. 2014. Prognostic impact of fatty acid synthase 
239 
 
expression in upper urinary tract urothelial carcinoma. Jpn J Clin Oncol, 44, 
486-92. 
HAMBLIN, T. J. 2001. Achieving optimal outcomes in chronic lymphocytic leukaemia. 
Drugs, 61, 593-611. 
HAMILTON, E., PEARCE, L., MORGAN, L., ROBINSON, S., WARE, V., 
BRENNAN, P., THOMAS, N. S., YALLOP, D., DEVEREUX, S., FEGAN, C., 
BUGGINS, A. G. & PEPPER, C. 2012. Mimicking the tumour 
microenvironment: three different co-culture systems induce a similar phenotype 
but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. 
Br J Haematol, 158, 589-99. 
HAN, S., HATHCOCK, K., ZHENG, B., KELPER, T.B., HODES, R., & KELSOE, G. 
1995. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in 
established germinal centers. J Immunol, 155, 556-567. 
HARTMANN, S., AGOSTINELLI, C., DIENER, J., DOERING, C., FANTI, S., 
ZINZANI, P. L., GALLAMINI, A., BERGMANN, L., PILERI, S. & 
HANSMANN, M.-L. 2012. GLUT1 expression patterns in different Hodgkin 
lymphoma subtypes and progressively transformed germinal centers. Bmc 
Cancer, 12. 
HASHIMOTO, T., HUSSIEN, R., OOMMEN, S., GOHIL, K. & BROOKS, G. A. 2007. 
Lactate sensitive transcription factor network in L6 cells: activation of MCT1 
and mitochondrial biogenesis. Faseb Journal, 21, 2602-2612. 
HASSANEIN, M., HOEKSEMA, M. D., SHIOTA, M., QIAN, J., HARRIS, B. K., 
CHEN, H., CLARK, J. E., ALBORN, W. E., EISENBERG, R. & MASSION, P. 
P. 2013. SLC1A5 mediates glutamine transport required for lung cancer cell 
growth and survival. Clin Cancer Res, 19, 560-70. 
HAYDEN, R. E., PRATT, G., DAVIES, N. J., KHANIM, F. L., BIRTWISTLE, J., 
DELGADO, J., PEARCE, C., SANT, T., DRAYSON, M. T. & BUNCE, C. M. 
2009. Treatment of primary CLL cells with bezafibrate and 
medroxyprogesterone acetate induces apoptosis and represses the pro-
proliferative signal of CD40-ligand, in part through increased 15d 
Delta(12,14,)PGJ(2). Leukemia, 23, 292-304. 
HAYDEN, R. E., PRATT, G., DRAYSON, M. T. & BUNCE, C. M. 2010. Lycorine 
sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to 
bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib 
does not overcome reported CD40-mediated drug resistance. Haematologica, 95, 
1889-96. 
HE, Y., JIANG, X. & CHEN, J. 2013. The role of miR-150 in normal and malignant 
hematopoiesis. Oncogene, 1-7. 
HENDRIKS, R. W., YUVARAJ, S. & KIL, L. P. 2014. Targeting Bruton's tyrosine 
kinase in B cell malignancies. Nature Reviews Cancer, 14, 219-232. 
HILLMEN, P. 2004. Advancing therapy for chronic lymphocytic leukemia - The role of 
rituximab. Seminars in Oncology, 31, 22-26. 
HO, A. D., FIEHN, W. & HUNSTEIN, W. 1982. Intracellular lactic dehydrogenase and 
phosphohexose isomerase activity in leukemia and malignant lymphoma. British 
Journal of Haematology, 50, 637-645. 
240 
 
HOWLADER, N., NOONE, A., KRAPCHO, M., GARSHELL, J., NEYMAN, N., 
ALTEKRUSE, S., KOSARY, C., YU, M., RUHL, J., TATALOVICH, Z., CHO, 
H., MARIOTTO, A., LEWIS, D., CHEN, H., FEUER, E. & CRONIN, K. E. 
2012. SEER Cancer Statistics Review 1975-2010 [Online]. Bethesda, MD.  
[Accessed 12.9.13 2013]. 
JIANG, S., ZHANG, L.-F., ZHANG, H.-W., HU, S., LU, M.-H., LIANG, S., LI, B., LI, 
Y., LI, D., WANG, E.-D. & LIU, M.-F. 2012. A novel miR-155/miR-143 
cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. 
Embo Journal, 31, 1985-1998. 
JITSCHIN, R., HOFMANN, A. D., BRUNS, H., GIESSL, A., BRICKS, J., BERGER, 
J., SAUL, D., ECKART, M. J., MACKENSEN, A. & MOUGIAKAKOS, D. 
2014. Mitochondrial metabolism contributes to oxidative stress and reveals 
therapeutic targets in chronic lymphocytic leukemia. Blood, 123, 2663-72. 
JONES, R. V., GOFFI, G. P. & HUTT, M. S. 1962. Lymphocyte glycogen content in 
various diseases. Journal of Clinical Pathology, 15, 36-9. 
JOSE, C., BELLANCE, N. & ROSSIGNOL, R. 2011. Choosing between glycolysis and 
oxidative phosphorylation: a tumor's dilemma? Biochimica Et Biophysica Acta-
Bioenergetics, 1807, 552-561. 
KARAM, M., NOVAK, L., CYRIAC, J., ALI, A., NAZEER, T. & NUGENT, F. 2006. 
Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in 
the evaluation and follow-up of patients with low-grade lymphomas. Cancer, 
107, 175-183. 
KASINRERK, W., PENG-IN, P., KHUNKAEWLA, P. & CHIAMPANICHAYAKUL, 
S. 2006. CD147 contains different bioactive epitopes involving the regulation of 
cell adhesion and lymphocyte activation. Journal of Immunology, 176, S210-
S211. 
KENNEDY, K. M. & DEWHIRST, M. W. 2010a. Tumor metabolism of lactate: the 
influence and therapeutic potential for MCT and CD147 regulation. Future 
Oncol, 6, 127-48. 
KENNEDY, K. M. & DEWHIRST, M. W. 2010b. Tumor metabolism of lactate: the 
influence and therapeutic potential for MCT and CD147 regulation. Future 
Oncology, 6, 127-148. 
KIM, H. S., MASKO, E. M., POULTON, S. L., KENNEDY, K. M., PIZZO, S. V., 
DEWHIRST, M. W. & FREEDLAND, S. J. 2012. Carbohydrate restriction and 
lactate transporter inhibition in a mouse xenograft model of human prostate 
cancer. BJU Int, 110, 1062-9. 
KIRK, P., WILSON, M. C., HEDDLE, C., BROWN, M. H., BARCLAY, A. N. & 
HALESTRAP, A. P. 2000. CD147 is tightly associated with lactate transporters 
MCT1 and MCT4 and facilitates their cell surface expression. Embo Journal, 19, 
3896-3904. 
KITADA, S., ANDERSEN, J., AKAR, S., ZAPATA, J. M., TAKAYAMA, S., 
KRAJEWSKI, S., WANG, H. G., ZHANG, X., BULLRICH, F., CROCE, C. M., 
RAI, K., HINES, J. & REED, J. C. 1998. Expression of apoptosis-regulating 
proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo 
chemoresponses. Blood, 91, 3379-3389. 
241 
 
KLEIN, U., TU, Y., STOLOVITZKY, G. A., MATTIOLI, M., CATTORETTI, G., 
HUSSON, H., FREEDMAN, A., INGHIRAMI, G., CRO, L., BALDINI, L., 
NERI, A., CALIFANO, A. & DALLA-FAVERA, R. 2001. Gene expression 
profiling of B cell chronic lymphocytic leukemia reveals a homogeneous 
phenotype related to memory B cells. J Exp Med, 194, 1625-38. 
KOCH, C., STAFFLER, G., HUTTINGER, R., HILGERT, I., PRAGER, E., CERNY, 
J., STEINLEIN, P., MAJDIC, O., HOREJSI, V. & STOCKINGER, H. 1999. T 
cell activation-associated epitopes of CD147 in regulation of the T cell response, 
and their definition by antibody affinity and antigen density. International 
Immunology, 11, 777-786. 
KOMINSKY, D. J., CAMPBELL, E. L. & COLGAN, S. P. 2010. Metabolic shifts in 
immunity and inflammation. Journal of Immunology, 184, 4062-4068. 
KRYSOV, S., POTTER, K. N., MOCKRIDGE, C. I., COELHO, V., WHEATLEY, I., 
PACKHAM, G. & STEVENSON, F. K. 2010. Surface IgM of CLL cells 
displays unusual glycans indicative of engagement of antigen in vivo. Blood, 
115, 4198-4205. 
KUMAR, A., KANT, S. & SINGH, S. M. 2013. alpha-Cyano-4-hydroxycinnamate 
induces apoptosis in Dalton's lymphoma cells: role of altered cell survival-
regulatory mechanisms. Anticancer Drugs, 24, 158-71. 
LAMBERT, D. W., WOOD, I. S., ELLIS, A. & SHIRAZI-BEECHEY, S. P. 2002. 
Molecular changes in the expression of human colonic nutrient transporters 
during the transition from normality to malignancy. British Journal of Cancer, 
86, 1262-1269. 
LANDGREN, O., RAPKIN, J. S., CAPORASO, N. E., MELLEMKJAER, L., 
GRIDLEY, G., GOLDIN, L. R. & ENGELS, E. A. 2007. Respiratory tract 
infections and subsequent risk of chronic lymphocytic leukemia. Blood, 109, 
2198-2201. 
LARSEN, S., WRIGHT-PARADIS, C., GNAIGER, E., HELGE, J. W. & BOUSHEL, 
R. 2012. Cryopreservation of human skeletal muscle impairs mitochondrial 
function. Cryo Letters, 33, 170-6. 
LEBIEN, T. W. & TEDDER, T. F. 2008. B lymphocytes: how they develop and 
function. Blood, 112, 1570-1580. 
LEONTIEVA, O. V., NATARAJAN, V., DEMIDENKO, Z. N., BURDELYA, L. G., 
GUDKOV, A. V. & BLAGOSKLONNY, M. V. 2012. Hypoxia suppresses 
conversion from proliferative arrest to cellular senescence. Proceedings of the 
National Academy of Sciences of the United States of America, 109, 13314-
13318. 
LIN, R. Y., VERA, J. C., CHAGANTI, R. S. & GOLDE, D. W. 1998a. Human 
monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J 
Biol Chem, 273, 28959-65. 
LIN, R. Y., VERA, J. C., CHAGANTI, R. S. K. & GOLDE, D. W. 1998b. Human 
monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. 
Journal of Biological Chemistry, 273, 28959-28965. 
LINET, M. S., SCHUBAUER-BERIGAN, M. K., WEISENBURGER, D. D., 
RICHARDSON, D. B., LANDGREN, O., BLAIR, A., SILVER, S., FIELD, R. 
W., CALDWELL, G., HATCH, M. & DORES, G. M. 2007. Chronic 
242 
 
lymphocytic leukaemia: an overview of aetiology in light of recent developments 
in classification and pathogenesis. British Journal of Haematology, 139, 672-
686. 
LIU, A. G., HU, Q., TAO, H. F., LIU, S. Y., ZHANG, L. Q. & HU, Y. 2009. 
[Expression of CD147 and matrix metalloproteinase-9 in children with non-
Hodgkin's lymphoma and its correlation with prognosis]. Zhonghua Er Ke Za 
Zhi, 47, 785-8. 
LONG, Q. Q., YI, Y. X., QIU, J., XU, C. J. & HUANG, P. L. 2014. Fatty acid synthase 
(FASN) levels in serum of colorectal cancer patients: correlation with clinical 
outcomes. Tumour Biol, 35, 3855-9. 
MACINTYRE, D. A., JIMÉNEZ, B., LEWINTRE, E. J., MARTÍN, C. R., SCHÄFER, 
H., BALLESTEROS, C. G., MAYANS, J. R., SPRAUL, M., GARCÍA-CONDE, 
J. & PINEDA-LUCENA, A. 2010. Serum metabolome analysis by 1H-NMR 
reveals differences between chronic lymphocytic leukaemia molecular 
subgroups. Leukemia, 24, 788-797. 
MANSOUR, T. E. 1963. Studies on heart phosphofructokinase purification, inhibition 
and activation. Journal of Biological Chemistry, 238, 2285-&. 
MARTINEZ-OUTSCHOORN, U. E., CURRY, J. M., KO, Y. H., LIN, Z., TULUC, M., 
COGNETTI, D., BIRBE, R. C., PRIBITKIN, E., BOMBONATI, A., PESTELL, 
R. G., HOWELL, A., SOTGIA, F. & LISANTI, M. P. 2013. Oncogenes and 
inflammation rewire host energy metabolism in the tumor microenvironment: 
RAS and NFkappaB target stromal MCT4. Cell Cycle, 12, 2580-97. 
MARTINEZ-OUTSCHOORN, U. E., LIN, Z., TRIMMER, C., FLOMENBERG, N., 
WANG, C., PAVLIDES, S., PESTELL, R. G., HOWELL, A., SOTGIA, F. & 
LISANTI, M. P. 2011. Cancer cells metabolically "fertilize" the tumor 
microenvironment with hydrogen peroxide, driving the Warburg effect 
Implications for PET imaging of human tumors. Cell Cycle, 10, 2504-2520. 
MELCHERS, F. 2005. B cell development and its deregulation to transformed states at 
the pre-B cell receptor-expressing pre-BII cell stage. Curr Top Microbiol 
Immunol, 294, 1-17. 
MELLMAN, I. & NELSON, W. J. 2008. Coordinated protein sorting, targeting and 
distribution in polarized cells. Nature Reviews Molecular Cell Biology, 9, 833-
845. 
MENENDEZ, J. A. & LUPU, R. 2007. Fatty acid synthase and the lipogenic phenotype 
in cancer pathogenesis. Nat Rev Cancer, 7, 763-77. 
MEREZHINSKAYA, N., OGUNWUYI, S. A., MULLICK, F. G. & FISHBEIN, W. N. 
2004. Presence and localization of three lactic acid transporters (MCT1, -2, and -
4) in separated human granulocytes, lymphocytes, and monocytes. Journal of 
Histochemistry & Cytochemistry, 52, 1483-1493. 
MESSMER, B. T., ALBESIANO, E., EFREMOV, D. G., GHIOTTO, F., ALLEN, S. L., 
KOLITZ, J., FOA, R., DAMLE, R. N., FAIS, F., MESSMER, D., RAI, K. R., 
FERRARINI, M. & CHIORAZZI, N. 2004. Multiple distinct sets of stereotyped 
antigen receptors indicate a role for antigen in promoting chronic lymphocytic 
leukemia. Journal of Experimental Medicine, 200, 519-525. 
MESSMER, B. T., MESSMER, D., ALLEN, S. L., KOLITZ, J. E., KUDALKAR, P., 
CESAR, D., MURPHY, E. J., KODURU, P., FERRARINI, M., ZUPO, S., 
243 
 
CUTRONA, G., DAMLE, R. N., WASIL, T., RAI, K. R., HELLERSTEIN, M. 
K. & CHIORAZZI, N. 2005. In vivo measurements document the dynamic 
cellular kinetics of chronic lymphocytic leukemia B cells. Journal of Clinical 
Investigation, 115, 755-764. 
MICHALEK, R. D. & RATHMELL, J. C. 2010. The metabolic life and times of a T-
cell. Immunological Reviews, 236, 190-202. 
MIRANDA-GONCALVES, V., HONAVAR, M., PINHEIRO, C., MARTINHO, O., 
PIRES, M. M., PINHEIRO, C., CORDEIRO, M., BEBIANO, G., COSTA, P., 
PALMEIRIM, I., REIS, R. M. & BALTAZAR, F. 2013. Monocarboxylate 
transporters (MCTs) in gliomas: expression and exploitation as therapeutic 
targets. Neuro-Oncology, 15, 172-188. 
MITUS, W. J., BERGNA, L. J., MEDNICOFF, I. B. & DAMESHEK, W. 1958. 
Cytochemical studies of glycogen content of lymphocytes in lymphocytic 
proliferations. Blood, 13, 748-756. 
MOLICA, S. & ALBERTI, A. 1987. Prognostic value of the lymphocyte doubling time 
in chronic lymphocytic leukemia. Cancer, 60, 2712-2716. 
MONTSERRAT, E., SANCHEZ-BISONO, J., VINOLAS, N. & ROZMAN, C. 1986. 
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its 
prognostic significance. Br J Haematol, 62, 567-75. 
MORAN, E. C., KAMIGUTI, A. S., CAWLEY, J. C. & PETTITT, A. R. 2002. 
Cytoprotective antioxidant activity of serum albumin and autocrine catalase in 
chronic lymphocytic leukaemia. British Journal of Haematology, 116, 316-328. 
MOREAU, E. J., MATUTES, E., A'HERN, R. P., MORILLA, A. M., MORILLA, R. 
M., OWUSU-ANKOMAH, K. A., SEON, B. K. & CATOVSKY, D. 1997. 
Improvement of the chronic lymphocytic leukemia scoring system with the 
monoclonal antibody SN8 (CD79b). Am J Clin Pathol, 108, 378-82. 
MORRIS, M. E. & FELMLEE, M. A. 2008. Overview of the proton-coupled MCT 
(SLC16A) family of transporters: characterization, function and role in the 
transport of the drug of abuse gamma-hydroxybutyric acid. Aaps Journal, 10, 
311-321. 
MORRISON, V. A. 2010. Infectious complications of chronic lymphocytic leukaemia: 
pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin 
Haematol, 23, 145-53. 
MURRAY, C. M., HUTCHINSON, R., BANTICK, J. R., BELFIELD, G. P., 
BENJAMIN, A. D., BRAZMA, D., BUNDICK, R. V., COOK, I. D., CRAGGS, 
R. I., EDWARDS, S., EVANS, L. R., HARRISON, R., HOLNESS, E., 
JACKSON, A. P., JACKSON, C. G., KINGSTON, L. P., PERRY, M. W. D., 
ROSS, A. R. J., RUGMAN, P. A., SIDHU, S. S., SULLIVAN, M., TAYLOR-
FISHWICK, D. A., WALKER, P. C., WHITEHEAD, Y. M., WILKINSON, D. 
J., WRIGHT, A. & DONALD, D. K. 2005. Monocarboxylate transporter MCT1 
is a target for immunosuppression. Nature Chemical Biology, 1, 371-376. 
MUSOLINO, C., ALONCI, A., ALLEGRA, A., DICESARE, E., ORLANDO, A., 
GROSSO, P., BUDA, G. & SQUADRITO, G. 1992. Intracellular and serum 
levels of aldolase activity in B chronic lymphocytic leukemia. International 
Journal of Hematology, 56, 213-217. 
244 
 
NABESHIMA, K., SUZUMIYA, J., NAGANO, M., OHSHIMA, K., TOOLE, B. P., 
TAMURA, K., IWASAKI, H. & KIKUCHI, M. 2004. Emmprin, a cell surface 
inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas. 
J Pathol, 202, 341-51. 
NAGASAWA, T. 2006. Microenvironmental niches in the bone marrow required for B-
cell development. Nat Rev Immunol, 6, 107-16. 
NOWAKOWSKI, G. S., HOYER, J. D., SHANAFELT, T. D., GEYER, S. M., 
LAPLANT, B. R., CALL, T. G., JELINEK, D. F., ZENT, C. S. & KAY, N. E. 
2007. Using smudge cells on routine blood smears to predict clinical outcome in 
chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin 
Proc, 82, 449-53. 
NUTT, S. L. & KEE, B. L. 2007. The transcriptional regulation of B cell lineage 
commitment. Immunity, 26, 715-725. 
O'BRIEN, S. M., KANTARJIAN, A. M., CORTES, J., BERAN, M., KOLLER, C. A., 
GILES, F. J., LERNER, S. & KEATING, M. 2001. Results of the fludarabine 
and cyclophosphamide combination regimen in chronic lymphocytic leukemia. 
Journal of Clinical Oncology, 19, 1414-1420. 
OKKENHAUG, K. & VANHAESEBROECK, B. 2003. PI3K in lymphocyte 
development, differentiation and activation. Nat Rev Immunol, 3, 317-30. 
OSCIER, D., DEARDEN, C., EREM, E., FEGAN, C., FOLLOWS, G., HILLMEN, P., 
ILLIDGE, T., MATUTES, E., MILLIGAN, D. W., PETTITT, A., SCHUH, A., 
WIMPERIS, J. & BRITISH COMM STAND, H. 2012. Guidelines on the 
diagnosis, investigation and management of chronic lymphocytic leukaemia. 
British Journal of Haematology, 159, 541-564. 
OSCIER, D., FEGAN, C., HILLMEN, P., ILLIDGE, T., JOHNSON, S., MAGUIRE, P., 
MATUTES, E. & MILLIGAN, D. 2004. Guidelines on the diagnosis and 
management of chronic lymphocytic leukaemia. British Journal of Haematology, 
125, 294-317. 
PASCUTTI, M. F., JAK, M., TROMP, J. M., DERKS, I. A. M., REMMERSWAAL, E. 
B. M., THIJSSEN, R., VAN ATTEKUM, M. H. A., VAN BOCHOVE, G. G., 
LUIJKS, D. M., PALS, S. T., VAN LIER, R. A. W., KATER, A. P., VAN 
OERS, M. H. J. & ELDERING, E. 2013. IL-21 and CD40L signals from 
autologous T cells can induce antigen-independent proliferation of CLL cells. 
Blood, 122, 3010-3019. 
PATTEN, P. E. M., BUGGINS, A. G. S., RICHARDS, J., WOTHERSPOON, A., 
SALISBURY, J., MUFTI, G. J., HAMBLIN, T. J. & DEVEREUX, S. 2008. 
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor 
microenvironment. Blood, 111, 5173-5181. 
PEPPER, C., HOY, T. & BENTLEY, D. P. 1997. Bcl-2/Bax ratios in chronic 
lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical 
resistance. British Journal of Cancer, 76, 935-938. 
PEREZ-VERA, P., REYES-LEON, A. & FUENTES-PANANA, E. M. 2011. Signaling 
proteins and transcription factors in normal and malignant early B cell 
development. Bone marrow research, 2011, 502751-502751. 
PERTEGA-GOMES, N., VIZCAINO, J. R., MIRANDA-GONCALVES, V., 
PINHEIRO, C., SILVA, J., PEREIRA, H., MONTEIRO, P., HENRIQUE, R. 
245 
 
M., REIS, R. M., LOPES, C. & BALTAZAR, F. 2011. Monocarboxylate 
transporter 4 (MCT4) and CD147 overexpression is associated with poor 
prognosis in prostate cancer. Bmc Cancer, 11. 
PETTITT, A. R., SHERRINGTON, P. D. & CAWLEY, J. C. 1999. The effect of p53 
dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. 
British Journal of Haematology, 106, 1049-1051. 
PINHEIRO, C., ALBERGARIA, A., PAREDES, J., SOUSA, B., DUFLOTH, R., 
VIEIRA, D., SCHMITT, F. & BALTAZAR, F. 2010. Monocarboxylate 
transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology, 56, 
860-867. 
PINHEIRO, C., LONGATTO-FILHO, A., AZEVEDO-SILVA, J., CASAL, M., 
SCHMITT, F. C. & BALTAZAR, F. 2012. Role of monocarboxylate 
transporters in human cancers: state of the art. Journal of Bioenergetics and 
Biomembranes, 44, 127-139. 
PINHEIRO, C., LONGATTO-FILHO, A., SIMOES, K., JACOB, C. E., CALDAS 
BRESCIANI, C. J., ZILBERSTEIN, B., CECCONELLO, I., FERREIRA 
ALVES, V. A., SCHMITT, F. & BALTAZAR, F. 2009. The prognostic value of 
CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-
expression in gastric cancer. European Journal of Cancer, 45, 2418-2424. 
PLEYER, L., EGLE, A., HARTMANN, T. N. & GREIL, R. 2009. Molecular and 
cellular mechanisms of CLL: novel therapeutic approaches. Nature Reviews 
Clinical Oncology, 6, 405-418. 
POLANSKI, R., HODGKINSON, C. L., FUSI, A., NONAKA, D., PRIEST, L., 
KELLY, P., TRAPANI, F., BISHOP, P. W., WHITE, A., CRITCHLOW, S. E., 
SMITH, P. D., BLACKHALL, F., DIVE, C. & MORROW, C. J. 2014. Activity 
of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung 
Cancer. Clin Cancer Res, 20, 926-37. 
PUT, N., VAN ROOSBROECK, K., KONINGS, P., MEEUS, P., BRUSSELMANS, C., 
RACK, K., GERVAIS, C., NGUYEN-KHAC, F., CHAPIRO, E., RADFORD-
WEISS, I., STRUSKI, S., DASTUGUE, N., GACHARD, N., LEFEBVRE, C., 
BARIN, C., ECLACHE, V., FERT-FERRER, S., LAIBE, S., 
MOZZICONACCI, M. J., QUILICHINI, B., POIREL, H. A., WLODARSKA, I., 
HAGEMEIJER, A., MOREAU, Y., VANDENBERGHE, P. & MICHAUX, L. 
2012. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC 
translocations: a subgroup with an aggressive disease course. Ann Hematol, 91, 
863-73. 
RAHMAN, B., SCHNEIDER, H. P., BROER, A., DEITMER, J. W. & BROER, S. 
1999. Helix 8 and helix 10 are involved in substrate recognition in the rat 
monocarboxylate transporter MCT1. Biochemistry, 38, 11577-11584. 
RAI, K. R., SAWITSKY, A., CRONKITE, E. P., CHANANA, A. D., LEVY, R. N. & 
PASTERNACK, B. S. 1975. Clinical staging of chronic lymphocytic leukemia. 
Blood, 46, 219-34. 
RAMPAZZO, E., BONALDI, L., TRENTIN, L., VISCO, C., KEPPEL, S., GIUNCO, 
S., FREZZATO, F., FACCO, M., NOVELLA, E., GIARETTA, I., DEL 
BIANCO, P., SEMENZATO, G. & DE ROSSI, A. 2012. Telomere length and 
telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia 
246 
 
with different biological characteristics and clinical outcomes. Haematologica-
the Hematology Journal, 97, 56-63. 
RAMSAY, A. D. & RODRIGUEZ-JUSTO, M. 2013. Chronic lymphocytic leukaemia - 
the role of the microenvironment pathogenesis and therapy. British Journal of 
Haematology, 162, 15-24. 
REFAELI, Y., YOUNG, R. M., TURNER, B. C., DUDA, J., FIELD, K. A. & BISHOP, 
J. M. 2008. The B cell antigen receptor and overexpression of MYC can 
cooperate in the genesis of B cell lymphomas. PLoS Biol, 6, e152. 
REGO, N., BIANCHI, S., MORENO, P., PERSSON, H., KVIST, A., PENA, A., 
OPPEZZO, P., NAYA, H., ROVIRA, C., DIGHIERO, G. & PRITSCH, O. 2012. 
Search for an aetiological virus candidate in chronic lymphocytic leukaemia by 
extensive transcriptome analysis. Br J Haematol, 157, 709-17. 
REITZER, L. J., WICE, B. M. & KENNELL, D. 1979. Evidence that glutamine, not 
sugar, is the major energy source for cultured HELA cells. Journal of Biological 
Chemistry, 254, 2669-2676. 
RICCIARDI, M. R., PETRUCCI, M. T., GREGORJ, C., ARIOLA, C., LEMOLI, R. M., 
FOGLI, M., MAURO, F. R., CERRETTI, R., FOA, R., MANDELLI, F. & 
TAFURI, A. 2001. Reduced susceptibility to apoptosis correlates with kinetic 
quiescence in disease progression of chronic lymphocytic leukaemia. British 
Journal of Haematology, 113, 391-399. 
RODRIGUEZ, D., RAMSAY, A. J., QUESADA, V., GARABAYA, C., CAMPO, E., 
FREIJE, J. M. P. & LOPEZ-OTIN, C. 2013. Functional analysis of sucrase-
isomaltase mutations from chronic lymphocytic leukemia patients. Human 
Molecular Genetics, 22, 2273-2282. 
ROSEN, A., BERGH, A. C., GOGOK, P., EVALDSSON, C., MYHRINDER, A. L., 
HELLQVIST, E., RASUL, A., BJORKHOLM, M., JANSSON, M., 
MANSOURI, L., LIU, A., TEH, B. T., ROSENQUIST, R. & KLEIN, E. 2012. 
Lymphoblastoid cell line with B1 cell characteristics established from a chronic 
lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology, 1, 18-
27. 
ROSILIO, C., BEN-SAHRA, I., BOST, F. & PEYRON, J. F. 2014. Metformin: A 
metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer 
Lett, 346, 188-96. 
ROSSI, D. & GAIDANO, G. 2010. Biological and clinical significance of stereotyped 
B-cell receptors in chronic lymphocytic leukemia. Haematologica, 95, 1992-5. 
SCIELZO, C., APOLLONIO, B., SCARFO, L., JANUS, A., MUZIO, M., TEN 
HACKEN, E., GHIA, P. & CALIGARIS-CAPPIO, F. 2011. The functional in 
vitro response to CD40 ligation reflects a different clinical outcome in patients 
with chronic lymphocytic leukemia. Leukemia, 25, 1760-1767. 
SEIFERT, M., SELLMANN, L., BLOEHDORN, J., WEIN, F., STILGENBAUER, S., 
DUERIG, J. & KUEPPERS, R. 2012. Cellular origin and pathophysiology of 
chronic lymphocytic leukemia. Journal of Experimental Medicine, 209, 2183-
2198. 
SHACHAR, I., COHEN, S., MAROM, A. & BECKER-HERMAN, S. 2012. Regulation 




SHERBORNE, A. L. & HOULSTON, R. S. 2010. What are genome-wide association 
studies telling us about B-cell tumor development? Oncotarget, 1, 367-372. 
SHI, B., HSU, H. L., EVENS, A. M., GORDON, L. I. & GARTENHAUS, R. B. 2003. 
Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid 
malignancies. Blood, 102, 297-302. 
SHIM, C. K., CHEON, E. P., KANG, K. W., SEO, K. S. & HAN, H. K. 2007. 
Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in 
Caco-2 cells. J Pharm Pharmacol, 59, 1515-9. 
SLOAN, E. J. & AYER, D. E. 2010. Myc, mondo, and metabolism. Genes & cancer, 1, 
587-96. 
SMOLEJ, L., DOUBEK, M., PANOVSKA, A., SIMKOVIC, M., BRYCHTOVA, Y., 
BELADA, D., MOTYCKOVA, M. & MAYER, J. 2012. Rituximab in 
combination with high-dose dexamethasone for the treatment of 
relapsed/refractory chronic lymphocytic leukemia. Leuk Res, 36, 1278-82. 
SONVEAUX, P., VEGRAN, F., SCHROEDER, T., WERGIN, M. C., VERRAX, J., 
RABBANI, Z. N., DE SAEDELEER, C. J., KENNEDY, K. M., DIEPART, C., 
JORDAN, B. F., KELLEY, M. J., GALLEZ, B., WAHL, M. L., FERON, O. & 
DEWHIRST, M. W. 2008. Targeting lactate-fueled respiration selectively kills 
hypoxic tumor cells in mice. Journal of Clinical Investigation, 118, 3930-3942. 
SPANER, D. E., LEE, E., SHI, Y., WEN, F., LI, Y., TUNG, S., MCCAW, L., WONG, 
K., GARY-GOUY, H., DALLOUL, A., CEDDIA, R. & GORZCYNSKI, R. 
2013. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. 
Leukemia, 27, 1090-1099. 
SU, J., CHEN, X. & KANEKURA, T. 2009. A CD147-targeting siRNA inhibits the 
proliferation, invasiveness and VEGF production of human malignant melanoma 
cells by down-regulating glycolysis. Cancer Letters, 273, 140-147. 
TAUSCH, E., MERTENS, D., & STILGENBAUER, S. 2014. Advances in treating 
chronic lymphocytic leukaemia. F1000Prime Rep, 6, 65. 
TEMBHARE, P. R., MARTI, G., WIESTNER, A., DEGHEIDY, H., FAROOQUI, M., 
KREITMAN, R. J., JASPER, G. A., YUAN, C. M., LIEWEHR, D., VENZON, 
D. & STETLER-STEVENSON, M. 2013. Quantification of expression of 
antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. 
Am J Clin Pathol, 140, 813-8. 
THORNS, C., FELLER, A. C. & MERZ, H. 2002. EMMPRIN (CD 174) is expressed in 
Hodgkin's lymphoma and anaplastic large cell lymphoma. An 
immunohistochemical study of 60 cases. Anticancer Res, 22, 1983-6. 
TIDMARSH, G. F., TANNER, L. I., O'CONNOR, J., ENG, C. & MORDEC, K. 2004. 
Effect of 2-deoxyglucose, a glycolytic Inhibitor, on the ATP levels and viability 
of B lymphocytes from subjects with chronic lymphocytic leukemia (CLL). ASH 
Annual Meeting Abstracts, 104, 4810-. 
TILI, E., MICHAILLE, J.-J., LUO, Z., VOLINIA, S., RASSENTI, L. Z., KIPPS, T. J. & 
CROCE, C. M. 2012. The down-regulation of miR-125b in chronic lymphocytic 
leukemias leads to metabolic adaptation of cells to a transformed state. Blood, 
120, 2631-2638. 
TORRES DE OLIVEIRA, A. T., PINHEIRO, C., LONGATTO-FILHO, A., BRITO, M. 
J., MARTINHO, O., MATOS, D., CARVALHO, A. L., VAZQUEZ, V. L., 
248 
 
SILVA, T. B., SCAPULATEMPO, C., SAAD, S. S., REIS, R. M. & 
BALTAZAR, F. 2012. Co-expression of monocarboxylate transporter 1 (MCT1) 
and its chaperone (CD147) is associated with low survival in patients with 
gastrointestinal stromal tumors (GISTs). Journal of Bioenergetics and 
Biomembranes, 44, 171-178. 
TRUSAL, L. R., GUZMAN, A. W. & BAKER, C. J. 1984. Characterization of Freeze-
Thaw Induced Ultrastructural Damage to Endothelial Cells in vitro. In Vitro, 20, 
353-364. 
TSUTSAEVA, A. A. & GORDIENKO, A. D. 1982. [Respiration activity of frozen-
thawed lymphoid cells]. Ukr Biokhim Zh, 54, 89-92. 
TUNG, S., SHI, Y., WONG, K., ZHU, F., GORCZYNSKI, R., LAISTER, R. C., 
MINDEN, M., BLECHERT, A. K., GENZEL, Y., REICHL, U. & SPANER, D. 
E. 2013. PPARalpha and fatty acid oxidation mediate glucocorticoid resistance 
in chronic lymphocytic leukemia. Blood, 122, 969-80. 
TURA, S., CAVO, M., GOBBI, M. & FRANCHI, P. 1984. Lonidamine in the treatment 
of chronic lymphocytic leukemia. Oncology, 41, 90-93. 
TWOMEY, B., MUID, R. E. & DALE, M. M. 1990. The effect of putative protein 
kinase C inhibitors, K252A and staurosporine, on the human neutrophil 
respiratiory burst activated by both receptor stimulation and post-receptor 
mechanisms. British Journal of Pharmacology, 100, 819-825. 
ULLAH, M. S., DAVIES, A. J. & HALESTRAP, A. P. 2006. The plasma membrane 
lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a 
HIF-1 alpha-dependent mechanism. Journal of Biological Chemistry, 281, 9030-
9037. 
VALCOURT, J. R., LEMONS, J. M. S., HALEY, E. M., KOJIMA, M., DEMUREN, O. 
O. & COLLER, H. A. 2012. Staying alive: metabolic adaptations to quiescence. 
Cell Cycle, 11, 1680-1696. 
VAN GENT, R., KATER, A. P., OTTO, S. A., JASPERS, A., BORGHANS, J. A. M., 
VRISEKOOP, N., ACKERMANS, M. A. T., RUITER, A. F. C., WITTEBOL, 
S., ELDERING, E., VAN OERS, M. H. J., TESSELAAR, K., KERSTEN, M. J. 
& MIEDEMA, F. 2008. In vivo dynamics of stable chronic lymphocytic 
leukemia inversely correlate with somatic hypermutation levels and suggest no 
major leukemic turnover in bone marrow. Cancer Research, 68, 10137-10144. 
VANDER HEIDEN, M. G., CANTLEY, L. C. & THOMPSON, C. B. 2009. 
Understanding the Warburg effect: the metabolic requirements of cell 
proliferation. Science (New York, N.Y.), 324, 1029-33. 
VANGEEPURAM, N., ONG, G. L. & MATTES, M. J. 1997. Processing of antibodies 
bound to B-cell lymphomas and lymphoblastoid cell lines. Cancer, 80, 2425-
2430. 
VILPO, J., TOBIN, G., HULKKONEN, J., HURME, M., THUNBERG, U., 
SUNDSTROM, C., VILPO, L. & ROSENQUIST, R. 2005. Mitogen induced 
activation, proliferation and surface antigen expression patterns in unmutated 
and hypermutated chronic lymphocytic leukemia cells. European Journal of 
Haematology, 75, 34-40. 
249 
 
VISSER, W. E., FRIESEMA, E. C. H., JANSEN, J. & VISSER, T. J. 2007. Thyroid 
hormone transport by monocarboxylate transporters. Best Practice & Research 
Clinical Endocrinology & Metabolism, 21, 223-236. 
VIVES CORRONS, J. L., COLOMER, D., PUJADES, A., MATUTES, E., PASTOR, 
C. & AYMERICH, M. 1989. Relationship between lymphocyte size and enzyme 
activities in two morphological variants of B chronic lymphocytic leukemia. 
Acta Haematologica (Basel), 82, 22-26. 
VOUSDEN, K. H. 2010. Alternative fuel-another role for p53 in the regulation of 
metabolism. Proceedings of the National Academy of Sciences of the United 
States of America, 107, 7117-7118. 
VOUSDEN, K. H. & RYAN, K. M. 2009. p53 and metabolism. Nature Reviews 
Cancer, 9, 691-700. 
WARBURG, O., POSENER, K. & NEGELEIN, E. 1924. On the metabolism of 
carcinoma cells. Biochemische Zeitschrift, 152, 309-344. 
WILLIMOTT, S., BAOU, M., NARESH, K. & WAGNER, S. D. 2007. CD154 induces 
a switch in pro-survival Bcl-2 family members in chronic lymphocytic 
leukaemia. British Journal of Haematology, 138, 721-732. 
WILLIMOTT, S. & WAGNER, S. D. 2012. Stromal cells and CD40 ligand (CD154) 
alter the miRNome and induce miRNA clusters including, miR-125b/miR-
99a/let-7c and miR-17-92 in chronic lymphocytic leukaemia. Leukemia, 26, 
1113-1116. 
WOODS, B., HAWKINS, N., DUNLOP, W., O'TOOLE, A. & BRAMHAM-JONES, S. 
2012. Bendamustine versus chlorambucil for the first-line treatment of chronic 
lymphocytic leukemia in England and Wales: a cost-utility analysis. Value 
Health, 15, 759-70. 
XIE, J., WANG, B. S., YU, D. H., LU, Q., MA, J., QI, H., FANG, C. & CHEN, H. Z. 
2011. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation 
and exhibits synergistic growth inhibition with cisplatin in HeLa cells. Int J 
Oncol, 38, 409-17. 
YE, M. & GRAF, T. 2007. Early decisions in lymphoid development. Curr Opin 
Immunol, 19, 123-8. 
ZAJA, F., MIAN, M., VOLPETTI, S., VISCO, C., SISSA, C., NICHELE, I., 
CASTELLI, M., AMBROSETTI, A., PUGLISI, S., FANIN, R., 
CORTELAZZO, S., PIZZOLO, G., TRENTIN, L., RODEGHIERO, F., 
PAOLINI, R., VIVALDI, P., SANCETTA, R., ISOLA, M. & SEMENZATO, G. 
2013. Bendamustine in chronic lymphocytic leukemia: Outcome according to 
different clinical and biological prognostic factors in the everyday clinical 
practice. American journal of hematology, 88, 955-960. 
ZENZ, T., MERTENS, D., KUEPPERS, R., DOEHNER, H. & STILGENBAUER, S. 
2010. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature 
Reviews Cancer, 10, 37-50. 
ZHANG, G. Z., HUANG, G. J., LI, W. L., WU, G. M. & QIAN, G. S. 2002. [Effect of 
co-inhibition of MCT1 gene and NHE1 gene on proliferation and growth of 
human lung adenocarcinoma cells]. Ai Zheng, 21, 719-23. 
ZHANG, Q., IIDA, R., YOKOTA, T. & KINCADE, P. W. 2013. Early events in 
lymphopoiesis: an update. Current opinion in hematology, 20, 265-72. 
250 
 
ZHAO, Y., BUTLER, E. B. & TAN, M. 2013a. Targeting cellular metabolism to 
improve cancer therapeutics. Cell Death Dis, 4, e532. 
ZHAO, Y., BUTLER, E. B. & TAN, M. 2013b. Targeting cellular metabolism to 
improve cancer therapeutics. Cell Death & Disease, 4. 
ZHAO, Z., WU, M.-S., ZOU, C., TANG, Q., LU, J., LIU, D., WU, Y., YIN, J., XIE, X., 
SHEN, J., KANG, T. & WANG, J. 2014. Downregulation of MCT1 inhibits 
tumor growth, metastasis and enhances chemotherapeutic efficacy in 
osteosarcoma through regulation of the NF-κB pathway. Cancer Letters, 342, 
150-158. 
ZHU, X., SONG, Z., ZHANG, S., NANDA, A. & LI, G. 2013. CD147: a Novel 
Modulator of Inflammatory and Immune Disorders. Curr Med Chem. 
 
 
 
